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Summary
In order to investigate the role of nonsynonymous variants of the APC gene in 
inherited predisposition to colorectal adenomas (CRAs) the entire APC ORF was 
sequenced in 691 unrelated North American patients with CRAs and 969 healthy 
controls. There was significant over representation of rare inherited nonsynonymous 
variants in patients who did not carry conventional pathogenic mutations in APC or 
MUTYH (P = 0.0113) when compared to patients with familial adenomatous 
polyposis (FAP) and MUTYH associated polyposis (MAP). The over representation 
was highest in non-FAP non-MAP patients with 11 to 99 CRAs (P = 0.0103). More 
non-FAP non-MAP patients carried rare nonsynonymous variants within the 
functionally important p-catenin down-regulating domain compared with healthy 
controls (P = 0.0166). In silico analyses predicted that approximately 46% of the 
variants identified were expected to affect function. Functional characterisation in 
vitro showed that 7 of 16 nonsynonymous variants altered p-catenin-regulated 
transcription consistent with a role in predisposition to CRAs.
An optimum level of (3-catenin signalling is proposed to drive colorectal 
tumourigenesis, mediated by selection for APC genotypes retaining one, or rarely 
two, 20 amino acid (3-catenin down regulating repeats (20AARs). We investigated 
the mechanism through which the APC variant E1317Q contributes to colorectal 
tumourigenesis. We compared the somatic mutation spectra of APC in tumours from 
AFAP patients that did (Family B) or did not (Family S) co-inherit E1317Q. Significant 
differences were identified between these tumours, 8.2% of tumours carrying 
E1317Q had somatic mutations predicted to result in mutant polypeptides retaining a 
single 20AAR, as compared to 62.1% of those which did not carry this variant 
(P=5.64x10‘9). In vitro assays showed that E1317Q significantly impaired p-catenin 
regulated transcription when expressed with ‘weak* truncating mutations (P<0.05) 
suggesting that E1317Q relaxes the target for tumourigenic somatic APC mutations 
through its own effects on p-catenin-associated signalling.
Inherited mutations in the MUTYH gene predispose to an autosomal recessive 
disorder characterise by multiple CRAs and carcinomas (MAP). MUTYH is a DNA 
glycosylase which removes adenines that are misincorporated opposite 8-oxo-7,8-
dihydro2’deoxyguanosine (8-oxoG), one of the most stable products of oxidative 
DNA damage. Tumours from patients with MAP display a high proportion of somatic 
G:C->T:A mutations due to a failure to repair these mismatches, and it is presumed 
that this mutator phenotype drives tumourigenesis. We studied the response of 
primary Ml/TYH-deficient fibroblasts to oxidative stress and found that significantly 
more of these cells survived exposure to hydrogen peroxide and f-butyl- 
hydroperoxide as compared to wild type cells. We found that MUTYH-deficient cells 
failed to enter apoptosis and showed that this may be mediated via an inability to 
recruit Rad9 to the correct nuclear position, indicating a failure to engage the 9-1-1 
DNA damage sensor complex. Consistent with this, we found that MUTYH-deficient 
cells failed to activate the downstream checkpoint protein Chk1, after exposure to 
oxidative stress. We propose that MAP-associated tumourigenesis is driven by 
failure to undergo apoptosis in conjunction with an underlying mutator phenotype.
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Chapter One: General Introduction
1.1 Colorectal Cancer
In developed countries, colorectal cancer (CRC) is the most common non­
tobacco related cancer in both sexes combined and the fourth commonest 
type of cancer worldwide (Parkin et al, 2001; Boyle et al, 2000). CRC is the 
second most common cause of death by cancer in the United Kingdom (Office 
of National Statistics, 2006) and although mortality rates are now decreasing 
due to the implementation of improved screening and treatment, it is still 
estimated that 492,000 CRC deaths occur globally each year (Weitz et al, 
2005).
Both environmental and genetic factors contribute to development of CRC and 
either can be the predominant cause of the disease whilst also being able to 
interact with each other thereby compounding risk. Environmental or non- 
genetic risk factors include age, since approximately 90% of all CRCs are 
found in individuals over the age of 50. So-called ‘lifestyle choices’ such as 
lack of exercise, smoking, alcohol intake and poor diet may somewhat 
increase the risk of developing CRC. Epidemiological studies have shown that 
poor diet is a significant factor influencing the incidence of CRC as a diet high 
in fat, red meat consumption and low vegetable intake has been associated 
with an increased risk (World Cancer Research Fund, 1997) and evidence 
exists supporting the theory that differences in diet account for the 
geographical difference in CRC incidence (Flood et al, 2002). Inflammatory 
bowel disease (IBD), specifically ulcerative colitis, is a precancerous condition 
predisposing to cancers of both the colon and rectum; an individual with IBD is 
estimated to have a lifetime CRC risk of 15 to 40% (Zisman and Rubin, 2008)
1.2 Colorectal Tumourigenesis: the adenoma-carcinoma sequence
Independent of the initiating factor of CRC, the development of malignancy 
requires multiple mutations. The stages of tumourigenesis have been 
relatively well defined and usually occur over several years (Figure 1.1) 
(Kinzler and Vogelstein, 1996). Each stage results from mutations in genes
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involved in specific cell cycle control and signalling pathways. Different genes 
involved in the same pathway can be mutated in different CRCs but these 
mutations are generally mutually exclusive (Kinzler and Vogelstein, 1996). 
Mutation within genes involved in the transforming growth factor-p (TGF- p) 
pathway is a good example of this, since mutations in TGFpRII and SMAD4 
are found separately in CRC, but not together in the same tumour (Woodford- 
Richens et al, 2000).
Most CRCs develop from normal epithelium through sequentially worsening 
degrees of adenomatous dysplasia. CRC appears to be the best studied 
cancer in terms of a putative sequence of genetic events in its pathogenesis 
(Luebeck and Moolgavkar, 2002) and the genetic pathway model for the 
pathogenesis of sporadic CRC proposed by Fearon and Vogelstein (1990) is 
based upon this concept of an adenoma to carcinoma sequence. Although the 
total accumulation of mutations is the principal factor, the model proposes that 
causative mutations in tumour suppressor genes and oncogenes occur in a 
specific order in most CRCs and are implicated in both hereditary and 
sporadic cancers in humans (Kennedy and Hamilton, 1998).
Genes that are mutated in CRC and directly contribute to the adenoma to 
carcinoma sequence fall into two categories: oncogenes and tumour 
suppressor genes (Vogelstein and Kinzler 2002). Mutations in oncogenes 
cause them to become constitutively active or active when the wild type gene 
would not be. Such activation can be caused by chromosomal translocations, 
gene amplifications or subtle mutations within the gene that affect residues 
important for the activity of the protein (Vogelstein and Kinzler, 2004). Notably 
the gene mutated in a particular pathway is influenced by the type of genomic 
instability present in the adenoma or carcinoma. An oncogene often mutated 
in CRC is the k-ras gene. The k-ras protein is involved in signal transduction 
and couples growth factors
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Figure 1.1. Multi-step genetic model for adenoma to carcinoma progression in CRC. Schematic diagram showing the sequence of events driving colorectal 
tumourigenesis. Genes shown in red are generally mutated in tumours with CIN and those in green are generally mutated in MSI tumours. Genetic instability plays 
a key role in tumourigenesis, contributing to the accumulation of mutations in genes involved in CRC. Stromal defects, shown in orange and blue, include the over- 
co expression of key genes, occur in a number of hereditary gastrointestinal cancers such as juvenile polyposis (Adapted from Mishra, L. et al, 2005).
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to the mitogen activated protein kinase (MAPK) cascade which results in 
expression of genes involved with cell proliferation. K-ras is a monomeric 
guanosine triphosphate (GTP)ase which is inactive when bound to guanosine 
diphosphate (GDP), but when GTP is bound, k-ras is activated and the MAPK 
cascade is stimulated. Normally, the GTPase activity of k-ras would then 
hydrolyse the bound GTP thus inactivating itself. The most common mutations 
in the k-ras gene affect codons 12,13 and 61, all of which result in disrupted 
GTPase activity. This enables k-ras to remain active and stimulate cell 
proliferation (Grady and Markowitz, 2002). Only one allele of an oncogene 
needs to be somatically mutated to elicit a tumourigeneic effect. Other 
oncogenes involved in CRC tumourigenesis include CTNNB1 (Morin et a/, 
1997), BRAF (Davies et at, 2002) and PIK3CA (Samuels et al, 2006).
Loss of function in tumour suppresser genes results from mutations that 
cause a truncated protein or lead to nonsense mediated decay (NMD), 
nonsynonymous mutations at functionally important residues, insertions, 
deletions or gene silencing by promoter hypermethylation (Vogelstein and 
Kinzler, 2004). A tumour suppressor gene mutated in the majority of CRCs is 
the adenomatous polyposis coli (APC) gene. The APC protein has multiple 
cellular functions including an inhibitory role preventing over-activation of the 
Wnt signalling pathway. This pathway stimulates cell growth when activated. 
APC mutations are often protein-truncating mutations and chromosomal 
deletions. These inactivate the APC protein so it can no longer regulate 
intracellular (3-catenin turnover.
Loss of APC either by mutation or allelic loss is detected in -75% of sporadic 
CRCs (Miyaki et al, 1994) and is often cited as an early event in 
tumourigenesis having been observed in early adenomas (Powell etal, 1992; 
Groden et al, 1991; Kinzler et al, 1991). Several genes are implicated in the 
progression of early adenoma to early carcinoma and initiating mutations 
alone appear insufficient for adenomas to progress (Giardello, 1994). 
Activation of the k-ras oncogene is detected in more than 40% of CRCs, with 
an increasing frequency in larger and more advanced tumours (Smith et al, 
1994). Inactivating mutations in both APC and k-ras are thought to provide a
selective growth advantage to the nascent tumour cell as lone k-ras mutations 
are observed in histologically normal mucosa but are only present in 
dysplastic mucosa in-conjunction with APC mutations (Minamoto et al, 1995; 
Pretlow 1995; Bird 1995).
The DCC gene, is another putative tumour suppressor gene, located on 
chromosome 18 along with SMAD2 and SMAD4, and is often deleted in CRCs 
(Thiagalingam et al, 1996). In addition, p53 is mutated or deleted in many 
colorectal neoplasms (Fearon and Vogelstein, 1990). It has been suggested 
that chromosome 3p at the von Hippel-Lindau (VHL) disease gene locus may 
be implicated in the development or progression of sporadic colorectal 
carcinoma (Zhuang et al, 1996), since VHL disease gene deletion frequently 
occurs in sporadic colon carcinoma but not present in adenomas. Therefore, 
VHL may play a role in colonic carcinogenesis and represent a relatively late 
event in colonic neoplasia progression.
1.2.1 Genomic Instability
Contributing to the accumulation of mutations in genes involved in CRC, 
genomic instability plays a crucial role in tumourigenesis, (Grady and 
Markowitz, 2002). Loss of genomic stability can arise via chromosomal 
instability (CIN), microsatellite instability (MSI) or epigenetic silencing of gene 
promoters. CIN leads to genetic alterations through chromosomal loss and 
gains whereas MSI causes genetic alterations through defective DNA 
mismatch repair (MMR) proteins (SOreide et al, 2006).
CIN results in gross changes in DNA by increasing the rate of chromosomal 
gains or losses (Rajagopalan et al, 2003). This arises because of errors 
during mitotic recombination or aberrant segregation of chromosomes at 
mitosis lead to aneuploidy, a condition often observed in cancers with CIN 
(Kinzler and Vogelstein, 1996). Whilst the molecular mechanism responsible 
for CIN is not yet fully understood it is thought to occur at an early stage of 
colorectal tumourigenesis (Shih etal, 2001). Genes involved in accurate 
mitotic segregation of chromosomes have long been implicated as a causative 
factor of CIN and mutations in the genes hBUB1 (Cahill et al, 1998), APC
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(Fodde et al, 2001) and hCDC4 (Rajagopalan et al, 2004), have all been 
suggested as possible cause of CIN. Chromosomal arms that are frequently 
lost in tumours with CIN are the loci of genes important in tumourigenesis, 
suggesting that the chromosomal changes are not random but are driven by 
natural selection based on the growth advantage conferred to the nascent 
tumour. Allelic loss often occurs at 17p, 18q and 5q, the loci of p53, SMAD4 
and APC respectively (Teridman 2002).
MSI induces smaller changes in DNA than CIN and affects short repetitive 
sequences called microsatellites that are prone to misalignment errors during 
replication. Such errors are repaired by the MMR proteins in normal cells but 
defects in these proteins result in a germline microsatellite allele undergoing a 
somatic change in length by gaining or losing tandem repeats. MSI influences 
which genes are mutated in colorectal tumours since genes containing 
microsatellites are susceptible to mutation (Sdreide et al, 2006).
Whilst CIN is the mode of genetic instability observed in the majority of CRCs 
(approximately 85%) (Kinzler and Vogelstein, 1996), aCpG island methylator 
phenotype (CIMP) has been identified in some CRCs. The hypermethylation 
of CpG islands often found within the promoter region of genes. This 
epigenetic instability results in tumourigenesis because of the transcriptional 
silencing tumour suppressor genes (Toyota et al, 1999). Genetic and 
epigenetic instability are not mutually exclusive; Samowitz et al, (2005) 
identified colorectal tumours with CIMP and MSI, or less frequently, CIN. In 
some CRCs, promoter hypermethylation of the MMR gene hMLH1 has lead to 
defects in the MMR pathway (Herman et al, 1998).
Whilst the majority of CRC cases are sporadic with no known genetic cause, 
the remaining cases arise as a result of inherited genetic factors. Twin studies 
have often been used to elucidate genetic mechanisms of human disease and 
have been successfully applied to show that genetic factors also play an 
important role in causing CRC. Lichtenstein et al (2000) estimated that 
genetic factors could account for up to 20% of CRC by comparing 
concordance for CRC in monozygotic twins with that in dizygotic twins.
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Approximately 2-6% of all CRCs are the result of known genetic predisposition 
syndromes accounted for by established CRC predisposition genes 
(Feamhead etal, 2002, Kemp etal, 2004) (Figure 1.1).
1.3 Inherited CRC Syndromes
Of the several autosomal dominant syndromes, the two commonest familial 
forms are familial adenomatous polyposis (FAP) (MIM17500), which 
historically accounted for <1% (Hodgson and Maher, 1999; Lynch and de la 
Chappelle, 1999) and hereditary non-polyposis colorectal cancer (HNPCC) 
(MIM 114500) which accounts for up to 5% (Lynch and de la Chappellle,
1999). The importance of a correct diagnosis of an inherited CRC syndrome 
is essential to provide long term clinical management of the disease and 
associated surveillance and genetic counselling of the immediate family.
1.3.1 Familial adenomatous polyposis
FAP is a rare, autosomal dominant inherited disorder caused by mutations in 
the APC gene (Kinzler and Vogelstein, 1996).It is characterised by the 
development of hundreds to thousands of colorectal adenomas (CRAs) within 
the colon and the rectum (Wallis and MacDonald, 1996) (Figure 1.3). These 
polyps usually develop during the second and third decade of life (Kinzler and 
Vogelstein, 1996) and if left untreated, one or more will progress to carcinoma 
often by the fourth decade of life (Hodgson and Maher, 1999; Kinzler and 
Vogelstein, 1996). Whilst predominantly manifesting within the colon and 
rectum, cancer is not limited to these areas since malignant tumours may 
occur in the duodenum, liver, brain and thyroid (Hodgson and Maher, 1999). 
Extracolonic manifestations of FAP and include adenoma and 
adenocarcinoma of the stomach, periampullary region, pancreas and thyroid, 
osteomas, desmoids, dental abnormalities, epidermal cysts, congenital 
hypertrophy of the retinal pigmented epithelium (CHRPE) and central nervous 
system (CNS) tumours (Kinzler and Vogelstein, 1996). A variant of FAP 
known as attenuated FAP (AFAP) is characterised by the development of a
7
Other
familial
(-15%)
Sporadic 
(up to 75%)
Rare CRC syndromes \
•PJS I
• FJP \
•CD
• BRRS M UTYH-associated
polyposis (MAP) (<1%)
Hereditary nonpolyposis 
colorectal cancer (2-6%)
Familial adenomatous 
polyposis (FAP) (<1%)
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lower number (<100) of CRAs (Figure 1.3) by the fourth decade, a later age of 
onset and is associated with germline mutations in specific regions of the APC 
gene.
1.3.2 The APC gene
The APC gene is located on chromosome 5q21 and consists of 21 exons 
(Thliveris 1996). The initial link between FAP and chromosome 5 came with 
the identification of a deletion in the long arm of this chromosome in a patient 
with CRC (Herrera et al, 1986). Subsequent linkage analysis in FAP families 
narrowed the region containing the gene to 5q21-5q22 (Bodmer et al, 1987; 
Leppert et al, 1987), from which the APC gene was subsequently cloned and 
sequenced (Groden etal, 1991; Joslyn etal, 1991; Kinzler etal, 1991).
The APC gene includes 21 exons contained within a 98-kilobase locus 
(Thliveris, 1996). Different combinations of splice donor and acceptor sites 
are utilised, resulting in a range of alternative transcripts and tissue specific 
expression patterns. In addition to the conventional form of APC encoded by 
exons 1 to 15, alternatively expressed exons of the gene (0.3, brain specific 
[BS], 0.1, 0.2,1, 9, and 10A)(Thliveris etal, 1994; Horii etal 1993; Sulekova 
and Balhausen, 1995) encode alternate protein isoforms (Pyles etal, 1998). 
Exon 15 comprises more than 75% of the coding sequence (Figure 1.4) and is 
the target of most germline mutations in FAP patients and somatic mutations 
in tumours. Although the tissue-specific expression patterns of these isoforms 
differ from conventional APC (Pyles et al, 1998), their function is not yet 
completely understood. They are found generally in post mitotic tissues and 
terminally differentiated cell lines (Pyles et al, 1998) and differ most 
significantly from conventional APC in their amino-termini and predicted ability 
to homo- or heterodimerize.
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A) Classic FAP B) Attenuated FAP (AFAP)
Figure 1.3. Gross appearance of colon from A) a patient with classical FAP showing a profuse carpet of 
polyps and b) a patient with AFAP displaying the attenuated phenotype (<100 colorectal adenomas). 
Pictures courtesy of Prof. J. Sampson, Cardiff University, UK.
A) Gene
1 23 4 5 6 7 8 i<y10a 15
B) Protein p-Catenin binding region
P-Catenin binding degradation
Mutation Cluster Region (MCR) I-----------1
1 IIIIII! Ill 11 LWt
C) Interactions
Binding to Asefl, Asef2 
& IQGAP1
1
Cdc42, Rac1 & ..__
CLIP-170 |
Binding to p-catenin
/  I_____ 1
Axin
_ l CtBP
1 i
Binding to Binding EB1 
microtubules
Cell adhesion
Inhibition of p-catenin/TCF/Lef 
transcription I
Kinetochore
functions
4
mDia
Stimulation of Myc 8> cyclin D1I Chromosomal
cell migration 4 segregation
Activation
Inhibition
Control of proliferation and 
differentiiation
Stabilization of 
microtubules
“ I i i i | i i i “ ii i r ~  i i | r
400 800 1200 1600 2000
Codon Number
2400 2800
Oligomerisation
domain
SAMP repeats 
(Axin-binding domain)
Homology
domain
Basic region
Armadillo
repeats
EB1-binding 
domain
15-aa
repeats □ 20-aarepeats
□DLG-bfnding 0  NESdomain ^  NL§
Figure 1 .4  Schematics of: A) the conventional form of the APC gene showing 15 exons, with exon 15 containing over 75% of the coding sequence. The alternatively spliced exons 1, 9 and 10a are also shown. B) Full 
length APC protein illustrating multiple domains and their functions. C) APC stimulates cell migration through interactions with Asef, IQGAP1 or mDia. APC is involved in cell adhesion through controlling 3-catenin 
distribution between the nucleus/cytoplasm and the plasma membrane. APC inhibits 3 -catenin/TCF/Lef transcription through interactions with 3 -catenin or CtBP. APC regulates chromosome segregation through 
kinetochore binding and through suppression.
1.3.3 Mutations in APC: Knudson's two-hit hypothesis
Knudson’s two-hit hypothesis states that tumour formation is initiated by 
biallelic inactivation of a tumour suppressor gene and that both inherited and 
sporadic cancers can arise as a result of mutations in the same gene 
(Knudson 1971; Figure 1.5). Inherited predisposition to tumourigenesis results 
from a germline mutation in a tumour suppressor gene e.g. APC (the ‘first hit’), 
but that this alone is not sufficient for tumour development; inactivation of the 
wildtype allele by a somatic mutation (second hit) is required. Development of 
sporadic tumours requires somatic mutational events to inactivate both wild 
type APC alleles (Ichii et al, 1992; Powell et al 1992) consistent with the lower 
number of tumours and late age of onset in sporadic cases (Knudson 1996).
1.3.3.1 Distribution of germline mutations in APC
The vast majority of germline APC mutations are predicted to result in the 
synthesis of a C- terminal truncated protein (Beroud and Soussi, 1996; Laken 
et al, 1999; Powell et al, 1992). Nonsense point mutations and frame-shifts 
(due to small insertions and deletions) that result in a truncated protein 
account for greater than 98% of APC mutations (Giardello et al 1994). Most 
germline mutations are scattered throughout the 5’ half of the gene with two 
common hotspots for mutations occurring at codons 1309 (Beroud and 
Soussi, 1996; Miyoshi etal 1992) and 1062 (Beroud and Soussi, 1996; Mandl 
et al, 1994) (Figure 1.5). Recurrent mutations at these two codons account for 
10 - 30% of germline mutations (Beroud and Soussi, 1996; Miyoshi etal, 
199a). Mutations throughout the 3’ end of the gene are less frequent and 
rarely occur downstream of codon 1600 (Friedl et al, 1996; Miyoshi et al,
1992).
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Figure 1.5 Knudson’s 2-hit hypothesis of tumourigenesis in A) sporadic and B) inherited forms of cancer.
1.3.3.2 Distribution of somatic mutations in APC
Somatic APC mutations are detected in over 75% of sporadic CRC cases as 
well as in tumours from FAP patients (Ichii etal, 1993: Rowan etal, 2000). 
Over 60% of somatic mutations are concentrated between codons 1281 and 
1556, a region referred to as the mutation cluster region (MCR) (Beroud and 
Soussi, 1996). (Figure 1.6) There are three somatic mutation hotspots located 
at codons 1309,1450 and 1556 (Miyoshi etal, 1992; Cheadle etal, 2002). 
Somatic mutations are rare in the terminal third of the gene (Laurent-Puig et 
al, 1998, Beroud and Soussi, 1996).
The majority of somatic point mutations are cytosine (C) to thymine (T) 
transitions at CGA codons resulting in a stop signal, indicating a selective 
pressure to truncate APC (Beroud and Soussi, 1996; Miyoshi etal, 1992; 
Nagase et al, 1992). Higher proportions of single base pair (bp) insertions and 
deletions (£ 2bps) are more common in somatic cells than in the germline 
(Marshall et al, 1997) suggesting possible mechanistic differences for 
mutation in somatic cells (Laurent-Puig et al, 1998). Loss of heterozygosity 
(LOH) at 5q21-22 is observed in FAP-assodated (Okamoto etal, 1994; Miyaki 
et al, 1994) and sporadic tumours, but is more frequent in sporadic tumours 
(Solomon etal, 1987; Rowan etal, 2000). Hypermethylation of the 1A 
promoter region of APC has been detected in CRCs (Hiltunen et al, 1997). 
This mechanism prevents expression of the APC protein (Esteller et al, 2000), 
suggesting that this is an alternative, although infrequent mechanism for APC 
inactivation.
A significant observation in colorectal adenomas and carcinomas due to 
inactivation of both APC alleles is the interdependence between the so called 
‘first’ and ‘second hit* (Lamlum et al, 1999; Rowan et al, 2000; Albuquerque et 
al, 2002) (Figure 1.6). In familial tumours, ‘first hit’ mutations between codons 
1194-1392 within the MCR are associated with loss of the other allele as a 
second hit and these patients tend to display more severe phenotype, 
whereas mutations outside this region are associated with an MCR truncating 
mutation (Lamlum et al, 1999; Rowan et al, 2000). This suggests that 
mutations in the APC gene are not selected for simple loss of protein function
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(Lamlum et al, 1999; Rowan et al 2000) but that there is in-fact, a strong 
selection for the retention of at least one truncated APC product containing 
the first 20-amino acid p-catenin down-regulating domain. Smits et al (1999), 
showed that truncated APC is required for maximuml cell proliferation and that 
there exists an almost systematic selection for truncating mutations occurring 
before the first Ser-Ala-Met-Pro (SAMP) repeat implying that such mutant 
proteins are selected to eliminate the binding sites for axin/conductin on APC, 
thereby inactivating this function of the protein. The idea that truncated 
mutants are selected for based on the provision of growth advantages for the 
nascent tumour cell is reinforced by findings of the Cheadle group (2002), 
which showed that different combinations of APC mutations confer different 
growth advantages. Using a statistical model based on the data from sporadic 
tumours it was found that biallelic truncating mutations within in the MCR were 
3.9 times more likely to be selected than one truncating mutation in the MCR 
combined with either a truncating mutation outside the MCR or an incidence 
of LOH, which in turn were 27.8 times more likely to be selected than two 
truncating mutations outside the MCR or a truncating mutation outside the 
MCR and an LOH.
1.3.3.3 Genotype - phenotype correlations in FAP
The correlation between genotype and phenotype of FAP has been the 
subject of much investigation: the clinical manifestation of FAP varies greatly 
between individuals; Giardello et al (1994) were able to show that patients 
with identical mutations could develop different clinical features. However, 
mutational analyses indicate an association between the FAP phenotype and 
the position of the germline APC mutation (Table 1.1 and Figure 1.7). These 
relationships involve both the severity of the polyposis phenotype as well as 
several other features that are subject to phenotypic variability such as the 
age of onset of CRC and the development of extracolonic manifestations.
Severe polyposis (> 5000 CRAs) is typically seen in individuals with germline 
mutations in the MCR (codons 1250 and 1464; Nagase etal, 1992), although 
a similar phenotype has been found in individuals with APC mutations at
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codon 233 in exon 6 (Nugent et al, 1994) and at codons 486 and 499 in exon 
11 (Eccles et al, 1997). AFAP is typified by mutations at the extreme 5' (Spirio 
et al, 1993; Dobbie et al, 1994; Wallis et al, 1994) or 3' (van der Luijt et al, 
1996; Friedl et al, 1996) ends of the APC gene, or in the alternatively spliced 
region of exon 9 (Rozen etal, 1999; Soravia eta., 1998).
Extracolonic manifestations (i.e. desmoids, osteomas, epidermoid cysts and 
upper gastrointestinal polyps) occur most commonly in FAP patients with 
mutations between codons 1445 and 1578 (Caspari etal, 1995) or between 
codons 1395 and 1493 (Wallis etal, 1996). CHRPE is only present in 
individuals with mutations between codons 457 and 1444 (Spirio etal, 1993; 
Wallis etal, 1994; Olschwang etal, 1993).
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Figure 1. 6 A) Histogram indicating the frequency of somatic and germline 
mutations in APC. Germline mutations are distributed all over APC, with two 
‘hotspots’ at codons 1061 and 1309. Somatic mutations show a propensity to 
lie within the mutation cluster region (MCR). B) The interdependent 
association between the positions of the initial germline mutation and the 
somatic mutation. (Figure adapted from Klaus and Birchmeier 2008).
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FAP
Phenotype
No. of 
Polyps
Age of 
onset of 
polyps
Mean 
age of 
onset 
of CRC 
(Yr)
Site
of
CRC
Sites of 
mutation 
codon 
no.
Extracolonic
manifestations
Severe
(classical
FAP)
>5000 I and II 
Decades
34 Left 1250-
1464
(MCR)
Extreme
Intermediate
(classical
FAP)
1 0 0 -
5000
II and III 
decades
42 Left 1 5 7 - 
311 and 
412-1597 
(excludes 
MCR)
Common
Attenuated
(AFAP)
<100 IV and V 
decades
delayed Right 1-57a, 
311 -  
412b and 
1596- 
2644c
Limited
Table 1.1 Classification of FAP illustrating the phenotype-genotype correlation 
between various type of colonic polyposis and site of germline mutation. FAP: 
familial adenomatous polyposis; CRC: colorectal cancer. a=5’ end exons 4 
and 5; b= within exon 9; c=3’distal end of APC gene. (Adapted from Cetta and 
Dhamo, 2007)
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Figure 1.7 Schematic showing truncated APC proteins illustrating the association between position of germline APC mutation and 
FAP phenotype. Boxed area indicates position of mutation, codon range noted in figure. Adapted from Fearnhead et al, 2001
1.3.3.4 Low penetrance alleles in APC
Whether rare inherited nonsynonymous variants in APC act as low 
penetrance alleles that predispose to colorectal tumours remains highly 
speculative. The low penetrant nonsynonymous variant I1307K predisposes to 
multiple colorectal adenomas in the Ashkenazi Jewish population (Laken et al, 
1997). This variant allele was observed in 6% of Ashkenazi controls, 10% of 
Ashkenazi CRC cases, and 28% of Ashkenazim CRC cases who also had a 
family history of CRC. It is rarely present in non-Ashkenazi individuals. An A- 
to-T transition at codon 1307 creates a hypermutable [A]8 tract and appears to 
be associated with a 1.5 to 2 fold risk of colon cancer (Laken et al, 1997; 
Woodage etal, 1998; Rozen etal, 1999; Gryfe etal 1999).
The E1317Q nonsynonymous variant was first described by White et al 
(1996), in two of four siblings in an Ashkenazi Jewish CRC family. It is more 
common and widespread than I1307K and has been proposed to act as a 
CRA predisposition allele (Frayling etal, 1998) but the underlying mechanism 
is yet to be ascertained. Evidence exists to support the suggestion that 
E1317Q elicits a pathogenic effect because the amino acid substitution leads 
to a charge change in the critical 20 amino add repeat (20AAR) domain 
responsible for p-catenin binding. E1317Q has been identified as i) a somatic 
mutation in sporadic CRA development (White et al, 1996), ii) a somatic 
mutation in a colorectal adenocarcinoma from an I1307K patient (Laken et al, 
1997), iii) one of the two detected mutations in the colon cancer cell line 
SKC01 (Rowan etal, 1997), iv) it is overrepresented in the germline of 
patients with multiple CRAs (Lamlum et al, 2000) and v) it has also been 
identified as a somatic change in sporadic CRC (Frayling et al, 1998).
The APC germline variant N1026S was identified in a Spanish AFAP family 
and characterised by Menendez et al (2008). It is located within the highly 
conserved region of the first 15AAR within the p-catenin binding domain. 
Menendez et al (2008) suggested a pathogenic role via a dominant-negative 
effect on APC function. Functional characterisation showed that APC-N1026S 
failed to reduce repression of p-catenin regulated transcription when
20
compared to wildtype APC (constitutively active p-catenin regulated 
transcription in colon cancer cell lines is greatly reduced upon the introduction 
of wild-type APC), strongly supporting the hypothesis of a pathogenic role for 
APC N1026S variant in the AFAP phenotype.
1.3.4 Domains of the APC protein
Mammalian APC is expressed in the majority of foetal tissues and in adult 
epithelial cells (Midgley et al, 1997) and occurs in several isoforms, arising 
through several mechanisms i.e. alternative splicing at the mRNA level, post- 
translational modification and nascent protein degradation. The most 
abundant isoform, APC is present as a 2843-amino acid (Horii et al, 1993). It 
is detected in both the nucleus and the cytoplasm (Neufeld and White, 1997) 
of cells in a variety of organs including the brain, lung aorta, spleen, heart, 
kidney, liver, stomach, placenta and colonic mucosa (Groden etal, 1991).
APC is a large multifunctional protein consisting of 2843-amino adds; is 
approximately 311kDa in size (Groden etal, 1991) and consists of several 
functional domains, each of which enables an interaction with several protein 
partners in numerous cellular processes (Figure 1.4); mammalian APC has an 
oligomerization domain, an armadillo repeat-domain, 15- and 20AAR domains 
important for binding to p-catenin, SAMP repeats for axin binding, a basic 
domain for microtubule binding and a C-terminal domain that binds to EB1 
and hDLG proteins. Through these multiple domains APC performs functions 
in not only tumour suppression but also cell differentiation, adhesion, polarity 
formation, migration, development, apoptosis and neuronal functions (Senda 
etal, 2007; Figure 1.4). Table 1.2 lists known APC binding partners and 
summarises their proposed function.
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1.3.4.1 Oligomerization domain
Heptad repeats enable APC to homodimerize (Groden et al, 1991, Su et al, 
1993; Joslyn et al, 1991). Since this domain lies at the N-terminus of the 
protein it consequently facilitates homodimerisation of wildtype APC 
polypeptides with truncated APC mutant polypeptides (Polakis 1997).
1.3.4.2 Armadillo repeat domain
The armadillo domain at the N-terminus consists of seven repeats with a high 
degree of homology to Drosophila armadillo and the mammalian homologue 
p-catenin (Rubinfeld etal, 1993). It is the most highly conserved region of 
APC being 60% identical with the Drosophila APC as compared to an overall 
identity of less than 30% (Hayashi et al, 1997). The armadillo domain appears 
to mediate protein/protein interaction; it is able to bind the APC-stimulated 
guanine nucleotide exchange factor (ASEF), which is a Rac specific guanine 
nucleotide exchange factor (Kawasaki etal, 2000); Kap3, the kinesin super 
family associated protein 3, which is a mediator between APC and kinesin 
motor proteins (Jimbo et al, 2002); and IQGAP1, which is an effecter of Rac1 
and Cdc42 (Watanabe et al, 2004). These binding partners suggest that the 
armadillo domain of APC may be involved in cell morphology, motility and 
migration through the actin and microtubule cytoskeleton.
1.3.4.3 15-amino acid and 20-amino acid repeat domain
Three highly conserved 15AARs and seven 20AARs are located within the 
central portion of APC and provide critical binding sites for p-catenin 
(Rubinfeld et al, 1993 Su et al 1993; Rubinfeld et al, 1995; Rubinfeld et al,
1997). The binding of p-catenin to the 15AARs does not lead to the down 
regulation of p -catenin. Rather, p -catenin down regulation requires the 
presence of at least three of the seven 20AARs (Rubinfeld et al, 1997).
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1.3.4.4 Samp repeats
Three SAMP repeats lie between the third and fourth, the fourth and fifth, and 
after the seventh 20AARs (Behrens et al, 1998) respectively. They contain the 
conserved sequence (I/LxxxCLxSxMxK/R) and are binding sites for axin and 
its homologue, conductin.
1.3.4.5 NES and NLS domains
Highly conserved nuclear export signals (NES) that are essential for shuttling 
the nuclear (3 -catenin to the cytoplasm were identified at the N-terminus and 
within the 20 amino acid repeats (Henderson 2000). Each carried one of the 
following motifs LxxxLxxLxL or VxxxVxxVxV (Henderson 2000). Two nuclear 
localisation signals (NLS) necessary for nuclear import of APC were 
recognised between amino adds 1767 -1772 and between amino adds 
2048-2053 (Hang etal, 2000).
1.3.4.6 Basic domain
The basic domain is localized between amino acids 2200 and 2400 within the 
C-terminus of APC (Groden etal, 1991). This region is rich in arginine, lysine 
and proline. This type of basic region is also found in microtubule-assodated 
proteins and confers the microtubule binding function of APC (Deka et al,
1998). Studies have shown that this domain stimulates polymerization of 
tubulin in vitro, and binds to microtubules when expressed in epithelial cells 
(Munemitsuetal, 1994; Smith etal, 1994; Deka etal, 1998).
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Binding
partner
APC domain Function References
Aaef Armadillo
repeats
Rac GEF, cell migration, cell adhesion Kawasaki et al, 2000 and Kawasaki et al, 2003
P-catenin 15 and 20 aa 
repeats
Cell adhesion, membrane attachment of 
mitotic spindle, Wnt signaling
Barth et al, 1987, Pollack et al, 1997, McCartney et al, 1999, Yu et al, 1999, Townsley 
and Blenz, 2000, Lu et al, 2001, McCartney et al, 2001, Hamada and Blenz, 2002, 
Kllngelhofer et al, 2003 and Faux et al, 2004
Bub Kinases Unknown Chromosome segregation Kaplan et al, 2001 and Green and Kaplan, 2003
EB1 EB1 binding 
domain
Cell migration, chromosome segregation, 
spindle assembly, neuronal differentiation
Askham et al, 2000, Barth et al, 2002, Lu et al, 2001, Nakamura et al, 2001, Rogers et 
al, 2002, Liakopoulos et al, 2003, Louie et al, 2004, Temburni et al, 2004 and Wen et 
al, 2004
hOLG PDZ binding 
motif
Cell cycle, neuronal differentiation Matsumine et al, 1996 and Ishidate et al, 2000
IQGAP1 Armadillo
repeats
Rho GTPase regulation, cell migration, cell 
adhesion
Watanabe et al, 2004
KAP3 Armadillo
repeats
Cell migration Jimbo et al, 2002
Microtubules Basic domain Cell migration, cell adhesion, chromosome 
segregation, spindle assembly, neuronal 
differentiation
Matsumine et al, 1996, Smith et al, 1994, Nathke et al, 1966, Morrison et al, 1997, 
Fodde et al, 2001, Kaplan et al, 2001 and Zumbrunn et al, 2001
mDia Basic domain Rho GTPase regulation, cell migration, cell 
adhesion
Wen et al, 2004
Plakogiobin 15 and 20 aa 
repeats
Cell adhesion, Wnt signaling Rubinfeld etal, 1995
PSD-93 Aa 2498- 
2844
Neuronal differentiation Temburni et al, 2004
XMCAK Basic domain Chromosome segregation, spindle assembly Banks and Heald, 2004
Table 1.2 APC interacts with multiple binding partners that contribute to its function outside the 
Wnt signalling pathway. APC binding partners summarised, the domains of APC they interact with and 
the function they participate in with APC
1.3.4.7 C-terminal domains
The C-terminal region of APC contains a 170 amino acid binding site for EB1 
(Su et al, 1995). EB1 associates with the centromere, mitotic spindles and 
plus-end of microtubules throughout the cell cycle (Berrueta et al, 1998; 
Morrison et al, 1998; Juwana et al, 1999) and EB1 is required for microtubule 
integrity, the maintenance of cell form (Beinhauer et al 1997) and the cell 
cycle checkpoint mechanism (Muhua et al, 1998).
The most C-terminal portion of APC contains the Ser-Thr-X-Val (S/TXV) 
amino acid sequence, (where X is any amino acid). Two unique proteins bind 
to this site, the human homologue of Drosophila DSG tumour suppressor 
(Matsumine et al, 1996) and the protein tyrosine phosphatase PTP-BL 
(Erdmann et al, 2000). The co-localization of APC and PTP-BL was first 
observed in the nucleus and cellular protrusions of MDCK cells and this 
interaction may indirectly modulate the steady-state levels of tyrosine 
phosphorylations of associated proteins such as (3 -catenin (Erdmann et al, 
2000).
1.3.5 APC functions
The most studied role of APC protein is an involvement in Wnt signalling and 
P -catenin degradation. It also plays roles in cell-cell adhesion, cell cycle 
regulation and chromosome stability.
1.3.5.1 Wnt Signalling
APC plays a critical role suppressing the Wnt signalling pathway that controls 
cell proliferation and differentiation. When this pathway is stimulated, (3 - 
catenin activates TCF/LEF-dependent transcription of Wnt-target genes such 
as CCND1 (Tetsu and McCormick, 1999), c-myc (He et al, 1998) and EphB 
(Batlle et al, 2002) (Figure 1.8).
Wnt ligands are secreted glycoproteins (Polakis 2000) expressed in a tissue 
specific manner (Seidensticker and Behrens, 2000). They bind to a class of 
seven transmembrane receptors (eleven in vertebrates) encoded by the 
frizzled genes through their N-terminal cysteine rich extracellular domains and
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activate them, leading to the phosphorylation of a protein called dishevelled 
(Polakis 2000; Seidensticker and Behrens, 2000). Dishevelled prevents 
phosphorylation of axin, APC and p-catenin by GSK3p (Kishida etal, 1999). 
Dishevelled binds and alters the conformation of axin via two domains 
(Kishida etal, 1999, Seidensticker and Behrens, 2000). This leads to an 
increase in mature unphosphorylated p -catenin, which cannot be degraded, 
causing intracellular accumulation in the cytoplasm and the nucleus 
(Seidensticker and Behrens, 2000). In the nucleus, p -catenin binds to 
members of T-cell factor (TCF) and lymphoid enhancer factor (LEF) family of 
transcriptional activators (Behrens et al, 1996). This leads to the formation of 
complexes that transmit the Wnt signal into the nucleus and activate Wnt 
target genes.
In the absence of exogenous Wnt signalling factors, APC provides a scaffold 
for a destruction complex together with GSK3p and axin that promotes 
phosphorylation and consequent ubiquitin-dependent degradation of p - 
catenin by the 26S proteosomes (Rubinfeld etal, 1996). APC inactivation, 
aberrantly switches on the Wnt pathway (Peifer and Polakis, 2000) since APC 
is a negative regulator of the Wnt signalling. Truncating mutations in APC 
have been reported in the majority of CRCs and the spectrum of these 
mutations suggests a selection against p -catenin regulating domains 
(reviewed in Polakis 2000). Activating mutations in p -catenin, which affect N- 
terminus serine and threonine residues, have been reported in ~50% of colon 
tumours without an APC mutation (Sparks etal, 1998). Biallelic inactivation of 
axin in human hepatocellular cancers and cell lines has also been reported 
(Satoh et al, 2000).
Several lines of evidence indicate that APC inhibits p -catenin/TCF/LEF- 
dependent transcription through other mechanisms: i) APC promotes export of 
p -catenin from the nucleus, which reduces the amount of nuclear p - 
catenin/TCF (Henderson and Fagotto, 2002; Neufeld et al, 2000; Rosin- 
Arbesfeld et al, 2003), ii) APC binds to p -catenin, blocking the interaction with 
TCF (Neufeld et al, 2000; Rosin-Arbesfeld et al, 2003) and iii) recent studies 
show that APC can inhibit p -catenin/TCF/LEF-dependent transcription
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through a direct interaction with a repressor complex: APC binds to p 
transdudn repeat containing protein (bTrCP) and transcriptional repressor C- 
terminal binding protein (CtBP) and forms a stable complex with additional co­
repressors TLE-1 and HDAC1 (Hamada and Bienz, 2002; Sierra etal, 2006). 
Because APC interacts with bTrCP at the MYC enhancer, it may facilitate 
CtBP-mediated repression of Wnt-target genes (Hamada and Bienz, 2004; 
Sierra et al, 2006). Because the C-terminal half of APC mediates binding to 
CtBP, truncated APC mutants found in cancer cannot stimulate the CtBP- 
mediated transcriptional repression (Hamada and Bienz, 2004; Sierra et al, 
2006). Such mutations thus activate p -catenin/TCF-dependent transcription 
by both increasing levels of p -catenin-TCF complexes in the nucleus and 
reducing CtBP-mediated inhibition of the complex.
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Figure 1.8.Wnt signalling in normal colonic epithelial cells. A) In the absence of Wnt signalling factors, a p-catenin-axin-APC complex is formed and 
phosphorylated by GSK3P. This promotes the degradation of intracellular p-catenin via the ubiquitin/proteasome pathway, resulting in the repression of 
Wnt target genes. B) Binding of exogenous Wnt ligand to it’s transmembrnae receptor, results in the recruitment of dishevelled from the cytosol leading to 
the inhibition of the (3-catenin destruction complex formation by dephosphorylating axin. P-catenin accumulates in the cytosol and translocates to the 
nucleus where it binds with TCF/LEF transcription factors and activates the transcription of target genes.
1.3.5.2 Role for APC in cell migration
APC binds with microtubules directly through the C-terminal microtubule 
binding domain or indirectly through association with EB1. The observation 
that APC localizes to the plus ends of microtubules in mammalian cells 
provided the first evidence that APC might play a role in cell migration. APC is 
prominently localized in puncta at the plus end tips of microtubules (Nathke et 
al, 1996; Mimori-Kiyosue etal, 2000; Etienne-Manneville and Hall, 2003; Zhou 
et al, 2004) and is also present diffusely along the length of microtubules 
(Nathke etal, 1996, Barth etal, 2002). Interaction of APC with the kinesin 
super family-associated protein (KAP3) facilitates the transport of APC along 
microtubules to their plus ends (Jimbo et al, 2002). Nathke et al (1996) 
observed that APC localisation occurred at a higher affinity at the tips of 
actively migrating cells during wound healing assays. APC has since been 
shown to act as a positive regulator of microtubuie stability by binding to non­
assembled tubulin and promotes the assembly of branched microtubuie 
arrays (Munemitsu etal, 1994; Zumbrunn etal, 2001). Additionally, deletion of 
the microtubule-binding domain of APC results in a decrease in microtubuie 
stability (Smith etal, 1994; Zumbrunn etal, 2001).
Binding with EB1 via the C-terminal EB1 binding domain at the plus end of 
microtubules is thought to regulate its role in cell migration (Su etal, 1995) 
since EB1 is known to localise to the plus ends of microtubules and targets 
APC to the proximal tips (Morrison etal, 1998; Barth etal, 2002) and EB1 
promotes polymerisation of microtubules only when bound to APC (Nakamura 
etal, 2001). Phosphorylation of APC by protein kinase A and p34cdc2 inhibits 
microtubuie polymerisation by reducing its association with EB1 (Nakamura et 
al, 2001) further modulating the role of APC in stabilising and promoting 
microtubuie polymerisation. Cell migration is thought to be promoted via 
interactions with Rho and the formamin family protein mDia to facilitate 
microtubuie stability at the leading edge of the plasma membrane (Wen et al,
2004).
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Binding of APC to IQ containing GTPase activating protein 1 (IQGAP1) at the 
leading edge’ of the microtubuie also regulates cell migration (Noritake et al,
2005) by forming a scaffold structure complex with microtubuie binding protein 
CLIP-170 and the activated forms of Rac1 and Cdc42 (Watanabe et a/, 2004; 
Briggs and Sacks, 2003).
Cell migration is also promoted by the binding of APC to Asef via the 
Armadillo repeat domain, which leads to increased cell spreading and 
membrane ruffling (Kawasaki et al, 2000). This activity has been implicated by 
the ability of truncated APC proteins to stimulate inappropriate cell migration 
by constitutively activating the guanine nucleotide exchange factor activity of 
Asef. (Kawasaki et al, 2003).
Defects in cell migration due to a loss of APC function could lead to the 
accumulation of cells in an environment which might promote their 
proliferation. Moreover, impaired cell migration might increase the survival 
rate of cells with defective genetic material (Dikovskaya et al, 2001).
1.3.5.3 Role for APC in cell-cell adhesion
In addition to its function in gene regulation, p-catenin also participates in cell­
cell adhesion via interactions with the members of the cadherin family of 
proteins (Gumbiner, 2000; Polakis et al, 2000). The C-terminal domain of E- 
cadherin is shown to interact with p- and y -catenin, which associate with a- 
catenin and form an E-cadherin complex with the actin cytoskeleton. This 
complex is known to maintain stable cell-cell adhesion (Gumbiner, 2000).
APC is also a part of the cell-cell adhesion complex linked with E-cadherin, 
since it directly binds with p-catenin, y-catenin, and actin filament (Ben-Ze'ev 
and Geiger, 1998; Polakis 2000).
In cells, in addition to its association with Wnt signalling and cell-cell adhesion 
complexes, p-catenin exists as a free pool in the cytosol (Papkoff, 1997).
Thus, the dynamic distribution of p-catenin in different pools may determine its 
role in different cellular functions adding another facet of importancet of
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controlled rates of p-catenin turnover mediated by the 
axin/conduction/APC/GSK3p destruction complex.
1.3.5.4 Regulation of the cell cycle
Several studies involving the transfection of full length, wildtype APC into 
human colon adenocarcinoma cell lines such as NIH3T3 and SW480 (Groden 
et al, 1995; Baeg et al, 1995) have shown that similar to other tumour 
suppressor genes, such as Rb or p53, APC plays a role in controlling cell 
cycle progression. These experiments indicate that maintenance of the Gi-S 
checkpoint by APC is mediated through effecting components of the Rb 
pathway and is attributable, at least in part to regulation of p-catenin/Tcf/Lef- 
mediated transcription of S-phase regulators such as cyclin D1 and c-myc. A 
role for APC at the G2-M transition is also likely given the observations that 
APC is hyperphosphorylated during M-phase (Bhattacharjee et al, 1996) and 
is a target of the M-phase kinase p34cdc2(Trzepacz et al, 1997).
The binding of APC to hDLG also implicates a role for APC in control of cell 
cycle progression. Over expression of APC suppresses cell proliferation 
through blocking cell cycle progression from G0/G1 to the S phase (Baeg et al,
1995) and the APC-hDLG protein complex is a negative regulator of cell 
growth and is essential for cell cycle inhibition (Ishidate et al, 2000).
1.3.5.5 Chromosome stability
The localisation of APC to chromosomes during interphase and mitosis are 
consistent with and imply a role in maintaining chromosomal stability; 
furthermore, this role was shown not to involve p-catenin (Fodde et al, 2001, 
Kaplan et al, 2001), indicating that it occurs independently of APCs role in 
signal transduction and is mediated through the C-terminal end domain.
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Throughout interphase APC is localised in cellular protrusions of microtubules 
(Nathke etal, 1996); during mitosis APC has been reported at kinetochores 
(Fodde etal, 2001; Kaplan etal, 2001) and atcentrosomes (Banks and Heald, 
2004; Louie et al, 2004). At kinetochores, it might regulate microtubule- 
kinetochore attachment or the spindle assembly checkpoint; at centrosomes it 
could influence centrosome duplication or nucleation of spindle/astral 
microtubules during mitosis.
By interacting with a complex set of proteins and pathways, APC contributes 
to differentiation, cell migration, proliferation and adhesion. High cell turnover 
in the gut lumen means that all cells other than stem cells have a shortlife 
span in this tissue. Active migration accompanies cell differentiation to ensure 
that epithelial cells in the gut are usually replenished within 3-5 days. As a 
consequence, normal gut maintenance requires that cell-cell and cell- 
substrate adhesion along with migration, proliferation and differentiation are 
balanced and maintained at all times. Mutations in APC are likely to affect all 
of these processes, which may explain why mutations in this single gene are 
sufficient to initiate the development of cancer.
1.3.6 MUTYH associated polyposis (MAP)
MAP (MIM 608456) is an autosomal recessive colorectal adenoma and 
carcinoma predisposition syndrome identified in 2002 by Al - Tassan et al, and 
is thought to be responsible for -1%  of all CRCs (Fleischmann et al, 2004). 
The MAP phenotype closely resembles the AFAP phenotype and presents as 
i) a variable number of polyps, ranging from a few to >100 (Figure 1.8), ii) 
early onset of CRC, iii) an absence of vertical transmission from parent to 
child and iv) sporadic or multiple-case presentations within one generation 
(Sieber et al, 2003; Wang et al, 2004; Croitoru et al, 2004; Gismondi et al, 
2004; Farrington e ta l2005; Balaguer etal, 2007). Clinically, differentiating 
between patients with de novo APC mutation (~20% of all FAP cases) and 
MAP patients can be difficult since there is no family history of polyposis in 
either case (Grady et al, 2003), indeed, Sampson et al (2003) reported that 9 
of 25 patients with MAP had a phenotype indistinguishable from FAP. 
Duodenal adenomas that are frequently present in FAP also appear to be the
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most common extracolonic feature of MAP (Aretz et al, 2006) although other 
extracolonic manifestations have been reported in MAP patients but not at 
significant frequencies.
The identification of MAP arose from investigating several siblings from a 
single family presenting with an AFAP-like phenotype, but in whom a germline 
truncating APC mutation was not identified. Somatic APC mutation analysis in 
colorectal tumours from the affected siblings revealed that the majority were 
G:C to T:A transversions resulting in stop codons. The pattern of APC somatic 
mutations was then linked to functionally compromising biallelic germline 
MUTYH mutations in the affected cases (Al-Tassan et al, 2002), an 
association that was subsequently confirmed in further unrelated MAP cases 
(Jones et al, 2002). A mouse model has also shown that homozygous Mutyh 
deficiency increases intestinal tumourigenesis in ApcP™* mice and some 
polyps from these mice harboured G:C to T:A transversions resulting in 
termination codons (Sieber et al, 2004). A specific k-ras mutation has been 
identified in some MAP adenomas and is associated with increased dysplasia. 
The G12C activating mutation is the result of a G:C to T:A transversions 
(Lipton et al, 2003; Jones et al, 2004).
1.3.7 The MUTYH gene
The MUTYH gene is located on the short arm of chromosome 1, between 
p32.1 and p34.3 and consists of 16 exons and is 7.1 kb in size (Slupska etal, 
1999). Three major mRNA transcripts (a, p and y) which differ in their 5’ 
sequence have been observed, indicating that MUTYH has three independent 
transcription initiation sites (Ohtsubo et al, 2000). Each transcript can be 
alternatively spliced giving rise to at least ten different mature transcripts.
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1.3.8 Domains of the MUTYH protein
In its most abundant isoform as encoded by transcript a3, MUTYH is a 59kDA 
protein (Slupska 1999; Tsai-Wu etal, 2000) and exhibits 41% similarity to the 
MutY homologue in Eschericia coli (E. coli). MUTYH consists of several 
functional domains enabling it to interact with several protein partners and to 
bind directly to DNA (Figure 1.10). Located at the N-terminus of the protein 
the replication protein A (RPA) binding domain facilitates binding of RPA via a 
conserved motif which includes the sequence K/RXK/R (Parker et al, 2001). 
Several other domains within the N-terminus have been identified as highly 
conserved motifs due of their homology to MutY. These include the DNA 
minor groove motif, the pseudo helix-hairpin-helix (HhH) motif, the HhH motif, 
the iron-sulphur cluster and the adenine recognition motif (Guan et al, 1998). 
The MSH6 binding domain is a 23 amino add region at the centre of the 
protein that enables interaction with MutS homologue 6 (MSH6) (Gu et al,
2002). The apurinic/apyramidinic endonudease 1 (APE1) binding site 
contains the SGXXDV motif (Parker et al, 2001) and overlaps with the recently 
identified Hus1 binding site (Shi et al, 2001). The N-terminus also contains the 
mitochondrial localisation signal (MLS) motif and a functional NLS motif is 
found at the C-terminus (Takao et al, 1999). Parker et al (2003) identified six 
putative MUTYH serine phosphorylation sites; three in the N-terminal region 
(codons 9,49 and 85) and the remaining 3 within the C-terminal half of the 
protein (codons 349,494 and 504).
34
Figure 1. 9 Gross appearance of colon from a patient with MAP showing few colorectal adenomas 
(indicated by back arrows). Pictures courtesy of Prof. J. Sampson, Cardiff University, UK
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Figure 1.10 Functional domains of the MUTYH protein. As encoded by MUTYH transcript a1.
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1.3.9 MUTYH Function
MUTYH is a DNA glycosylase that helps maintain genomic stability through its role in 
the base excision repair (BER) of oxidative DNA damage. Oxidative damage 
mediated by reactive oxygen species (ROS) has been linked to the initiation and 
progression of cancer (Klaunig and Kamendulis, 2004), implicated in 
neurodegenerative disorders and associated with the cellular deficiencies brought 
about by ageing. ROS such as hydrogen peroxide, superoxide and hydroxyl radicals 
are by-products of aerobic metabolism and endogenous inflammatory responses as 
well as products of environmental exposure to ionizing radiation, transition metals, 
chemical oxidants and free radicals. ROS are known to attack the lipids, proteins, 
and nucleic adds of cells and tissues (Lu et al, 2001; O'Reilly 2001). Oxidative DNA 
damage can cause numerous lesions because of the DNA base modification, 
apurinic/apyrimidinic sites, and DNA protein cross-links which can lead to single 
strand breaks.
In humans, the frequency of oxidative damage to DNA is estimated to be 104 lesions 
per cell, per day (Ames and Gold, 1991). The extent of the damage can be assessed 
through a number of intracellular mechanisms, leading to either programmed cell 
death if the damage is extensive or repair without consequence to the cell if the 
damage is minimal. If aberrant or modified bases are not repaired before DNA 
replication, they can subsequently be misread, resulting in mutations (Lu etal, 2001).
1.3.10 The BER process
BER is the main mechanism protecting the cell against oxidative DNA damage 
(Hazra et al, 2003). Lesions resulting from methylation, deamination and 
hydroxylation can also be repaired through this pathway (Hoeijmakers 2001). As 
shown in Figure 1.11, the damaged base is recognised by a DNA glycosylase and 
cleaved from the sugar-phosphate backbone, resulting in an apurinic/apyrimidinic 
(AP) site. Some glycosylases have an AP lyase activity and cleave the sugar- 
backbone 3’ to the AP site. The APE1 endonuclease then processes the DNA in 
preparation for DNA synthesis. In the absence of a glycosylase lyase activity, APE1 
prepares the DNA for synthesis by cleaving the sugar-phosphate backbone 5’ to the 
AP site (Wilson and Bohr, 2007). Recently, Wiederhold et al (2004) described an 
APE 1-independent BER pathway in which the NEIL1 or NEIL2 DNA glycosylase
cleaves the DNA at the AP site, leaving a 3’ phosphate group which is then removed 
by polynucleotide kinase (PNK) enabling DNA synthesis (Wiederhold, L. etal, 2004). 
The repair pathway involving monofunctional glycosylases then diverges into either 
short-patch or long-patch BER (Wilson and Bohr, 2007). If long-patch repair is 
carried out, DNA polymerase p incorporates the first nucleotide but elongation is 
carried out by DNA polymerase 5/e. A two or more nucleotide repair patch is 
synthesised from the damaged site, facilitated by proliferating cell nuclear antigen 
(PCNA) and replication factor C (RFC). Flap endonuclease 1 (FEN1) then removes 
the displaced DNA ‘flap’ and the nick is ligated by DNA ligase I. In short-patch repair, 
DNA polymerase P cleaves the sugar-phosphate backbone 3’ to the AP site through 
its phosphodiesterase activity and fills the one nucleotide gap. The remaining nick is 
sealed by DNA ligase III/XRCC1 (X-ray repair cross complementing 1) heterodimer. 
DNA synthesis in repair pathways initiated by glycosylases with AP lyase activity or 
the NEILs is also short-patch and carried out by DNA polymerase p, with the nick 
ligated by the DNA ligase III/XRCC1 complex. The choice of short patch or long 
patch repair is dependent on the DNA glycosylase recruited, type of DNA damage 
present and the cell cycle phase. Direct single strand breaks induced by ROS can 
also be repaired by either short-patch or long-patch BER once their termini have 
been prepared for DNA synthesis by the addition of a 3’ hydroxyl group and a 5’ 
phosphate group (Fortini and Dogliotti 2007).
1.3.10.1 8-oxoG repair
The DNA base guanine (G) is particularly susceptible to oxidative damage because 
of its low redox potential (Neeley and Essigmann, 2006). 8-oxo-7, 8 
dihydro2’deoxyguanosine (8-oxoG) is one of the most stable deleterious products of 
oxidative DNA damage and is often used as a cellular biomarker to indicate the 
extent of oxidative stress in tissues (Klaunig and Kamendulis, 2004) and has been 
detected in high concentrations in breast, lung and kidney cancers (Okamoto et al, 
1994; Olinski etal, 1992; Malins and Haimanot, 1991; Jaruga etal, 1994).
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Figure 1.11 Base excision repair of a damaged DNA base. Implementation of short- or long- 
patch repair is determined by the DNA glycosylase recruited, type of DNA damage and cell- 
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DNA replication with 8-oxoG lesions present in the template strand results in 
G:C—>T:A transversion mutations in the DNA daughter strands (Neeley and 
Essigmann, 2006) since 8-oxoG functionally mimics thymine (T) and readily mispairs 
with adenine (A) residues during replication. This has been observed to occur at a 
rate of between five and 200 times greater than the incorporation of cytosine (C) 
opposite 8-oxoG lesions (Shibutani etal, 1991). The BER pathway is an important 
defence mechanism initiated by lesion-specific DNA glycosylases that repair the 
effects of oxidative damage (Swanson et al 1999) and was initially characterised in 
E. coli. The bacterial enzymes MutT, MutM and MutY were identified as having key 
roles (Michaels and Miller, 1992) (Figure 1.12). MutT is a nucleoside triphosphate 
which hydrolyses 8-oxoGTP in the nucleotide pool, preventing its incorporation into 
nascent DNA (Maki and Sekiguchi, 1992). The MutM DNA glycosylase recognises 
and excises 8-oxoG paired opposite cytosine (Boiteux et al, 1992) and MutY is a 
DNA glycosylase responsible for removing adenine residues misincorporated into 
the daughter strand opposite 8-oxoG following replication (Michaels and Miller,
1992). Cytosine is then inserted in place of the excised adenine, resulting in an 8- 
oxoG:C pair which can be repaired by MutM. The MutS DNA glycosylase is part of 
the mismatch repair (MMR) system and can perform the same function as MutY 
(Zhao and Winkler, 2000). Another DNA glycosylase, endonuclease VIII (or Nei) 
provides a backup pathway for 8-oxoG repair as it can excise this damaged base 
from 8-oxoG:C pairs (Blaisdell et al, 1999) from within the nascent strand when 
misincorporated opposite adenine during replication (Hazra etal, 2001). Human 
homologues of mutT, mutM, MutY, MutS and nei have been identified as NUDT1 
(Sakumi etal, 1993), OGG1 (Roldan-Arjona etal, 1997), MUTYH(Slupska etal,
1996), the MSHs (Fishel et al, 1993) and the NEILs (Bandaru et al, 2002) 
respectively.
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1.3.10.2 MutY catalytic mechanism
Bacterial MutY has been characterised more than human MUTYH and as such, has 
provided the majority of the structural and biochemical data on this enzyme. It is a 
member of the helix-hairpin-helix (HhH) super family of proteins which all have a 
conserved catalytic domain containing an HhH motif proceeded by a glycine/proline- 
rich loop and a catalytic residue (Fromme et al, 2004). The N-terminal catalytic 
domain of MutY consists of two modules: a six-helix barrel containing the HhH motif 
and an iron-sulphur cluster (Guan et al, 1998). The C-terminal domain of MutY is 
unique among HhH proteins and is necessary for substrate specificity (Noll et al,
1999)
The mechanism by which MutY searches for mismatches within the vastness of the 
entire genome remains unknown, but several models have been proposed. Boon et 
al (2003) suggested a model of long range scanning for mismatches via DNA- 
mediated charge transport chemistry. Non-specific binding of MutY to DNA causes 
the oxidation of its iron-sulphur cluster and loss of an electron which is then 
transported along the DNA. This is eventually intercepted by a second MutY 
molecule, already non-spedfically bound and its iron-sulphur cluster similarly 
reduced, promoting dissociation of the protein from the DNA. If a mismatch is 
encountered between the two MutY molecules, the DNA-mediated charge transport 
cannot occur and the protein remains bound to the DNA and progressively diffuses 
to the mismatch. The charge transport process is continuous in the absence of a 
mismatch and may explain why small numbers of MutY molecules can rapidly and 
effectively scan the genome (Boon et al, 2003). Lee et al (2004) proposed a model 
that also required co-operation between MutY molecules. Two MutY monomers 
simultaneously bind around the same region of DNA to form a dimer. The MutY 
dimer slides along the DNA until one of the molecules binds specifically to a 
mismatch resulting in a conformational change occurring in the active monomer and 
DNA (Lee et al, 2004). This is consistent with a report that upon DNA binding, MutY 
assembles into a dimer and that this is the functionally active state (Wong et al,
2003). However in Lee’s model the dimer searches for a mismatch but only the 
active MutY molecule remains bound for catalysis (Lee etal, 2004). The six-helix 
barrel motif interacts with the backbone of the DNA strand containing the 
complementary 8-oxoG residue (Fromme et al, 2004). The C-terminal domain of
MutY confers specificity for 8-oxoG:A mispairs by recognising the 8-oxoG base (Noll 
et al, 1999; Li et al, 2000). Extensive contacts are made with the 8-oxoG strand of 
DNA and the oxidised base itself. 8-oxoG is hydrogen bonded to both the C-terminal 
and catalytic domains, ensuring that adenines correctly paired opposite thymines are 
not excised (Fromme et al, 2004). MutY mainly contacts the 8-oxoG strand and 
interacts with DNA via at least five phosphates and purine bases on either side of the 
mismatch (Lu et al, 1995). A double base flipping mechanism was proposed to 
facilitate recognition of the 8-oxoG:A mispair and aid adenine extrusion into the 
active site (Bernards et al, 2002) but crystal structures of MutY bound to DNA have 
shown that although the DNA is bent and the mispaired adenine is extruded, 8-oxoG 
remains within the helix (Fromme et al, 2004). The HhH and pseudo HhH motifs at 
either end of the DNA binding groove compress the DNA intra-strand phosphate 
diester either side of the mispaired adenine causing the DNA to bend and the target 
base to Hip out1 of the DNA helix, into the active pocket site (Guan et al, 1998).
When MutY binds to an 8-oxoG:A mispair, the 8-oxoG nucleoside changes its 
glycosydic bound conformation from a syn to an anti orientation. The anti 
conformation of 8-oxoG would sterically dash with an adenine base opposite and so 
may also promote flipping of adenine into the active site (Fromme et al, 2004). 8- 
oxoG binding to the C-terminal domain facilitates base-flipping and thus accelerates 
the glycosylase reaction (Noll etal, 1999). The active site pocket is complementary 
to the extrahelical adenine residue, which is deeply sequestered and hydrogen 
bonded by the MutY protein. The catalytic and C-terminal domains interact and allow 
the enzyme to surround the DNA duplex (Fromme et al, 2004). The Hipped-out’ 
adenine leaves a gap in the DNA base stack which may be stabilised by the minor 
groove reading motif. MutY then deaves the N-glycosylic bond through a hydrolytic 
mechanism (Guan etal, 1998).
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1.3.10.3 MUTYH in human BER repair
In humans, the enzymes MTH1, OGG1 and MUTYH constitute the 8-oxoG repair 
pathway, often referred to as the GO repair pathway (Figure 1.13).The human MutY 
homologue, MUTYH, demonstrates glycosylase activity with DNA substrates 
containing the following mispairs: A:G, 2-hydroxyadenine (2-OH-A):8-oxoG; A:8- 
oxoG, 2-OH-A:G and 2-OH-A:A but exhibits little AP lyase activity (Ohtsubo, T. et al,
2000). 2-OH-A is another product of oxidative DNA damage (Lu et al, 2001). OGG1 
is a purine oxidation glycosylase that recognizes and excises 8-oxoG lesions paired 
with cytosine. The repair enzyme MTH1 hydrolyzes oxidized purine nucleoside 
triphosphates such as 8-oxo-dGTP, 8-oxo-GTP, 8-oxo-dATP, and 2-hydroxy-dATP, 
effectively removing them from the nucleotide pool and preventing their incorporation 
into nascent DNA (Fujikawa et al, 1999).
Mutant MUTYH is defective in binding and repair of A:8-oxoG and 8-oxoA:G mispairs 
(Parker et al, 2005). Phosphorylation of serine residues enhances MUTYH repair of 
A:8-oxoG mispairs and may regulate protein-protein interactions (Parker et al, 2003). 
MUTYH interacts with APE1, PCNA and RPA1 suggesting that repair of DNA lesions 
by MUTYH occurs via the long-patch pathway of BER (Parker et al, 2005). Indeed, 
short-patch BER initiated by murine MUTYH is futile and the repair has to proceed to 
the long patch pathway of BER (Hashimoto et al, 2004). MUTYH can interact with 
Hus1 (part of the 9-1-1 DNA damage sensor complex) and may act as an adaptor for 
sensor checkpoint proteins following oxidative DNA damage (Shi et al, 2006).
Nuclear MUTYH co-localises with PCNA at replication foci and levels of MUTYH are 
maximal during S-phase indicating that MUTYH repair may be coupled to replication 
(Boldogh etal, 2001). Consistent with this, DNA replication enhances murine 
MUTYH repair through its interaction with PCNA (Hayashi et al, 2002). The coupling 
of replication and MUTYH repair allows MUTYH to be directed to the daughter 
strand, thereby preventing the A:T to C:G transversions that would arise from 
adenine glycosylase activity on the template strand.
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Figure 1.13 The role of mammalian BER enzymes. MUTYH excises adenine residues incorrectly mispaired with 8-oxoG post­
replication. 0GG1 excises the 8-oxoG lesion and MTH is an 8-oxo-dGTPase that prevents incorporation into nascent DNA.
MUTYH also interacts with the MMR protein MSH6 which forms a heterodimer with 
MSH2. The mammalian MSH2/MSH6 complex can repair 8-oxoG incorporated into 
the daughter strand during replication (Colussi et al, 2002) and A:8-oxoG 
mismatches where the adenine is on the template strand are mainly recognised by 
this complex (Gu et al, 2002). However, it has been reported that MSH2/MSH6 
repair of 8-oxoG incorporated during replication opposite adenine or cytosine is 
inefficient (Larson et al, 2003). Recently Macpherson et al (2005) have shown 
MSH2/MSH6 can efficiently recognise 8-oxoG opposite adenine or cytosine when 
these mispairs lie within repetitive sequences that have undergone a slippage event 
(Macpherson et al, 2005). The MSH2/MSH6 complex binds 8-oxoG:G and 8-oxoG:T 
mispairs efficiently and although such mispairs are rare in vivo, when the oxidised 
base is on the template strand MMR can result in 8-oxoG: A mispairs which are 
recognised by MUTYH (Larson et al, 2003). The MSH2/MSH6 dimer can enhance 
binding of MUTYH to A:8-oxoG mismatches and interactions between these repair 
proteins may help target MUTYH to the daughter strands (Gu et al, 2002). Wong et 
al (2003) proposed a mechanism by which dimeric MutY could determine the level of 
oxidative damage present and remove adenines only present on the nascent strand. 
A:8-oxoG mispairs resulting from incorporation of adenine into the nascent strand 
opposite 8-oxoG are found in isolation and repaired by MutY. However, A:8-oxoG 
mispairs formed as a result of incorporation of 8-oxo-GTP into the nascent strand 
opposite adenine would arise as patches of damage. Wong et al (2003) suggested 
that concurrent binding of two of these mispairs by dimeric MutY would inhibit its 
glycosylase activity, thereby preventing A:T to C:G transversions and allow 
recruitment of more appropriate repair enzymes such as those involved in MMR 
(Wong et al, 2003). Mammalian MUTYH protects its DNA product from OGG1 as this 
DNA glycosylase could excise 8-oxoG opposite the AP site, resulting in a loss of 
informative bases on both strands and a double break strand. MUTYH may encircle 
and tightly bind the DNA duplex much like its bacterial homologue, thus physically 
preventing OGG1 from accessing the DNA (Tominaga et al, 2004).
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1.3.11 Germline mutations in MUTYH
To date, approximately 85 mutations have been described in MAP patients from 
Western populations (Cheadle and Sampson; 2007). Around thirty percent are 
predicted result in a truncated protein and comprise of nonsense, small 
insertion/deletions and splice site variants (Fig. 1.14). Additionally, 52 missense 
variants and three small inframe insertion/deletions have been reported and are 
distributed throughout the gene. The Y165C (Tyr165Cys) and G382D (Gly382Asp) 
nonsynonymous mutations account for approximately 73% of all MUTYH mutations 
reported in Caucasian MAP patients but this is likely to be an overestimation as 
many groups search specifically for these mutations. The Y165C mutation is located 
in the pseudo HhH region that is involved in mismatch specificity and flipping of the 
adenine into the base specificity pocket whilst the G382D variant is located in the C- 
terminal domain involved in 8-oxoG recognition.
To-date, a limited amount of functional characterisation of a few MUTYH mutations 
has been carried out. Al-Tassan et al (2002) initially showed that the Y82C and 
G253D MutY proteins in E. coli (homologues of Y165C and G382D variants of 
human MUTYH, respectively) were partially defective in removing mispaired adenine 
bases. Wooden et al (2004) reported that recombinant Y165C and G382D MUTYH 
proteins were totally devoid of glycosylase activity. Parker et al (2005) confirmed 
these findings using lysates derived from lymphoblastoid cell lines from MAP 
patients who expressed either the Y165C and G382D variants as well as the 
1103delC mutation to show they exhibited lowered DNA binding and adenine 
cleavage activities with heteroduplex oligonucleotides containing A:8-oxoG and 8- 
oxoA:G mispairs. Bai et al (2005) characterised the R227W and V232F MUTYH 
mutants known to lie within the putative hMSH6 binding domain and showed that 
they were also defective in both DNA substrate binding and glycosylase activity 
whilst observing that physical interaction with the hMutSa heterodimer was 
unaffected. Both of these mutants also failed to complement bacterial MutY 
deficiency when expressed in E coli cells in vivo. The R231L nonsynonymous variant 
has also been shown to be severely defective in DNA substrate binding and in 
adenine removal activity and whilst the variant showed normal binding activity with 
hMutSa, it did not complement MutY deficiency in E coli. (Bai et al, 2007).
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Unlike other genes involved in inherited CRC predisposition, somatic mutations in 
MUTYH do not appear to be involved in sporadic colorectal tumourigenesis. No 
somatic MUTYH mutations were found in 75 sporadic CRCs and functional MUTYH 
mRNA and protein were detected in all of the 35 CRC cell lines examined, indicating 
that epigenetic silencing was not occurring (Halford et al, 2003).
1.3.12 Hereditary non-polyposis colorectal cancer (HNPCC)
HNPCC (MIM 114500) is the most common hereditary form of CRC, accounting for 
2-5% of cases. HNPCC, also known as Lynch Syndrome, is an autosomal dominant 
inherited disease (Potter, 1999) predisposing to CRC and characterised by an early 
age at onset (average age is typically 44 years compared to an average age of 64 
for sporadic CRC in the general population). HNPCC related CRCs have a 
propensity to develop in the right colon with the majority of carcinomas probably 
develop from pre-existing adenomatous polyps. Despite the development of pre- 
cancerous adenomas in HNPCC, individuals do not exhibit the same florid polyposis 
phenotype associated with FAP (Lynch et al, 1991).
HNPCC patients can exhibit synchronous and metachronous CRCs as well as other 
primary extracolonic malignancies, such as carcinomas of the endometrium, 
stomach, small intestine, liver and biliary tract, pancreas, ovary, brain and 
transitional cell carcinoma of the urethra and renal pelvis (Bellacosa etal', 1996, 
Mecklin and Jarvenin, 1991; Watson and Lynch, 1993); predisposed individuals have 
lifetime risk of 50-60% of developing colorectal carcinoma, 50-60% of endometrial 
carcinoma and below 15% risk for other tumours (Watson and Lynch, 1991; Aamio 
etal, 1995). Muir Torre syndrome (MIM 158320) is a rare autosomal dominant 
condition considered to be a variant of HNPCC and is characterised by the 
development of primary malignancies and sebaceous gland tumours. (Lynch and de 
la Chapelle, 2003). Turcots Syndrome (MIM 276300) is also considered to be a 
variant of HNPCC despite the full molecular pathogenesis of the disease being 
undetermined. It is characterized by the development of colorectal adenomas and 
central nervous system tumours such as medulloblastoma and gliomas.
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identified in MUTYH. Approximate positions of putative functional domains are indicated in relation to the MUTYH coding region. Missense variants proven or likely to 
be pathogenic are highlighted in bold (1: data demonstrating functionally compromised, 2: rare variant found in combination with a proven MUTYH mutation in a 
patient with CRAs, 3: rare variant found in a homozygous state in a patient with CRAs), those that are unlikely to pathogenic are italicised (4:common polymorphism, 
5: identified in cases with biallelic MUTYH mutations) and those that are undefined are in regular font (6: rare variant found in combination with another MUTYH 
mutation in a patient with CRC under the age of 60 and with 2 or more affected family members, 7: somatic mutation in gastric cancer, ?: no clear evidence for 
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1.3.13 DNA mismatch repair
HNPCC and its variants arise through germline mutations in one of several genes 
resulting in impaired DNA MMR function (Berends et al, 2002; Bronner et al, 1994; 
Leach etal, 1993; Liu etal, 1994; Nicolaides etal, 1994; Papadopolous etal, 1994) 
(Table 1.3). Each of these genes encodes a protein involved in MMR, a complex 
enzymatic proofreading system that corrects base pair mismatches and insertion- 
deletion loops that result in single base substitutions and microsatellite instability 
respectively. Such errors occur because of DNA polymerase slippage during DNA 
replication (Peltomaki, 2001).
Syndrome Mode of 
Inheritance
Gene/locus
Hereditary non-polyposis colorectal cancer AD MSH2, 2p21 
MLH1, 3p21-23 
MSH6, 2p21 
PMS2, 7p22 
(MLH3, 14q24.3)
Muir-Torre Syndrome AD MSH1, MLH1
Turcot’s syndrome AD MLH1, MSH2, 
PMS2, MSH6
Table 1.3. Genes causing predisposition to HNPCC and known variants. AD: 
autosomal dominant.
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Detection of DNA damage is the initial process for MMR (Figure 1.13) and in humans 
this role is carried out by two heterodimeric complexes: 1) MSH2/ MSH6 which is 
responsible for recognising single base mismatches and small insertion deletion 
loops (<12 unpaired bases) and 2) MSH2/MSH3, which predominantly recognises 
insertion deletion loops (small or large) (Kolodner 1993; Marsischky etal, 1996; 
Greene et al, 1997). Subsequent to this, a MLH1/PMS2 heterodimer is recruited to 
the MSH2 that is already bound to mispaired bases (Jascur and Boland 2006; Plotz 
et al, 2006). The MLH1/MLH3 heterodimer may function in repair of MSH2/MSH6 
substrates, but it is not thought to play a major role in MMR, in vivo (Cannavo et al, 
2005). A number of other proteins are involved in MMR and these include DNA 
polymerase 5, RPA, PCNA, RFC, exonuclease I, FEN1 (RAD27), DNA polymerase 
£ ad associated exonucleases (Syngal et al, 1999). Repair of the mismatched DNA 
proceeds by activating exonulcease mediated degradation of DNA from a "nick” that 
is a distance of up to 1-2 kb from the mismatch (Sancar 1999). Degradation 
continues until the mismatched base is removed. The resulting long excision tract is 
filled in by DNA polymerase 5 which inserts the correct nucleotide into the sequence 
and the resulting nick is ligated.
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Figure 1.15. The human mismatch repair pathway.
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1.3.13.1 Germline mutations in MMR genes
Germline mutations in MSH2 and MLH1 account for 38% and 49% of reported 
HNPCC cases respectively. The other four genes account for approximately 13% of 
cases (Peltom&ki and Vasen, 2004; Peltomaki, 2001). Germline mutations identified 
in MMR genes do not show a propensity to occur within specific regions or (hot 
spots’ and the majority of mutations have been reported only once. The nature of the 
reported germline mutations is heterogeneous and includes nonsynonymous, splice 
site, nonsense, small deletions and large deletions or insertions (Peltomdki and 
Vasen, 2004; Papadopoulos and Lindblom, 1997). The intragenic position of the 
germline mutation does not affoct the phenotype (de la Chapelle 2004) however 
MSH2 is more frequently mutated in patients presenting with extracolonic 
tumours(Lynch et al, 2006). An MSH6 germline mutation accounts for approximately 
10% of HNPCC associated germline mutations and is associated with the 
development of CRC at a later age when compared with MSH2 or MLH1 mutations 
(Peltomaki 2005). Women with a MSH6 mutation have a high risk of endometrial 
cancer (Wijnen et al, 199). Mutations in PMS2 are less frequent and were thought to 
result in severe, early onset HNPCC often associated with brain tumours (Turcot 
syndrome) (de la Chapelle 2004). Recently however, Hendriks et al (2006) reported 
that patients with a germline PMS2 mutation showed a milder phenotype than those 
with mutations in either MLH1 or MSH2 (Hendriks et al, 2006). Mutations in MLH3 
have been reported (Wu etal, 2001) but their contribution to HNPCC is unclear 
(Cannavo et al, 2005). Germline mutations in MSH2, or less frequently MLH1 (Ponti, 
and Ponz de Leon, 2005) and MSH6 (Arnold et al, 2007), can cause Muir-Torre 
syndrome and mutations in MSH2, MLH1 or PMS2 are associated with Turcot 
syndrome (Lucci-Cordisco et al, 2003). Homozygotes for either MSH2 (Whiteside et 
al, 2002), MLH1 (Wang et al, 1999) or PMS2 (De Vos et al, 2004) point mutations 
are rare and have a severe phenotype with haematological malignancies and some 
skin characteristics of neurofibromatosis type 1 (NF1). Compound heterozygotes for 
PMS2 point mutations have a phenotype consist with Turcot syndrome (De Rosa et 
al, 2000). Recently, Will e ta l(2007) described a large (400kb) homozygous PMS2 
deletion in a patient with 10 CRCs, 35 colorectal adenomas and duodenal cancer in 
his twenties. The patient had no brain tumour but had mental retardation and cafo au 
lait spots. This case shows that gross homozygous mutations in a MMR gene can 
result in a severe phenotype uncharacteristic of HNPCC (Will et al, 2007).
1.3.13.2 Somatic mutations in HNPCC
Somatic inactivation can occur via a deletion (LOH) (Parsons et al, 1993), mutation 
(Hemminki et al, 1994) or methylation of CpG islands in the MLH1 promoter 
(Kuismanen et al, 2000; Kuismanen et al, 1999). A somatic inactivating mutation in 
the inherited wildtype allele of the MMR gene results in defective MMR (Yuen et al, 
2002). The MMR genes behave like tumour suppressor genes since cells 
heterozygous for MMR gene mutation function normally (Parsons et al, 1993) but 
somatic inactivation of the wild type allele leads to loss of tumour suppressor 
function and is required for tumourigenesis (in accordance with Knudson’s 
hypothesis). Therefore, errors normally corrected by MMR are left unrepaired, 
leading to a mutator phenotype which increases the chance of mutations occurring in 
growth regulatory genes (Ionov etal, 1993, Fishel etal, 1993).
MMR deficiency increases mutation rates in tumour cells by 100-1000-fold 
compared to normal cells, so the development of CRC at an early age and 
accelerated tumour progression may be explained by the accumulation of replication 
errors over the first 4 decades of life. Also, de Jong et al (2004) identified that 
mutations in MMR genes also predisposed carriers to the development of CRAs 
effectively increasing the predisposition to CRC since adenomas may be considered 
carcinoma precursor lesions
1.3.14 Microsatellite instability (MSI)
MSI is a consequence of defective MMR (Thibodeau etal, 1993) and colorectal 
tumourigenesis in HNPCC. Microsatellites are short repetitive DNA motifs of 1 -  6 
nucleotides in length that are repeated about 1 0 -6 0  times (Beckmann and Weber, 
1992). They are present throughout the genome but are more common in non­
coding regions. They are highly polymorphic throughout the population, but uniform 
in the DNA of any one individual (Beckmann and Weber, 1992).
MSI is observed in the majority of tumours in HNPCC cases, whilst only being 
detected in approximately 10-15% of sporadic CRCs (Thibodeau etal, 1993; Ionov 
et al 1993). Tumours deficient in MLH1, MSH2 or PMS2 show MSI at no less than 
40% of loci and are termed MSI-high (Peltomaki 2005; Umar 2004), whereas 
tumours from patients with MSH6 mutations can have lower levels of instability
54
(Peltomdki 2005). Some sporadic tumours also display MSI but unlike HNPCC 
tumours, their MMR deficiency is most often the result of hypermethylation of the 
MLH1 promoter (Kuismanen et al, 2000).
MSI contributes to the development of cancer when microsatellites within coding 
regions of genes are disrupted i.e. through DNA slippage or ffameshift mutations. 
TGFpRU (transforming growth factor p receptor II), TCF-4 (T-cell transcription factor), 
the apoptosis related genes BAX, CASPASE-5 and AXIN2 are all susceptible to MSI 
and implicated in the development of various carcinomas (Duval et al, 1999;
Rampino etal, 1997; Liu etal, 2000; Markowitz etal, 1995; Myeroff etal, 1995).
1.4 Aims of this thesis
To address the potential role of rare inherited nonsynonymous variants of APC in 
inherited predisposition to CRAs.
To investigate the effect of the APC nonsynonymous variant E1317Q on 
mechanisms of somatic mutagenesis in colorectal tumourigenesis; specifically to 
examine itseffect on targeting of ‘2nd hif somatic mutations towards the MCR of APC.
To determine the extent to which tumourigenesis in MAP is driven by deficient BER 
activity and the subsequent mutator phenotype.
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Chapter Two: Materials and Methods
2.1 Suppliers
Consumables and equipment used throughout this study were purchased from the 
following companies:
Abgene (Surrey, UK),
Ambion (Cambridgeshire, UK),
GE Healthcare (Buckinghamshire, UK),
Anachem (Bedfordshire, UK),
Applied Biosystems (Cheshire, UK),
Beckman Coulter (Buckinghamshire, UK),
Bibby Streilin (Staffordshire, UK),
Bioquote (Yorkshire, UK),
Biorad (Hertfordshire, UK),
Cell Signalling Technologies (Danvers, MA, USA),
Corning CoStar (The Netherlands),
Difco Laboratories Ltd (Surrey, UK),
DuPont Instruments (Hertfordshire, UK),
Eppendorf (Cambrdgeshire, UK),
Eurogentec (Hampshire, UK),
European Collection of Cell Cultures (Salisbury, UK),
Fisher Scientific (Leceistershire, UK),
Fluka Biochemika (Dorset, UK),
IKA (Staufen, Germany),
Imgenex (San Diego, CA, USA)
Invitrogen Life Technologies (Strathclyde, UK),
Jencon-PLS (Bedfordshire, UK),
Kendro Laboratory Products (Hertfordshire, UK),
Labtech International (East Sussex, UK),
Leica (Wetzlar, Germany),
Millipore (Hertfordshire, UK),
MJ Research (Massachusetts, USA),
MWG Biotech (Buckinghamshire, UK),
New England Biolabs (Hertfordshire, UK),
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Olympus Optical (London, UK),
PALM (Bemried, Germany),
Promega (Hampshire, UK),
Qiagen (West Sussex, UK),
Roche Biochemicals (East Sussex, UK),
Sartorius (Epsom, UK),
Santa Cruz Biotechnologies (Santa Cruz, CA, USA),
Sigma Ltd (Dorset, UK),
StarLab (Milton Keynes, UK),
Starstedt (Germany),
Stratagene (California, USA)
Thermo Electron Corporation (Hampshire, UK),
VWR International Ltd (Dorset, UK)
2.2 Materials
2.2.1 Chemicals
Analytical grade chemicals were purchased from either Sigma Ltd or Fisher Scientific 
unless otherwise stated.
2.2.2 Nucleic acid extraction and purification
QIAamp DNA Micro and QIAprep Mini kits were purchased from Qiagen. Trizol 
reagent was obtained from Invitrogen Life Technologies. ON A-free kit was obtained 
from Ambion Inc.
2.2.3 First strand synthesis
Superscript III First-Strand Synthesis System for RT-PCR was purchased from 
Invitrogen Life Technologies.
2.2.4 PCR and PCR purification
AmpliTaq Gold DNA polymerase and GeneAmp PCR buffer were obtained from 
Applied Biosystems. Deoxynucleotidetriphosphates (dNTPs) were purchased from 
GE Healthcare. HPSF purified oligonucleotide primers were supplied by either 
MWG-Biotech or Eurogentec. Exonuclease 1 was purchased from New England
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Biolabs and Shrimp alkaline phosphatase as supplied by GE Healthcare 
respectively. QIAquick PCR purification kit was obtained from Qiagen.
2.2.5 Electrophoresis
Multipurpose agarose was purchased from Roche. Ethidium bromide was supplied 
by Fluka Biochemika whilst the 100bp and 1kb DNA ladders were supplied by New 
England Biolabs and Invitrogen Life Sciences, respectively.
2.2.6 Sequencing
BigDyeTerminator Cycle Sequencing Kit (Version 3.1), POP6 polymer, HiDi 
Formamide and Genescan 500-ROX size standard were all supplied by Applied 
Biosystems. Montage SEQge sequencing reaction clean up kits were obtained from 
Millipore and capillary electrophoresis running buffers were purchased from Sigma.
2.2.7 Antibodies
All antibodies were purchased from Cell Signalling Technology unless otherwise 
stated.
2.2.8 Protein purification and detection
Protein G-Sepharose beads were obtained from GE Health. Nupage Novex 3-8% 
Tris-Acetate Gels, Novex Sharp pre-stained protein ladders, SDS Running buffer 
and nitrocellulose transfer membranes were obtained from Invitrogen Life 
Technologies. Enhanced chemiluminescence (ECL) analysis system was purchased 
from GE Health.
2.2.9 Restriction enzymes
All restriction endonucleases were supplied, along with the appropriate buffer and 
BSA, by New England Biolabs.
2.2.10 Expression vector
The pCMV-APC vector contains a full length human APC cDNA under the control of 
a cytomegalovirus promoter and was a kind gift from B. Vogelstein at Johns Hopkins 
University, Baltimore, USA.
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2.2.11 Site directed mutagenesis
Quickchange XL Site Directed - Mutagenesis kit (which included PfuTurbo DIMA 
polymerase and Dpnl restriction endonuclease) was purchased from Stratagene.
2.2.12 Cloning
pGEM-T Easy Vector System I was obtained from Promega and subcloning 
efficiency DH5a chemically competent Escherichia coli (E. Co//) cells were obtained 
from Invitrogen Life Technologies. Tryptone, yeast extract and agar were supplied by 
Difco Laboratories Ltd. Ampicillin, X-gal (5-bromo-4-chloro-3-indoyl-D-galactoside) 
and IPTG (isopropyl-P-D-thio-galactopyranoside) were obtained from Sigma Ltd.
2.2.13 Clinical Material
All tissue and blood samples were obtained with patient consent and ethical approval 
for research in accordance with guidelines of the Welsh Polyp study.
2.2.14 Cell lines
The SW480 colon cancer cell line was obtained from the European Collection of Cell 
Cultures (ECACC). Primary cell lines were established in-house from clinical 
biopsies.
2.3 Equipment
2.3.1. Plastics and glassware
Sterile Gilson pipette tips were supplied by StarLab. RNase- and DNAse-free sterile 
barrier tips were obtained from Promega. Distristrips and sterile tips for multi-channel 
pipettes were from Anachem. Sterile 5ml, 10ml and 25ml stripettes were from 
Corning CoStar. 0.65ml, 1.5ml and 2.0ml plastic eppendorfs were supplied by 
Bioquote and 1.5ml microcentrifuge tubes were supplied by Fisher scientific. 96 well 
Thermo-fast PCR reaction plates were obtained from Thermo Electron Corporation 
whilst adhesive PCR sealing sheets, 0.2ml plastic strip tubes and 96 well Thermo­
fast skirted detection plates were purchased from ABgene. Sterile universals and 
petri dishes were obtained from Bibby Sterilin and Starstedt respectively. Glass 
flasks and beakers were provided by Jencon-PLS or Fisher Scientific. Optilux 96-well
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luminometer plates were purchased from VWR International. Tissue culture flasks 
(T25, T75 and T125) were purchased from Nunc.
2.3.2 Laser microdissection
Laser capture microdissection was carried out using the PALM Microlaser system 
and visualised using the PALM Robo software.
2.3.3 Thermocycling
Thermocycling was carried out using either an MJ Research DNA Engine Tetrad 
PTC-225 or an Applied Biosystems GeneAmp 9700 for PCR and RT-PCR 
respectively.
2.3.4 Electrophoresis
DNA electrophoresis was carried out using a Horizon 11.14 gel tank from Invitrogen 
Life Technologies. Visualisation of ethidium bromide stained gels was achieved 
using a BioRad GelDoc XR transluminator. Protein gel electrophoresis was carried 
out using NuPAGE Novex Tris-Acetate Gels and the XCell SureLock Mini horizontal 
gel tank from Invitrogen Life Technologies. Power packs were supplied by BioRad.
2.3.5 Other equipment
DuPont Instruments supplied the Sorvall RT6000B refrigerated centrifuge and the 
Sorvall Legend RT centrifuge was provided by Kendro Laboratory Products. The 
minishaker MS2 was obtained from IKA. The Biofuge pico centrifuge and the vortex 
genie 2 were obtained from Jencon-PLS. Sartorius supplied the B1200 top pan 
balance. Quantitation of DNA and RNA was carried out using the NanoDrop ND- 
1000 spectrophotometer (Labtech International). The Olympus BX51 BF fluorescent 
microscope with an attached mercury lamp CCD (charge coupled device) camera 
was obtained from Olympus Optical.
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2.3.6 Software
Fluorescent images were analysed using AxioVision software from Carl Zeiss Vision. 
Statistics and graphing was carried out using Minitab 15, Microsoft Excel and 
SPSS16.
2.4 Methods
2.4.1 General reagents
All solutions were made using MilliQ water and autodaved at 15lb/sq.in at 121 °C for 
40 minutes where necessary.
TAE buffer: 40mM Tris-acetate, 1m MEDTA pH8
2.4.2 Freezing and sectioning clinical samples
Clinical samples were processed immediately after pathological investigation. Tissue 
was placed onto cork disks and covered with OCT embedding medium. Disks were 
snap frozen by being plunged into liquid nitrogen-cooled isopentane until frozen and 
stored in cryotubes at -70°C. Frozen sections were routinely sectioned at 10pm on a 
Bright cryostat and placed onto poly-L-lysine and UV treated (254nm) PALM 
membrane covered glass slides. Sections were air-dried at room temperature for 2 
hours and stored at -20°C.
2.4.3 Laser capture microdissection (LCM)
Laser micromanipulation provides microscopic high-resolution control of sample 
composition by enabling the selection or rejection of user defined areas. For LCM, 
snap-frozen tissues were sectioned as detailed above and stained using toludene 
blue by immersion of a dean slide into solution for 2 seconds. Following a wash with 
water, sections were passed through 50%, 70% and 100% ethanol for 15 seconds 
and either air dried overnight or for 1 hour at 37°C in. A pulsed ultra-violet laser is 
interfaced into the microscope and focused through an objective. The laser cuts the 
tissue without the heating of adjacent material and results in a dear-cut gap between 
the desired sample area and the surrounding tissue. After microdissection, the 
isolated spedmens are ejected out of the object plane and catapulted directly into 
the cap of a microfuge tube containing 1pl of mineral oil positioned above the slide. 
DNA was extracted from their tissue samples using the QIAamp DNA micro kit.
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2.4.4 DNA extraction from laser microdissected tissue
DNA was extracted from laser captured tissue using the QIAamp DNA micro kit. 
Tissue was catapulted onto the lids of 0.6ml tubes. Forty micro litres of buffer ATL 
(contents trade secret, CTS) and 10pl of proteinase K were carefully placed into the 
lid of the tube and the tubes were left inverted at room temperature for ~3 hours. 
After the tissue was digested, 50pl of buffer AL (CTS) was added to the lysate and 
incubated at 70°C for 10 minutes. Fifty micro litres of 100% ethanol was added and 
the solution was applied to the QIAamp micro silica gel based spin column and 
centrifuged at 13,000 rpm for 1 minute. The column was transferred to a clean 
collection tube and 500pl of wash buffer AW1 (CTS) was added. The column was re- 
centrifuged at 13,000 rpm for 1 minute. The eluate was discarded before a second 
wash was carried out using 500pl of buffer AW2 (CTS). The column was re­
centrifuged at 13,000 rpm for 3 minutes followed by an extra 1 minute spin in an 
empty collection tube to remove residual ethanol. DNA was eluted into ~40pl of 
DNAse free water by incubating for 1 minute at room temperature and centrifuging at 
13000 rpm for 1 minute into a dean collection tube. Samples were stored at -20°C.
2.4.5 RNA extraction from adherent cell lines
Prior to RNA extraction adherent cell lines were washed 3 times using cold PBS. 
Samples were incubated for 5 minutes at room temperature in 1ml of Trizol reagent. 
Nought point two millilitres of 100% chloroform was added and gently agitated for 30 
seconds before further incubation for 5 minutes at room temperature. Samples were 
transferred into 1.5ml eppendotfs and centrifuged for 15 minutes at 12,000 x g at 
4°C. The aqueous phase of the solution was transferred to a fresh eppendorf (the 
remainder discarded) and RNA predpitated by addition of 500ml of isopropanol. The 
sample was then incubated at room temperature for 10 minutes and centrifuged for 
10 minutes at 12000 x g at 4°C to provide a translucent RNA pellet. The supernatant 
was carefully discarded and the pellet washed with 1 ml of 75% ethanol. The sample 
was then centrifuged at 7,500 x g for 5 minutes at 4°C and the subsequent 
supernatant discarded. The remaining pellet was air dried for 10 -  20 minutes and 
re-suspended in diethylene pyrocarbonate (DEPC) treated RNase Free H20 before 
being quantified.
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2.4.6 Quantification of nucleic acids
The concentration of eluted DNA and RNA samples was achieved using ultraviolet 
(UV) spectrophometry at wavelengths of 260nm and 280nm to determine the amount 
of DNA or RNA present and establish endogenous protein content. An absorbance 
ration of 1.8 at 260nm:280nm was used as an indicator of high sample purity (i.e. 
little contamination).
2.4.7 Polymerase chain reaction (PCR)
PCR allows the specific in vitro amplification of a defined DNA target sequence in an 
exponential manner. Double stranded DNA templates are heat denatured and 
oligonucleotides bind specifically to complementary target sites on each strand. 
Thermostable DNA polymerases extend the primers in the 5’ to 3’ direction by 
incorporating dNTPs to create a complementary DNA strand. This cycle is repeated 
20 -  40 times enabling newly synthesised DNA molecules to be used as templates 
at each new round. (Mullis et a/, 1986).
Complimentary oligonucleotide pairs were designed to have melting temperatures 
2°C of each, to be between 15 and 25 nucleotides in length, lacked repetitive motifs 
and had little predicted dimerization or secondary structure formation.
For standard PCR, 25ng template DNA, 0.25mM dNTPs, 25pmol forward and 
reverse primers, 2pl 10X GeneAmp PCR buffer (100mM Tris-HCI, pH 8.3, 500mM 
KCI, 15mM MgCfe, 0.01% wN gelatin), and 0.5U AmpliTaq Gold DNA polymerase 
were used in a total volume of 20pl. Cycling conditions were 95°C for 12 minutes, 
followed by 35 cycles of 95°C for 30 seconds, annealing temperature (52°C - 60°C) 
for 30 seconds, 72°C for 30 seconds and a final elongation step of 72°C for 10 
minutes.
A 20pl RT-PCR reaction contained 1ng cDNA, 0.25mM dNTPs, 25pmmol forward 
and reverse primers, 2pl 10X GeneAmp PCR buffer (100mM Tris-HCI, pH 8.3, 
500mM KCI, 15mM MgCfe, 0.01% w/v gelatine), and 0.5U AmpliTaq Gold DNA 
polymerase. Cycling conditions were 95°C for 12 minutes, followed by 35 cycles of
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95°C for 30 seconds, 58°C for 30 seconds, 72°C for 30 seconds and a final 
elongation step of 72°C for 10 minutes.
2.4.8 Agarose gel electrophoresis
Agarose gels were prepared with 1X TAE buffer to a concentration of 2.0%.
0.05pg/ml ethidium bromide was added to the gel to allow for DNA visualisation 
since it is a DNA intercalating agent that fluoresces under UV light at a wavelength of 
300nm. Three micro litres of loading dye (15%w/v ficol, 10mM Tris pH 8, 1mM 
EDTA, 0.2% orange G) was added to each sample before loading and 
electrophoresis was performed in 1X TAE buffer at 100V. 1kb or 100bp DNA ladders 
were used to allow fragment sizing. DNA was visualised on a UV transiluminator and 
photographed using the Bio-Rad XR system.
2.4.9 PCR purification
PCR products were purified using an ExoSap method. In a general 5pl reaction, 3pl 
of PCR product was purified by adding 10U exonuclease I and 0.5U shrimp alkaline 
phosphates. The sample was incubated at 37°C for 15 minutes to allow for digestion 
of excess primers and removal of phosphates groups from dNTPS before 
denaturation of the enzymes at 80°C for 15 minutes.
2.4.10 Cycle sequencing and purification
Sanger sequencing uses dideoxynudeotide triphosphates (ddNTPs) which lack the 
3’ hydroxyl group present in deoxyribose sugars. As a result of this, ddNTPs can be 
effidently incorporated into a nascent strand by DNA polymerases but prevent 
further extension of the growing chain (Sanger et a/, 1977). In automated sequendng 
the reaction can take place within a single tube because each ddNTP is labelled with 
a different fluorophore. The template DNA is denatured and bound by a single 
specific oligonudeotide. DNA polymerase extends this primer by incorporating either 
an unlabelied dNTP or chain terminating ddNTP at each position. The relative 
concentrations of dNTPs and ddNTPs are such that the labelled products formed 
differ in size by one nudeotide. Capillary electrophoresis is used to separate the 
single stranded DNAs, with smaller fragments migrating fastest through the polymer 
and passing through the laser beam first. The emitted wavelength of light is detected
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and used to determine the ddNTP incorporated at a particular position. The order of 
the nucleotides provides a sequence read of up to 500bp.
Sequencing reactions were performed using the BigDye Terminator Cycle 
Sequencing kit (Version 3.1) according to the manufacturer’s instructions. A total 
reaction volume of 10pl contained 0.6pl -  1.5pl purified PCR product (~5ng), 1pl 
Terminator ready Reaction Mix (labelled ddNTPs and dNTPs, AmpliTaq DNA 
polymerase FS, MgCI2and Tris-HCI buffer, pH 8), 1.6pmol primer and 1.5pl BigDye 
terminator buffer (CTS). Cycle sequencing conditions were 25 cycles of 96°C for 10 
seconds, 50°C for 5 seconds and 60°C for 3 minutes and 30 seconds.
The Montage SEQ96 Sequencing Reaction Cleanup Kit was used to purify 
sequencing reactions. Twenty micro litres of injection solution (CTS) was mixed with 
the reaction and transferred to a filter plate. A vacuum of was applied until the wells 
were empty, then a further 25pl injection solution was added and the vacuum applied 
again to ensure that all the contaminating salts and unincorporated dyes terminators 
were filtered out. Purified sequencing products were re-suspended in 25pl injection 
solution by shaking for 12 minutes. Samples were run on either an ABI 31000 or ABI 
3730 Genetic Analyser.
2.4.11 Bacteriological methods
2.4.11.1 Bacteriological media and solutions
LB -  Broth; 5g Bactotryptone, 2.5g yeast extract and 2.5g NaCI in 500ml dH20. LB 
agar: 5g bactotryptone, 2.5g yeast extract, 2.5g NaCI and 8g Bactoagar in 500ml 
dH20.
2.4.11.2 Site Directed Mutagenesis (SDM)
In vitro site-directed mutagenesis is an invaluable technique for studying protein 
structure-function relationships and the effects of gene expression. Mutations were 
introduced into the APC open reading frame (ORF) of the pCMV-APC vector, using 
the Quickchange XL Site-Directed Mutagenesis Kit (Figure 2.1). Nonsynonymous or 
synonymous mutations involving one base substitution were created using 
mutagenic oligonucleotides that were between 30-34bp in length with the mismatch
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near the centre, a melting temperature (Tm) £78°C, a minimum GC content of 40% 
and terminating in one or more C or G bases at the 3’ end. The forward and reverse 
primers were complimentary.
2.4.11.3 Mutant Strand Synthesis Reaction
Reactions were carried out using 10ng of DNA, 125ng of each primer, 2pl of 10X 
reaction buffer, 0.5pl of proprietary dNTP mix, 1.5MI of Quicksolution (CTS) and 
1.25U pfIUtra DNA polymerase and H2O to a volume of 25pl. This enzyme has 
proofreading activity and has to be added after the other components to prevent 
exonuclease digestion of the primers. Cycling parameters were 95°C for 1 minute, 
followed by 18 cycles of 95°C for 50 seconds, 60°C for 50 seconds and 68°C for 14 
minutes (1 minute per kb of plasmid). Following thermal cycling, reaction tubes were 
placed on ice for approximately 2 minutes to cool the reactions to £37°C
The subsequent mixture was then incubated with 0.5pl Dpn I at 37°C for 
approximately 1 hour. Dpn I endonuclease is specific for methylated and 
hemimethylated DNA (target sequence: 5’Gm6ATC-3’) and is used to digest the 
parental DNA template and to select for mutation-containing DNA. The remaining 
nicked SDM products were transformed into XL10-Gold Ultracompetent Cells and 
recircularised vectors were purified using the QIAprep miniprep kit. Plasmids were 
sequenced to confirm the presence of the desired mutation and lack of any 
additional errors.
2.4.11.4 XL10-Gold Ultracompetent Cell Transformation
Transformation of XL10-Gold Ultracompetent cells is mediated via a heat shock 
process which leads to semi-permeabilisation of the cell membrane enabling the 
uptake of ‘naked’ DNA molecules from the surrounding environment into the cell.
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TRANSFORMATION
Figure 2.1 Overview o f the QuikChange® XL site- directed mutagenesis 
method A) Methylated pCMV-APC vector containing the template codon sequence 
of interest (methylated sites indicated in blue); B) heat denaturation separates the 
double-stranded plasmid; C) mutagenic primers are then annealed to the region of 
interest (altered base in each primer is indicated in red); D) subsequent rounds of 
PCR exponentially amplify the plasmid containing the mutation using the non-strand 
displacing action of Pfu DNA polymerase. The mutated plasmids are ‘nicked’ circular 
strands; D) Dpn I digestion of non-mutated parental DNA (methylated wild-type) 
provides a population of 100% mutated DNA which can be then used to transform 
XL10-Gold ultracompetent cells.
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One micro litre of p-mercaptoethanol (ME) mix was added to 22.5pl of cells, mixed 
gently and incubated on ice for 10 minutes ensuring that gentle agitation occurred 
approximately every 2 minutes. One micro litre of the Dpn l-treated DNA was added 
to the ultracompetent cells, gently mixed and incubated in ice for 30 minutes. Each 
sample was then heat shocked by placing in a 42°C water bath for exactly 30 
seconds and incubated on ice for 2 minutes. The cells were then incubated at 37°C 
with agitation at 225rpm for 1 hour after adding 250pl of pre-warmed LB media.
200pl of the growing suspension was spread onto LB agar plates containing 
ampicillin, Xgal and IPTG. The transformation plates were incubated at 37°C 
overnight (>16 hours).The pCMV-APC vector carries the LacZ gene which encodes 
for the enzyme p-galactosidase and so it is possible to identify colonies that contain 
the insert according to their colour. Cells that contain the vector without the insert will 
produce p-galactosidase which will lead to the formation of blue colonies because of 
the utilisation of the enzymes’ substrate Xgal. Cells that contain the vector with the 
successful insert will appear white since the presence of the insert will have 
disrupted the LacZ gene and therefore (3-galactosidase will not be produced.
2.4.11.5 PCR confirmation for transformed colonies
Individual white colonies were picked, placed in 40pl of dH20 and heated for 10min at 
95°C to release the plasmid DNA. Cell debris was precipitated by centrifugation at 
3000g for 1 minute. One micro litre of the supernatant was used as a template for a 
standard PCR reaction using primers that were suitable for the insert. Clones that 
were PCR positive were sequenced to confirm the presence of the desired point 
mutation.
2.4.11.6 Small scale plasmid preparation
High quantity plasmid DNA for transfection was prepared using QIAprep Spin 
Miniprep Kit according to the manufacturer instructions. Around 5-1 Opg of plasmid 
DNA is generated from a 1.5ml overnight LB culture. The process involves alkaline 
lysis of cells accompanied by gentle mixing to release intact plasmid DNA and to 
denature the proteins. This is followed by neutralisation and adjustment of conditions 
to a high salt medium to bind the DNA to the column. High salt conditions cause 
proteins to denature and chromosomal DNA and cellular debris to precipitate whilst
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plasmid DNA stays in solution and binds to the silica-gel membrane. The membrane 
was washed to remove trace nucleases or carbohydrates and salts before the DNA 
was eluted.
Clones that successfully carried the correct insert were grown in 3ml of liquid LB 
containing ampidllin (50pg/ml) at 37°C with agitation (225rpm) for ~15 hours. Cells 
were centrifuged at 13000rpm for 1 minute and re-suspended in 250pl of Buffer P1 
(lOOpg/ml RNase A, 50mM Tris/HCI and 10mM EDTA). Two hundred and fifty micro 
litres of Buffer P2 (200mM NaOH, 1% SDS) was added and the tubes were gently 
inverted 4-6 times to mix. Three hundred and fifty micro litres of Buffer N3 (3M 
potassium acetate) was then added, the tubes were gently inverted 4 - 6  times and 
centrifuged at 13,000rpm for 10 minute. The supernatant was added to a QIAamp 
column and centrifuged at 13,000rpm for 1 minute. The column was washed with 
500pl of Buffer PB (CTS) and then centrifuged at 13,000rpm for 1 minute. The 
column was washed with 750pl of Buffer PE (containing ethanol and CTS) and 
centrifuged at 13,000rpm for 1 minute. Residual ethanol form Buffer PE was 
removed by centrifuging the column twice at 13,000rpm for 1 minute. DNA was 
eluted into 30pl of H2O after placing the column in a fresh 1.5ml microfuge tube and 
centrifuging at 13,000rpm for 1 minute. Tubes were stored at4°C for immediate use.
2.4.11.7 Storage of transformed XL10-told ultracompetent cells
For long term storage of transformed cells 900pl of bacteria culture was mixed with 
300pl of 80% sterile glycerol. Labelled samples were stored in a -80°C freezer.
2.4.11.8 Transient transfection and the p-Catenin regulated transcription (CRT) 
assay
SW480 cells were seeded into 96 well plates at 104 cells per well and allowed to 
settle and adhere for 24 hours. Media was then aspirated and 25pl of transfection 
mastermix, containing 25ng of the ludferase reporter plasmids pTOPFLASH and 
pFOPFLASH, 25ng of pCMV- APC variant plasmids and 2ng of the transfection 
efficiency control plasmid, pRL-SV40, was added and placed in the 37°C incubator 
for 1 hour. Following this incubation a further 40pl of DMEM complete was added. 
Luciferase assays were performed using the Dual Luciferase assay kit.
69
2.4.11.9 Immunocytochemistry
SW480 cells were cultured on glass cover slips and transfected with mutant pCMV- 
APC and left 24 hours before staining. Slides were removed from culture and 
washed in warm PBS. Cells were fixed for 10minutes in 4% formalin before rinsing 
with TBS at room temperature. Cells were permeabilised with 100% methanol at - 
20°C for 30 minutes before rinsing. Slides were blocked with 1.5% goat serum in 
TBS for 1 hour before rinsing and incubated with primary antibody overnight at a 
dilution of 1:10,000. Slides were washed with TBS/Triton solution and then incubated 
with biotinylated secondary antibody (TBS/3% BSA; 1:250 Rabbit antibody) for 1 
hour at room temperature.
2.4.11.10 qRT-PCR Analysis
Total RNA was extracted from transfected SW480 cells 24 hours post transfection 
with 25ng of mutant pCMV-APC vector. Quantitative real time PCR amplification and 
gene expression analysis were carried out in 20pl reaction volumes using 1ng cDNA, 
10pi Taqman Universal PCR mix, 1pl Taq Gene Assay Mix and 8.5pl of DEPC 
treated RNase free water using an Applied Biosystems 7500 Real-Time PCR 
system. Four reactions were carried out using proprietary primers contained within 
the Taqman Gene Assay Mix for cyclin D1, c-MYC and TATA binding box protein 
(TBP).
2.4.11.11 Cell suwival analysis
Cells were seeded in triplicate at 2x103 cells per well into Optilux 96-well plates 24 
hours before treatment with peroxide to allow sufficient adherence. ATP was 
quantified in wells containing medium alone, untreated control cells or treated cells 
treated immediately after treatment using the CellTiter-Glo Luminescent Cell Viability 
Assay with an Applied Biosystems Microplate Luminometer.
2.4.11.12 Detection of active Caspase-3
Active Caspase-3 quantification assays were performed using a Caspase-Glo™3/7 
assay kit according to the manufacturer's instructions. Briefly, cells were seeded in 
96-well plates at a density of 2x103 cells per well. After 24 hours, cells were exposed 
to H2O2 and t-butyl hydro-peroxide (TBH) solutions. Caspase-Glo 3/7 reagent (100pl)
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was then added to each well including medium alone, untreated control cells or cells 
treated with peroxide 1, 24,48 and 72 hours post exposure. The luminescence of 
each sample was measured with TR717 Microplate Luminometer.
2.4.11.13 Immunofluorescence
Cells were cultured on Lab Tek II Glass Chamber Slides to 75% confluence. Cells 
were fixed in 3.8% formalin for 10 minutes at room temperature and permeabilised 
with 100% methanol at -20°C for 5 minutes. Slides were blocked with 1.5% goat 
serum in TBS for 1 hour before rinsing and incubated with primary antibody 
overnight. Slides were washed with TBS/Triton solution and then incubated with 
fluorescent secondary antibody for 1 hour at room temperature
2.4.11.14 Immunoprecipitation and Western blotting
Treated cells were lysed on ice for 10 minutes in NP-40 lysis buffer (50mM Tris-HCI 
pH 8 ,150mM NaCI, 1% NP-40, 50mM PMSF in isopropanol, 1ug/ml of Leupeptin, 
Aprotinin, and Pepstatin). Heat a sample to 95-100°C for 5 minutes; cool on ice. Half 
volume was used to determine phosphorylation of Chk1 whilst the remaining half 
was used to determine total Chk1 as a control. Briefly, lysates were incubated with 
1pg of anti-phosphoChk1(Ser317) for 1 hour at 4°C (1:500 dilution). Twenty micro 
litres of Protein G-Sepharose bead solution was added and the mixture was 
incubated at 4°C for 2 hours. After three wash/centrifugation steps at 3000g for 
1 minute the pellet was resolved by SDS/PAGE and transferred to a nitrocellulose 
membrane. After transfer, wash nitrocellulose membrane with 25 ml TBS for 5 
minutes at room temperature. Incubate membrane in 25 ml of blocking buffer for 1 
hour at room temperature. Wash three times for 5 minutes each with 15 ml of TBS/T. 
Incubate membrane and primary antibody (at the appropriate dilution) in 10 ml 
primary antibody dilution buffer with gentle agitation overnight at 4°C. Wash three 
times for 5 minutes each with 15 ml of TBS/T. The membranes were allowed to react 
with antibodies against CHK1 at dilutions stated above. Western blotting was 
detected by the enhanced chemiluminescence (ECL).
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Chapter Three: Multiple Rare Nonsynonymous Variants in APC Predispose to
Colorectal Adenomas
3.1 Introduction
The Tare variant hypothesis’ proposes that genetic susceptibility to colorectal 
neoplasia within the general population is due to a number of low frequency variants 
in a number of different genes, where each variant confers a moderate, but 
detectable, increase in relative risk of developing the disease (Feamhead et a/, 
2005). We reason that since germline mutations in APC that are predicted to result 
in a truncated protein product cause the CRC predisposition syndromes FAP and 
AFAP that rare nonsynonymous variants within important functional domains of APC 
may also contribute to colorectal tumourigenesis. The precedent has already been 
set in other settings such as coronary heart disease where it has recently been 
shown that rare nonsynonymous variants in the genes encoding apolipoprotein A1, 
the adenosine triphosphate binding cassette transporter A1 and lecithin cholesterol 
acyltransferase, are over-represented in individuals with low plasma levels of high- 
density lipoprotein cholesterol, a major risk factor for coronary atherosclerosis 
(Cohen et at, 2004).
Whether rare inherited nonsynonymous variants in APC might act as low penetrance 
alleles remains highly speculative; however, the variant I1307K has been shown to 
create a hypermutable tract that predisposes to somatic mutations (Laken et at, 
1997) and E1317Q has been shown to be overrepresented in the germline of 
patients with multiple CRAs (Larrrium et al, 2000) and has also been identified as a 
somatic change in sporadic CRC (Frayling etal, 1998). To address the potential role 
of nonsynonymous variants of APC in inherited predisposition to CRAs, we 
undertook mutational analyses of APC in 691 unrelated North American patients with 
CRAs and 969 matched healthy controls. We also carried out functional and in silico 
analyses to compliment the genetic mutation analyses strategy.
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3.2 Methods
3.2.1 Patients and control samples
Mutation analysis of APC and MUTYH genes was undertaken by Myriad Genetics 
Inc. in 691 unrelated North American patients that were referred by their physicians 
for genetic testing because of a clinical diagnosis of either FAP or "multiple" 
colorectal polyps but in whom conventional truncating mutations of APC and MUTYH 
had not been identified. All results were made completely anonymous in accordance 
with institutional approved guidelines. Myriad Genetics Inc. also sought rare non­
synonymous variants in residual DNA samples from 969 unrelated North American 
healthy controls that were made available after routine carrier screening for cystic 
fibrosis. Samples were anonymised in accordance with institutional policies 
governing specimen use. No samples carried any of the 97 mutations that were 
tested for in the CFTR gene. The unrelated North American healthy controls were 
matched to the unrelated North American non-FAP non-MAP patients for age (mean,
41.6 years for controls and 47.8 years for patients), sex (-50% males/50% females in 
both groups), and self-reported ethnic backgrounds (Table 3.1).
FAP/MAP
patients
Non-FAP non-MAP Healthy controls 
patients
African 2% 5% 5%
Ashkenazi 2% 4% 4%
Asian 2% 2% 2%
Caucasian 66% 61% 61%
Latin American/Caribbean 1% 4% 4%
Native American 3% 2% 2%
Near Eastern 0% 1% 1%
None Specified 14% 15% 15%
Other 9% 5% 5%
Table 3.1 Self reported ethnic backgrounds of the patients and healthy controls from 
North America. Data generated by Myriad Genetics.
73
3.2.2 Mutation analyses
Peripheral blood DNA samples from all patients were sequenced for the entire open 
reading frame (ORF) and splice sites of APC and exons 7 and 13 of MUTYH (that 
harbour the two common MUTYH mutations Y165C and G382D respectively, which 
account for approximately 75-80%of MUTYH associated polyposis incidences', 
Sampson JR, et al, 2003) and screened for deletions at the APC locus by multiplex 
ligation-dependent probe amplification (MLPA) and by Southern blot analysis 
(mutational analysis performed by Myriad Genetics, Utah, USA). Samples with a 
single MUTYH mutation were then sequenced for the ORF and splice sites of 
MUTYH to identify biallelic mutations. Peripheral blood DNA samples from healthy 
controls were sequenced over a ~2.4-kb region of APC spanning the p-catenin 
down-regulating domain by Agencourt Biosciences using six overlapping PCR 
fragments (Table 3.2). Comparisons of numbers of patients harbouring variants were 
performed using either the Chi-squared test or Fisher's exact test.
Name
Primer Sequence (5’ -  3’) Amp I icon 
size (bp)
01F GTAAAACGACGGCCAGTCAGTGAGAATACGTCCACACC
513
01R CAGGAAACAGCTATGACCCTAAACATGAGTGGGGTCTCC
02F GTAAAACGACGGCCAGTGATCCTGTGAGCGAAGTTCC
564
02R CAGGAAAC AGCTAT GACCGCTGGAT GAACAAGAAAAT CC
03F GTAAAACGACGGCC AGTT CAAACAGCTCAAACCAAGC
563
03R CAGGAAAC AGCTATGACCTAACATGCTTTTGGGGTT GC
04F GTAAAACGACGGCCAGTATGCCAACAAAGT CAT CACG
491
04R CAGGAAACAGCTATGACCATCTTTTTCACACGGAAAGG
05F GTAAAACGACGGCCAGTAGGCTCAAGGAGGAAAAACC
591
05R CAGGAAACAGCTATGACCT GGTAACTTTAGCCT CT GATT CC
06F GTAAAACGACGGCCAGTTCATTACACGCCTATTGAAGG
507
06R CAGGAAACAGCTATGACCTGAAAT GATTTAGGAGCATAGCC
Table 3.2 Primers used to sequence the p-catenin down-regulating domain of APC. 
Complementary primer pairs indicated by identical number prefix. F = forward, R = 
reverse.
74
3.2.3 Site directed mutagenesis
Mutant APC constructs were created by site directed mutagenesis of the pCMV-APC 
vector provided by B. Vogelstein. Complementary oligonucleotides containing the 
appropriate mismatches for single nucleotide substitutions were designed using the 
Quickchange Primer Design program
(http://labtools.stratagene.com/QC/QCprimers). Primers sequences were annealed 
to the vector at 55°C and are shown in Table 3.3. In order to confirm the presence of 
the desired mutation and lack of any unwanted errors, the APC ORF was sequenced 
using the primers in Table 4.1.
3.2.4 Expression of stable APC constructs
The pCMV-APC vector is ~21kb in size. The large size of this vector means that 
efficient transfection may not be possible in all commercially available cell lines. 
Therefore, mutant and wild-type pCMV-APC constructs were initially transformed 
into a range of competent cells to establish the most efficient method of generating 
clones. ABLE K competent cells, SURE 2 Supercompetent cells and XL10-Gold 
Ultracompetent cells were chosen because of their efficacy in cloning of large DNA 
inserts. Transformations were carried out according to the manufacturer’s 
instructions. Since all cells were amenable to blue-white colour screening for 
successfully recombinant plasmids, transformed bacteria were plated out and 
incubated on LB-ampidllin agar plates containing 80pg/ml X-gal and 20mM IPTG. 
White colonies were grown further and screened for the presence of mutation.
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Name WT Codon Mutant Codon Forward Primer Sequence (6‘ - 3') Reverse Primer Sequence (6* -3 ')
Truncatin 8
1309 AAA TAA CAAATAGCAGAAATAAAAGAATAGATTGGAACTAGGTCAGCTGAA TTCAGCTGACCTAGTTCCAATCTATTCTTTTATTTCTGCTATTTC
1450 GAG TAG CCTCAAACAGCTCAAACCAAGTQAGAAGTACCTAAAAATAAAGCA TGCTTTATmTAGGTACTTCTCACTTGGTTTGAGCTGTTTGAGG
1517 AGA TGA AGCCTCGATGAGCCATTTATATAGAAAGATGTGGAATTAAGAATA TATTCTTAATTCCACATCTTTCTATATAAATGGCTCATCGAGGCT
1914 TGC TGA CACAGAACTAACCTCCAACTAACAATCAGCTAATAAGACACAAG CTTGTGTCTTATTAGCTGATTGTTAGTTGGAGGTTAGTTCTGTG
Silent
P1442P CCT CCG AGAAGTAAAACACCTCCACCACCGCCTCAAACAGCTCAAACCAAG CTTGGTTTGAGCTGTTTGAGGCGGTGGTGGAGGTGTTTTACTTCT
T1493T ACG ACT GATACTTTATTACATTTTGCCACTGAAAGTACTCCAGATGGATTT AAATCCATCTGGAGTACTTTCAGTGGCAAAATGTAATAAAGTATC
G1678G GGG GGT GCTGGAGAAGGAGTTAGAGGAGGTGCACAGTCAGGTGAATTTGAA TTCAAATTCACCTGACTGTGCACCTCCTCTAACTCCTTCTCCAGC
A1755A GCG GCT GACCAGGTCCAGCAAGCATCTGCtTCTTCTTCTGCACCCAACAAA TTTGTTGGGTGCAGAAGAAGAAGCAGATGCTTGCTGGACCTGGTC
S1756S TCT TCC CAGGTCCAGCAAGCATCTGCGTCcTCTTCTGCACCCAACAAAAAT ATTTTTGTTQGGTGCAGAAGAGGACGCAQATGCTTGCTGGACCTG
P1960P CCg CCT AATTTTGCTATTGAAAATACTCCTGTTTGCTTTTCTCATAATTCC GGAATTATGAGAAAAGCAAACAGGAGT ATTTTC AATAGCAAAATT
Nonsynonymous
I1307K ATA AAA AATACCCTGCAAATAGCAGAAAAAAAAGAAAAGATTGGAACTAGG CCTAGTTCCAATCTTTTCI I I I I I I ICTGCTATTTGCAGGGTATT
E1317Q GAA CAA AAGATTGGAACTAGGTCAGCTCAAGATCCTGTGAGCGAAGTTCCA TGGAACTTCGCTCACAGGATCTTGAGCTGACCTAGTTCCAATCTT
V1352A GTT GCT GAATCAGCCAGGCACAAAGCTGCTGAATTTTCTTCAGGAGCGAAA TTTCGCTCCTGAAGAAAATTCAGCAGCTTTGTGCCTGGCTGATTC
M1413V ATG GTG TCAGAGTGAACCATGCAGTGGAGTGGTAAGTGGCATTATAAGCCC GGGCTTATAATGCCACTTACCACTCCACTGCATGGTTCACTCTGA
T1445A ACA GCA AACACCTCCACCACCTCCTCAAGCAGCTCAAACCAAGCGAGAAGT ACTTCTCGCTTGGTTTGAGCTGCTTGAGGAGGTGGTGGAGGTGTT
A1446T GCT ACT ACCTCCACCACCTCCTCAAACAACTCAAACCAAGCGAGAAGTACC GGTACTTCTCGCTTGGTTTGAGTTGTTTGAGGAGGTGGTGGAGGT
K1454E AAA GAA TCAAACCAAGCGAGAAGTACCTGAAAATAAAGCACCTACTGCTGA TCAGCAGTAGGTGCTTTATTTTCAGGTACTTCTCGCTTGGTTTGA
P1467S CCT TCT TGCTGAAAAGAGAGAGAGTGGATCTAAGCAAGCTGCAGTAAATGC GCATTTACTGCAGCTTGCTTAGATCCACTCTCTCTCTTTTCAGCA
A1474T GCT ACT ACCTAAGCAAGCTGCAGTAAATACTGCAGTTCAGAGGGTCCAGGT ACCTGGACCCTCTGAACTGCAGTATTTACTGCAGCTTGCTTAGGT
I1572T ATT ACT GATGATTCAGATGATGATGATACTGAAATACTAGAAGAATGTATT AATACATTCTTCTAGTATTTCAGTATCATCATCATCTGAATCATC
C1578G TGT GGT TGATATTGAAATACTAGAAGAAGGTATTATTTCTGCCATGCCAAC GTTGGCATGGCAGAAATAATACCTTCTTCTAGTATTTCAATATCA
11579V ATT GTT TATTGAAATACTAGAAGAATGTGTTATTTCTGCCATGCCAACAAA TTTGTTGGCATGGCAGAAATAACACATTCTTCTAGTATTTCAATA
R1676G AGA GGA GTTAGCTGCTGGAGAAGGAGTTGGAGGAGGGGCACAGTCAGGTGA TCACCTGACTGTGCCCCTCCTCCAACTCCTTCTCCAGCAGCTAAC
D1714N GAT AAT ATCTGTAACCATACCTGAATTGAATGACAATAAAGCAGAGGAAGG CCTTCCTCTGCTTTATTGTCATTC AATTC AGGTATGGTTAC AGAT
G1921S GGT AGT TGCAAAGCAGCCAATAAATCGAAGTCAGCCTAAACCCATACTTCA TGAAGTATGGGTTTAGGCTGACTTCGATTTATTGGCTGCTTTGCA
P1934L CCC CTC CTTCAGAAACAATCCACTTTTCTCCAGTCATCCAAAGACATACCA TGGTATGTCTTTGGATGACTGGAGAAAAGTGGATTGTTTCTGAAG
Table 3.3 Primers used for site directed mutagenesis of the pCMV-APC vector. ‘WT codon’ refers to the codon sequence before 
mutagenesis and ‘Mutant Codon’ refers to codon sequence after successful mutagenesis.
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3.2.5 p-Catenin-regulated transcription (CRT) assays.
The luciferase reporter plasmids pTOPFLASH and pFOPFLASH, which contain 3 
copies of the optimal or mutant p-catenin/Tcf-binding motif, respectively, upstream of 
a firefly luciferase gene were used to assess the p-catenin-regulated transcription 
(CRT) mediated by transfected APC constructs. SW480 cells were transfected as 
described in section 2.4.11.4 with generated APC constructs.
Wildtype SW480 cells contain a large amount of cytoplasmic 0-catenin due to 
truncated, non-functional APC, and would therefore result in the production of a 
relatively high level luciferase and subsequently produce high luminescent output. 
Transfection of functional APC into this system would result in degredation of the 
cytoplasmic p-catenin, resulting in a reduced luminescent signal. Functionally 
compromised APC would hypothetically produce a luminescent signal that was 
closer to that produced by wildtype SW480 cells alone and significantly different to 
that produced by functional APC. Results were standardized for transfection 
efficiency, and the average of at least 10 independent experiments was analysed 
using Students’ t test.
3.2.6 qRT-PCR analysis
A total of 50ng RNA was used for first strand cDNA synthesis and subsequent PCR 
amplification and gene expression analysis were carried out as detailed in section 
2.4.11.10.
3.2.7 Immunocytochemical staining for p-catenin
Immunostaining for P-catenin in cultured SW480 cells was performed 24h post­
transfection with 25ng mutant APC using the rabbit VECTASTAIN ABC horseradish 
peroxidase kit as described in section 2.411.9
3.2.8 In silico analyses
Predictions using Polyphen (http://genetics.bwh.harvard.edu/pph/), were based on 
Homo Sapiens APC and predictions using Align-GVGD (http://agvgd.iarc.fr/), were 
based on a multiple sequence alignment (created using using t-coffee, 
http://www.igs.cnrs-mrs.fr/Tcoffee/tcoffeecgi/) of APC orthologues from Homo 
sapiens (ENSG00000134982), Echinops tetfairi (ENSETEP00000013272), Pan
troglodytes (ENSPTRP00000029327), Macaca mulatta (ENSMMUP00000000446), 
Oryctolagus cuniculus (ENSOCUP00000013423), Bos taurus 
(ENSBTAP00000025099), Xenopus tropicalis (ENSXETP00000046491), 
Monodelphis domestica (NSMODPOOOOO016609), Rattus norvegicus 
(ENSRNOP00000027691), Mus musculus (ENSMUSP00000078337), Dasypus 
novemcinctus (ENSDNOP00000006189) and Loxodonta africans 
(ESLAFP00000011382). All in silico analyses carried out by Mr. Edward Rawstorne.
3.3 Results
3.3.1 Contribution of germline mutations in APC and MUTYH to colorectal 
polyposis
Comprehensive mutation analysis of the APC and MUTYH genes in 691 unrelated 
North American patients presenting with a colorectal adenoma (CRA) phenotype 
was performed by Myriad Generics Inc. Truncating APC mutations were identified in 
178 patients and biallelic MUTYH mutations in 33 patients, confirming the clinical 
diagnoses of FAP and MAP, respectively.
Approximately 98% of the germline truncating mutations in APC were nonsense 
point mutations and ffame-shifts (due to small insertions and deletions) and were 
predominantly within the 5’ region (codons 1 >1400; Figure 3.1) predicted to result in 
a C-terminal truncated protein. We also observed two common hotspots for deletion 
mutations at codons 1309 and 1062. Of the 33 MAP patients identified 36% of cases 
were biallelic G382D/Y165C, 24% were homozygous for G382D and 18% were 
homozygous for Y165C. The 7 remaining incidences were heterozygotes with 
Y165C and frameshift deletions.
Of the 211 FAP/MAP patients, 3.3% had £10 CRAs, 20.9% had 11 to 99 CRAs, 46% 
had £100 CRAs, and 29.9% had multiple CRA (number unknown), as recorded at 
colonoscopy or colectomy. Among the 480 non-FAP non-MAP patients, 15.4% had 
£10 CRAs, 33.5% had 11 to 99 CRAs, 9.2% had £100 CRAs, and 41.9% had 
multiple CRA.
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Figure 3.1 Distribution o f germ line APC m utations in 178 FAP patients. There is an over representation o f m utations in the 5’ region o f the gene with the 
two corresponding hotspots at codons 1062 and 1309 annotated. Red dots indicate small deletion (£2bp) m utations, green dots indicate small insertion 
(<2bp) mutations, black dots indicate nonsense m utations, intronic m utations are shown as black arrows and large deletions are shown as black bars.
3.3.2 Nonsynonymous variants in patients with CRAs
From the sequencing performed by Myriad genetics Inc. forty-eight different rare 
(minor allele frequencies [MAFs] <2%) non-synonymous variants were identified 
spanning the APC ORF in 101 (14.6%) patients; 97 patients carried single 
heterozygous variants and 4 carried two heterozygous variants (three FAP patients 
carried A199T and L639S, R414C and G2502S, and, R1676G and P2467T, 
respectively, and one non-FAP non-MAP patient carried P870S and M949I). Only 20 
of the 211 (9.5%) FAP/MAP patients carried rare nonsynonymous variants. In 
contrast, 81 of the 480 (16.9%) patients without FAP or MAP carried such variants 
(x 2=6.42, P=0.0113), suggesting that some nonsynonymous variants in APC might 
predispose to CRAs (Table 3.4, Figure 3.2). When non-FAP non-MAP patients were 
classified according to the number of CRAs, the group with 11-99 CRAs had a higher 
frequency of rare nonsynonymous variants (18.6% of patients) as compared to the 
groups with £10 CRAs (13.5% of patients) or £100 CRAs (13.6% of patients; Table
3.4). Indeed, significantly more non-FAP non-MAP patients with 11-99 CRAs carried 
rare nonsynonymous variants as compared to the FAP/MAP patients (30/161 vs. 
20/211, x 2=6.579, P=0.0103).
I assessed whether the overrepresentation of the rare nonsynonymous variants in 
the non-FAP non-MAP patients was simply due to an overrepresentation of the 
previously studied variants M307Kand E1317Q. Similar proportions of non-FAP non- 
MAP and FAP/MAP patients were observed to carry I1307K (6 of 480 versus 2 of 
211, P = 0.538). Although we did find that more non-FAP non-MAP patients carried 
E1317Q than FAP/MAP patients [13 of 480 (2.7%) versus 3 of 211 (1.4%)], this was 
not significant (P = 0.229). Importantly, when only alleles with MAFs of <0.5% were 
considered (thereby excluding G2502S (1.74%), E1317Q (1.16%), and I1307K 
(0.58%)), more non-FAP non-MAP patients were observed to carry rare 
nonsynonymous variants compared with FAP/MAP patients (43 of480 versus 10 of 
211, x2 = 3.68; P = 0.0549) and a significant overrepresentation in the non-FAP non- 
MAP cases with 11 to 99 CRAs (18 of 161 versus 10 of 211, x2 = 5.443; P = 0.0197) 
was observed. In contrast, similar proportions of non-FAP non-MAP and FAP/MAP 
patients carried rare (MAFs, <2%) synonymous variants, and the frequencies of 
seven common polymorphisms were almost identical between the two groups (Table
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3.5). Both groups also had similar self-reported ethnic backgrounds (Table 3.1). It
was therefore highly unlikely that these findings could be attributed to population 
stratification.
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Category Non-synonymous variants Total (and frequency)
FAP/MAP patients (APC  ORF)
F A P
p a tie n ts
R 1 0 6 H , A 1 9 9 T + L 6 3 9 S , R 4 1 4 C + G 2 5 0 2 S , 
S 5 3 7 C , L 1 12 9S , I1 3 0 7 K  (2), E 1 3 1 7 Q  (2), 
R 1 6 7 6 G + P 2 4 6 7 T , H 2 1 4 9 P , A 2 2 7 4 V , 
G 2 5 0 2 S  (3), R 2 5 0 5 Q , S 2 6 2 1 C
1 7 /1 7 8  (9 .6 % )
M A P
p a tie n ts
E 1 3 1 7 Q , G 2 5 0 2 S  (2) 3 /3 3  (9 .1 % )
Total 20 /211 (9 .6% )*
non-FAP non-MAP patients (APC  O R F )
s 1 0 C R A s P 9 8 1 R , I1 3 0 7 K  (2), E 1 3 1 7 Q  (2), T 1 4 4 5 A , 
G 2 5 0 2 S , R 2 5 0 5 Q , N 2 5 9 3 S , S 2 6 2 1 C
10 /74  (1 3 .5 % )
11 -9 9  C R A s R 2 1 6 Q , P 9 8 1 R , V 1 1 2 5 A , L1 12 9S , 
T 1 1 6 0 K , I1 3 0 7 K  (3), E 1 3 1 7 Q  (4), 
V 1 3 5 2 A , M 1 4 1 3 V , C 1 5 7 8 G , 11579V, 
D 1 7 1 4 N , G 1 9 2 1 S , P 2 1 5 8 R , H 2 23 2D , 
A 2 2 7 4 V , G 2 5 0 2 S  (5), R 2 5 0 5 Q , I2573V , 
S 2 6 2 1 C , A 2 7 9 5 T
30 /161 (1 8 .6 % )
£ 1 0 0  C R A s K 1 5 0 R , S 64 3P , R 6 53 K , G 2 5 0 2 S  (3) 6 /4 4  (13 .6 % )
M u ltip le
C R A s,
n u m b e r
u n kn o w n
K 1 5 0 R , E 538V , P 87 0S , C 9 4 7 S , 
P 8 7 0 S + M 9 4 9 I, L 1 1 2 9 S , T 1 1 6 0 K , I13 07K , 
E 1 3 1 7 Q  (7), A 1 4 4 6 T , K 1 4 5 4 E , P 14 67 S , 
A 1 4 7 4 T , I1572T , P 1 9 3 4 L , R 2 06 6G , 
I2 3 2 9 V , G 2 5 0 2 S  (10 ), 12541V, I2 7 5 6 V
35 /201  (1 7 .4 % )
Total 8 1 /4 8 0  (16 .9 % )* 
*X2=6.42, Ps=0.0113
N .B . 3 2 /4 8 0  (6.7% )** in 
th e  p -c a te n in  
d o w n re g u la tin g  d o m a in
Healthy controls (P -ca ten in  d o w n re g u la tin g  d o m a in )
A 1 2 4 7 T , I1 3 0 7 K  (9), E 1 3 1 7 Q  (11 ), 
K 1 3 6 3 I, M 1 4 1 3 V  (3), K 1 4 5 4 E  (2), 
P 1 4 5 8 S , T 1 4 9 3 M , P 1 5 8 4 S , R 1 58 9G , 
R 1 5 8 9 C , T 16 3 3 K + T 16 5 5 A + N 1761T , 
R 1 6 7 6 G , S 1 7 3 0 F , Q 1 9 1 6 K , I19 7 5 F
3 7 /9 6 9  (3.8% )** 
**X2= 5 .7 4 , P = 0 .0 1 6 6
Table 3.4 Inherited nonsynonymous variants spanning the APC  ORF in 691 North 
American patients with CRAs (classified according to FAP/MAP status and number 
of adenomas) and in the p-catenin down regulating domain in 969 North American 
healthy controls. In total, 61 different rare non-synonymous variants in APC  were 
identified in this study. * Comparison between numbers of non-FAP non-MAP and 
FAP/MAP patients carrying rare nonsynonymous variants (MAFs, <2%) within the 
APC ORF (N.B. significantly more non-FAP non-MAP patients also carried rare 
nonsynonymous variants compared with FAP patients alone; x2 = 5.50, P = 0.0191). 
** Comparison between numbers of non-FAP non-MAP patients and healthy controls 
carrying rare nonsynonymous variants (MAFs, <2%) within the p-catenin down- 
regulating domain.
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Figure 3.2 Distribution of inherited APC  nonsynonymous variants in 480 non-FAP non-MAP patients and 211 FAP/MAP patients. Ninety-seven patients carried a 
single variant and four patients (a-d )  carried two variants. Functional domains are coloured: oligomerisation domain (codons 6-57), ■ armadillo region (codons 453-
767), ■ 15 amino acid repeat P-catenin binding domain (codons 1020-1169), ■ 20 amino acid repeat P-catenin downregulating domain (codons 1262-2033), •  SAMP 
repeats/axin binding domain (codons 1562-2056), * basic domain (codons 2200-2400), ■ EB1 binding domain (codons 2559-2771), and, ■ HDLG binding domain 
(codons 2771-2843) (domains not drawn to scale). Nonsynonymous variants are plotted as stars and coloured according to the domains in which they lie; black stars, 
nonsynonymous variants that do not lie within known functional domains.
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GO
FAP/MAP 
patients (211)
Non-FAP non- 
MAP patients 
(480)
Healthy 
controls (969)
Rare Synonymous variants
APC  ORF 16.1% 14.8% N/A
p-Catenin down- 
regulating domain
6.2% 6.0% 5.7%
Common polymorphisms
D1822V 24.1% 22.8% 21.1%
A545 (1635A>G) 45.5% 44.4% N/A
T1493 (4479A>G) 41.2% 39.7% N/A
G1678 (5034A>G) 41.0% 39.8% 38.4%
S1756 (5268G>T) 40.5% 39.2% 38.1%
Y486 (1458C>T) 41.2% 39.2% 38.3%
P1960 (5880A>G) 41.0% 39.8% 38.0%
Table 3.5 Twenty nine different rare (MAFs, <2%) synonymous variants were found 
spanning the APC  ORF in 105 patients (15.2%); 95 of these carried a single variant 
(93 in a heterozygous state), nine carried two heterozygous variants, and one carried 
three heterozygous variants. Eleven rare synonymous variants were found spanning 
the p-catenin down-regulating domain in 55 healthy controls (5.7%) N/A; not 
assessed.
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3.3.3 Nonsynonymous variants in healthy controls
Significantly more non-FAP non-MAP patients had rare non-synonymous variants in 
the p-catenin down regulating domain (spanning codons 1262 to 2033) as compared 
to FAP/MAP patients (32/480 vs. 6/211, %2=4.12, F=0.0423). Using a re-sequencing 
approach, Myriad genetics Inc. were again commissioned to identify rare 
nonsynonymous variants in the ~2.4kb p-catenin down-regulating domain in 969 
unrelated North American healthy controls that were matched to the unrelated North 
American non-FAP non-MAP patients for age, sex and race. In total, eighteen 
different rare non-synonymous variants were identified in the p-catenin down- 
regulating domain in 37 healthy controls; 36 controls carried single heterozygous 
variants and one carried three heterozygous variants (T1633K, T1655A and 
N1761T) (Table 3.4). Five out of eighteen of the nonsynonymous variants (I1307K, 
E1317Q, M1413V, K1454E and R1676G) were previously identified in the patient 
cohort, whereas the remaining thirteen variants were unique to the control group.
Significantly more non-FAP non-MAP patients carried rare non-synonymous variants 
in the p-catenin down-regulating domain as compared to the healthy controls (32/480 
vs. 37/969, x 2=5.74, P= 0.0166) and this over-representation was highest in the non- 
FAP non-MAP patients with 11-99 CRAs (13/161 vs. 37/969, x2=5.914, P=0.0150; 
Table 3.4). In terms of individual variants, we did not observe an over-representation 
of I1307K in the non-FAP non-MAP patients versus controls (6/480 vs. 9/969, 
respectively). However, significantly more non-FAP non-MAP patients carried 
E1317Q were found, as compared to healthy controls (13/480 vs. 11/969, x2=4.88, 
P=0.0272), although even when this variant was excluded from the analyses, 
significantly more non-FAP non-MAP patients with 11-99 CRAs carried other rare 
non-synonymous variants in the p-catenin down-regulating domain as compared to 
controls (9/161 vs. 26/969, x2=3.887, P=0.0487). In contrast, the frequencies of rare 
synonymous variants in this region and common polymorphisms were almost 
identical between the non-FAP non-MAP patients and controls (Tables 3.5). These 
data suggest that a proportion of non-synonymous variants in the p-catenin down- 
regulating domain of APC are likely to alter p-catenin signalling to promote 
tumourigenesis.
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3.3.4 Production of APC constructs for transfection.
We assessed the transformation efficiencies of three commercially available 
competent cells; ABLE K, XL-10 Gold Ultracompetent cells and SURE2 
supercompetent cells. Transformations using the wildtype, I1307K nonsynonymous 
mutant and the T1493T synonymous mutant were carried out alongside an internal 
kit control. Only the XL10-Gold ultracompetent cells consistently yielded white 
colonies from each transformation reaction. Colonies from each transformation were 
screened for the presence of a mutation (where appropriate). Amplicons of the 
correct size were detected (Figure 3.3) and sequenced to ensure that site directed 
mutagenesis had resulted in synthesis of a mutant transcript; the Stratagene XL10- 
Gold ultracompetent cells were subsequently used for the synthesis of all DNA 
transfection constructs. We generated six synonymous, four truncating mutants and 
sixteen nonsynonymous pCMV-APC constructs to carry out functional assays (i.e. 
CRT assays, qRT-PCRs and immunocytochemistry). Examples of each construct 
are shown in figure 3.4.
100bp DNA Ladder 
Colony 1
Colony 2
Colony 3
Colony 4
Colony 5
Colony 6
ddH jO f negative control)
Wild type A P C ( Positive control)
Figure 3.3 Agarose gel visualising PCR amplification of pCMV-APC vector in XL 10-Go Id 
ultracompetent cells using primers specific for exons human APC.
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Figure 3.4 Examples of sequencing analyses of site-directed mutant pCM\/-AP C  
constructs. Wild type sequences are shown on the left and A) two nonsynonymous 
mutations, B) two truncating mutations and C) two nonsynonymous mutations are 
shown on the right. Mutated base is red, bold and underlined.
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3.3.5 Functional analyses of nonsynonymous variants in the p-catenin down- 
regulating domain
We examined the functional consequences of 16 of the nonsynonymous variants 
identified within the P-catenin down-regulating domain using CRT assays as 
described in section 2.44.11.6. The four truncating mutations 1309A, 1450A, 1517A, 
and 1914 A were predicted to retain one, two, three, and five 20AARs, respectively. 
As expected, the six synonymous variants and the wild-type APC construct all 
suppressed CRT in an APC-defident cell line (figure 3.5A). The 1309A construct, 
which is associated with a severe FAP phenotype, failed to suppress CRT (P < 
0.0001) whereas 1450A, 1517A, and 1914A suppressed CRT more effectively than 
1309 A but not as effectively as the wild-type construct (P < 0.05; figure 3.5B). Next, 
we tested the 16 nonsynonymous variants, and in accordance with our hypothesis 
that some of these rare variants may compromise function, seven (43.8%) had a 
significantly reduced ability to suppress CRT (Figure 3.5C) Both I1307K and E1317Q 
were found to be functionally compromised.
3.3.6 Immunocytochemical analyses of p-catenin degradation
We aimed to explore whether the failure to suppress CRT in our in vitro model 
system would affect the subcellular distribution of endogenous p-catenin in 
transfected SW480 cells. No differences in p -catenin distribution could be detected 
after transfection with positive and negative control constructs (wild type APC and 
the three truncating mutations 1309A, 1450A and 1517A, Figure 3.6).
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Figure 3.6 SW480 cell line transfected with A) 1309A mutant APC  or B) wildtype APC  and stained for p-catenin. 
No difference can be seen in the distribution of intracellular p-catenin. Cells were seeded in low numbers (-1000 
per well) to prevent overgrowth and ‘clumping1 since SW480 is a transformed cell line that does not have a cell­
cell contact mediated growth inhibition response and are presented as a selection of neighbouring cells and lone 
cells.
3.3.7 qRT-PCR analysis to examine gene expression of downstream targets of 
Wnt signalling
We attempted to analyse the expression of Wnt target genes following transfection 
with pCMV-APC constructs containing nonsynonymous variants. We carried out 
quantitative real time PCR analysis using total RNA isolated from SW480 cells 
transfected with either wildtype or the 1309A truncating mutant pCMV-APC construct 
to validate our in vitro model system. Detection of c-myc and CCND mRNA levels 
was multiplexed alongside TATA -box binding protein (TBP), the endogenous 
control for normalization of all assays. Relative quantification of gene expression 
levels was determined using the Comparative Ct method (Schmittgen D and Livak 
KJ, 2008). This method compares the relative amount of the target sequence to any 
of the reference values chosen and the result is given as relative to the reference 
value. The medians of the comparative Ct values (2_AACt) values for c-myc and 
cyclinDI were compared using a Mann-Whitney U-test to determine if the relative 
fold change was significantly different between the two groups. No significant 
difference was found between the two groups (Figure 3.7).
3.3.8 In silica predictions of likely pathogenicity of nonsynonymous APC 
variants
An in silico approach was used to investigate whether nonsynonymous variants 
could interfere with APC’s roles in mediation of intercellular adhesion, stabilisation of 
the cytoskeleton, chromosome stability or regulation of the cell cycle and apoptosis. I 
used the programs PolyPhen and Align-Grantham Variation/Grantham Deviation 
(Align-GVGD) to help predict the functional consequences of all 61 different non­
synonymous variants that we identified in APC. PolyPhen uses empirically derived 
rules to predict the pathogenesis of SNPs. Results are scored as follows:
• 'probably damaging’: it is with high confidence supposed to affect protein 
function or structure;
• ‘possibly damaging’: it is supposed to affect protein function or structure;
• 'benign’:most likely lacking any phenotypic effect, and;
• ‘unknown’: when in some rare cases, the lack of data does not allow 
PolyPhen to make a prediction.
Variants are classified into 5 categories by Align-GVGD:
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• deleterious 1’: the position of interest is 100% conserved, so any mutation at 
the position is predicted as deleterious;
• ‘deleterious 2’: there is a small variation in amino adds at the given position 
(the residues encountered are biochemically similar) but the mutant amino 
acid does not fall within that range of variation;
• 'neutral 1 the composition, polarity and volume of the mutant amino acid fall 
within observed range of variation according to the alignment at that position 
so the mutant is predicted as neutral;
•  ‘neutral 2’: the position tolerates more than ‘conservative’ substitution, and 
lastly;
• ‘unclassified’: the mutant does not fall in the previous categories.
Both in silico analysis tools predict the possible impact of an amino add substitution 
on protein structure and function using proprietary algorithmic rules applied to the 
annotated sequence, the phylogenetic and structural information characterising the 
substitution i.e. changes in polarity, bulky structures, hrdrophilic changes within the 
presence of functional domains and distance to known active sites.
In silico analyses using PolyPhen predicted that 24 non-synonymous variants were 
likely to be damaging whereas Align-GVGD predicted that 28 variants, 17 of which 
were also called ‘damaging’ by PolyPhen, were likely to alter function (Table 3.6). 
Together, these analyses predicted that 35/61 (57.4%) non-synonymous variants 
were likely to alter function.
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Figure 3.7 qRT-PCR analyses of CCND  and c-m yc  gene expression 6 and 12 hours 
after transfection with pCMV-APC vector containing either the 1309A truncating or 
wildtype APC. Comparative Ct values of TATA binding box protein was used as 
endogenous control to normalise values
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Non-synonymous PolyPhen prediction Align-GVGD prediction
R106H benign neutral 1
K150R benign deleterious 2
A199T benign deleterious 2
R216Q benign neutral 2
R414C probably damaging unclassified
S537C possibly damaging deleterious 1
E538V possibly damaging deleterious 1
L639S possibly damaging deleterious 1
S643P possibly damaging deleterious 1
R653K benign deleterious 2
P870S benign neutral 1
C947S probably damaging deleterious 1
M949I benign neutral 1
P981R probably damaging deleterious 1
V1125A benign neutral 1
L1129S benign unclassified
T1160K benign unclassified
A1247T benign neutral 1
I1307K possibly damaging neutral 2
E1317Q benign neutral 1
V1352A benign deleterious 1
K1363I probably damaging deleterious 1
M1413V possibly damaging deleterious 2
T1445A benign neutral 1
A1446T benign neutral 1
K1454E benign deleterious 2
P1458S benign neutral 2
P1467S possibly damaging deleterious 2
A1474T benign neutral 2
T1493M possibly damaging deleterious 1
I1572T possibly damaging deleterious 1
C1578G probably damaging deleterious 1
11579V benign deleterious 2
P1584S probably damaging deleterious 1
R1589G probably damaging neutral 2
R1589C benign neutral 2
T1633K possibly damaging neutral 1
T1655A benign deleterious 2
R1676G benign neutral 1
D1714N benign deleterious 2
S1730F possibly damaging neutral 1
N1761T possibly damaging unclassified
Q1916K benign neutral 2
G1921S benign neutral 1
P1934L probably damaging unclassified
I1975F benign unclassified
R2066G benign neutral 2
H2149P probably damaging deleterious 1
P2158R possibly damaging deleterious 2
H2232D probably damaging deleterious 1
A2274V benign neutral 2
I2329V benign deleterious 2
P2467T benign neutral 2
G2502S possibly damaging deleterious 2
R2505Q benign deleterious 2
12541V benign neutral 1
I2573V benign neutral 1
N2593S benign neutral 1
S2621C benign deleterious 2
I2756V benign neutral 1
A2795T benign neutral 1
Table 3.6 In silico predictions of the likely functional consequences of the non­
synonymous variants identified in APC. See section 3.3.8 for results nomenclature
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3.4 Discussion
3.4.1 Identification of pathogenic mutations in APC and MUTYH in a minority of 
cases within a cohort presenting with a CRA phenotype.
In FAP cases we found that, in agreement with published literature, the majority of 
germline truncating mutations in APC were either nonsense point mutations or 
frameshifts and resulted in a C-terminal truncated protein. In keeping with previous 
observations regarding the germline mutation spectrum of APC (Beroud and Soussi, 
1996; Miyoshi et al 1992, Mandl et a/, 1994) we identified two common mutation 
hotspots at codons 1309 and 1062. Thirty three were diagnosed with MAP, conferred 
by biallelic inactivation of MUTYH. We therefore concluded that 211 out of 691 
individuals that presented with a CRA phenotype were associated with classical 
germline defects in known CRC predisposition genes.
3.4.2 An observed association between rare inherited nonsynonymous 
variants in APC and a CRA phenotype.
The potential role of rare non-synonymous APC variants in colorectal tumourigenesis 
is controversial. The APC nonsynonymous variant E1317Q was first described in 
1996 in two siblings from an Ashkenazi Jewish family with late onset CRC (White S, 
et at, 1996). Since then the variant has been reported to confer an increased risk of 
CRAs and CRC in some, but not all, case control studies (Table 3.8): Frayling et al,
(1998) found the E1317Q variant in 1.4% of patients with multiple CRAs (£3 
adenomas but without the ‘classical’ phenotype of FAP) and in 6.7% of CRC patients 
but in none of the 80 controls as well as also identifying the nonsynonymous 
mutation occurring as a somatic change in sporadic CRC. The combined data from 
the studies of White etal, (1996) and Frayling etal, (1998; n=80 and n=33 
respectively) found that E1317Q conferred an increased risk in individuals for CRC 
or CRAs (P = 0.035). Lamlum et al, (2000) later concluded that that the E1317Q 
allele contributes to a predisposition to colorectal adenomas and carcinoma, but with 
low and variable penetrance since they identified E1317Q in 4.3% (7 of 164) of 
patients with multiple (3 -1 0 0 ) CRAs compared to 0.4% (2 of 503) of a population 
based control sample (which also pooled together the control data of White et al, and 
Frayling et al,). Several other studies however (Table 3.7), have not supported an 
association between E1317Q and a significantly increased risk of CRC; Popat et al, 
(2000) identified the E1317Q variant a similar frequency amongst CRC patients and
the healthy spouse control group whilst Evertsson et al, (2001) failed to identify 
E1317Q in a Swedish CRC patient cohort. Hahnloser etal, (2003) screened 608 
individuals with CRC and adenomas, and healthy controls 679 controls for the 
E1317Q variant and found that the frequency of heterozygotes for E1317Q among 
patients with CRC, with 4-100 adenomas and <3 adenomas did not differ from 
healthy spouse controls. Rozek et al, (2006) investigated the relationship between 
E1317Q and CRC in a large population-based case-control study of CRC in northern 
Israel using 1,834 matched cases and controls and concluded that it was unlikely 
that E1317Q was associated with a clinically meaningful risk of CRC.
Taken together, these reports infer that whilst E1317Q is a colorectal adenoma 
predisposition variant, that it does not confer any risk of CRC in the general 
populace. However, the concept that genetic predisposition to CRAs would not result 
in an increased risk for CRC is inconsistent with our current understanding of the 
adenoma -carcinoma progression sequence that results in the majority of CRCs 
(Muto et al, 1976; Fearon and Vogelstein 1990). Our data clearly shows that the 
E1317Q variant is indeed one of several colorectal adenoma predisposition variants 
and that by extension their presence within the general population would confer a 
slight risk of CRC. What is not clearly understood is the mechanism by which these 
nonsynonymous variants exert a pathogenic effect. I could speculate that E1317Q 
could result in compromised function of APC protein by altering the structure of the 
protein as a result of the charge change occurring because of the amino acid 
substitution. This could act to impede the the binding of APC to p-catenin by 
preventing accessibility to the 20AAR down regulating domain(s).
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Incidence of B1317Q In
Study Design Multiple CRA patients CRC patients Controls P-Value OR *% C I Comments
White eta/. 1996 Family Study 2/4 (siblings) 0/133
Frayling et al. 1998 Case control, UK 2/134* 2/30b 0/80
07213°
P>0.1
P=0.035 (a and b Vs c) cPooled controls from White and Frayling ef al.
Popate/a/. 2000 Case control, UK 2/364 2/290 P>0.01
Lamlum e/a/. 2000 Case control, UK 7/184 2/503 
(290 new)
(213 from White/Fravlina) P<0.001 11.2 (2.3-54.3)
Evertsson et al. 2001 Case series, Sweden 0/88 (hereditary) 
0/106 /sporadic)
Figerefa/. 2001 Case series, Israel 1/21 4/85 2/148
Heinimann et al. 2001 Case series. Germany 1/100 FAP
Michils e/a/. 2002 Casa control, Belgium 2/75 FAP or AFAP 1/180 E1317Q carrier identified within the control group 
was homozvaous for the variant
Oismondie/a/. 2002 Case control, Italian 2/182 2/235 1.29 (0.009-18.0)
Hahnlosere/a/. 2003 Case control, USA 9/377 cases 
2/145 (4-100 adenomas) 
3/86 (1-3 adenomas) 
9/377 cases 
2/145 (4-100 adenomas) 
3/86 (1-3 adenomas)
10/362 
spouse controls
1/317 
colonoscopy controls
0.84
0.52
1.18
9.01
3.69
16.59
(0.31 - 2.28) 
(0.10-2.68) 
(0.28-4.78) 
(1.1-73.8) 
(0.2-56.0) 
(1.5-178.8)
Zhou etal. 2004 Case control, Sweden 1/97 (hereditary) 
0/92 /sporadic)
0/188
Guo et al. 2004 Case series, Singapore 0/147 Chinese 
0/20 Malay 
0/11 India
Kapltanovic et al. 20Q< Case control, Croatia 0/73 0/50 1 sporadic mutation identified in tumour DNA
Feamheade/a/. 2004 Casa control. UK 3/124 6/480 P=0.4 2.0
Fiddere/a/. 2005 Case control. Israel 6/538 5/440 P*0.975 0.98 (0.29 -3.24)
Rozeke/a/. 2006 Case control, Israel 26/1,970 23/1,994 
6/398 (polyp-free)
1.15
0.87
(0.65-2.02)
(0.36-2.14)
Cleary et al. 2008 Case series, Canada 
Case contol. Canada
2/39
17/971 18/954 1.08 .(^59-2,74}.,
Pooled group of patients with CRC and multiple CRAs
Table 3.7 Studies of APC E1317Q in chronological order. Abbreviations: FAP, familial adenomatous polyposis; AFAP, attenuated 
adenomatous polyposis
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The I1307K nonsynonymous variant, originally identified by Laken et al (1997) has 
been confirmed as a low penetrance pathogenic allele resulting in CRC 
predisposition amongst Ashkenazi Jews. The variant is a transversion mutation 
(T—>A) in APC at codon 1307 that results in a hypermutable poly-adenine tract, 
causing mutations due to slippage during DNA replication. The frequency and 
epidemiology of I1307K and CRC within the Ashkenazi Jewish ethnic group has 
been extensively reviewed by Locker and Lynch (2004). In the initial Ashkenazi 
Jewish population studied by Laken et a /(1997), the frequency of the variant was 6% 
in a sample set ascertained for Tay-Sachs testing, 10% (P <0.033 by x2) in CRC 
patients, 16% (16%vs. 6.6%, P <0.033 by x2) in Ashkenazim diagnosedwith 
colorectal cancer under age 66, and 28% (P<0.001) in affected individuals with a 
family history of colorectal cancer. Multiple studies have assessed the frequency and 
epidemiology of I1307K and the incidence of I1307K amongst the Ashkenazi Jewish 
populace is estimated to be between 5.4 -12.8%  and most studies suggest 
significantly associated with multiple CRA and CRC incidence (table 3.8).
The role of I1307K outside of the Ashkenazim ethnic group has been examined and 
only one study has provided data supporting a significant association between 
I1307K and CRA or CRC development (Table 3.9). Frayling et al, (1998) identified 
I1307K in 3 of 134 individuals presenting with multiple CRAs in a UK based study. 
These individuals were later determined to be of Ashkenazim Jewish descent. A 
carrier rate of 8.1% in the British Ashkenazi Jewish control group was ascertained 
and 0% in the non-Jewish control group. Yuan et al (1998) identified I1307K in 4 
members of a large French Canadian HNPCC kindred carrying a novel truncating 
mutation in hMLH1. Whilst the identification of the variant in this cohort is novel, no 
association between the CRC incidences was found. Lothe et al, (1999) determined 
that I1307K was rare in the Norwegian populace since it was present in 1 of 210 
patients with CRC and they were later determined to be of Jewish descent. Prior et 
al (1999) assessed whether I1307K was unique to the Ashkenazi population and did 
not find the variant in 105 African-American controls, 38 Italian CRC patients, 148 
Finnish CRC patients and 54 Hawaiian -  Japanese CRC patients. Nathanson etal,
(1999) did report a woman of Italian descent, affected with breast and ovarian cancer
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Study Design
Multiple CRA pts
Incidence of I1307K in 
CRC pts Controls
P-Value Reported Frequency 
In AJ population (95% Cl)
Comments
AJ Based Studies
Laken e ta l. 1997 Case control, USA 22/211 AJs'
14/89 Pts<66 years oldd 
8/121 Pts a66 years old* 
7/25 FH+'
0/13 FH-9
15/173 FH unkown"
0/243 Non-Jewlsh‘ 
47/766 A Jb
P< 0.0001 (a Vs. b) 
P< 0.033 (bVs. c) 
/X  0.033 (d Vs. e) 
P<0.001 (b Vs. f) 
P<0.02 (f Vs. h)
6.1% (4.4-7.8)
Woodage et al. 1998 Case series, USA 367/5,081 heterozygous* 
2/5,081 homozygous*
4,712/5,081 wildtype* P-0.06 7.0 % (6.3 - 7.7) Samples obtained from an 
Ashkanlzm DIMA Blobank
Drucker et al. 2000 Case series, Israel 12/71 AJs1
0/34 Sepharldlc Jews 
3/4 Yemenite Jews1
17/298 AJsk 
9/189 Yemenite Jews'
P *0.004 (i and ] Vs k and I) 5.7% (0.018-0.045)
Shtoyerman etal. 2001 Case series, asseslng incidence 
amongst pts of Jewish descent
29/227 AJs 
2/122 non-AJ
2/210 Moroccan Jews 
2/160 Iraqi Jews
12.8% (4.0-7.4)
Baharetal. 2001 Australia 104/1200 Australian AJ 8.67% (7.07 - 10.261
Non-AJ Based Studies
Frayling ef al. 1998 Case control, UK 3/134 pts but 3/3 AJs 8/98 AJ 3 carriers were determined to be 
of Ashenazlm descent
Yuanefa/. 1998 Case study, Canada 4 individuals within a large French Canadian kindred with HNPCC carried the I1307K variant 2 Individuals unaffected by 
HNPQQ also carried I1307K
Lothe eta/. 1998 Case series, Norway 1/210 Carrier was determined to be of 
Ashkenazim descent
Prior e ta l. 1999 Case control, misc. 0/38 Italian pts 105 African Americans
0/148 Finnish pts
0/54 Hawailan-Japanes pts
Nathanson ef el 1999 Case study, US 1 female out of 104 non-AJ pts with a family history of both breast and colon cancer.
Evertsson e ta l. 2001 Case series. Sweden 0/194
Mlchlisefa/. 2002 Case series/diagnostic validation, 
Belgium
1/75 0/180 Carrier was determined to be 
of Ashenazim descent
Guo etal. 2004 Case series, Singapore 0/147 Chinese 
0/20 Malay 
0/11 Indian
Dundareta l. 2007 -Qas? study, Turkey--------------------- 26/56 0/18 P<0.05
Table 3.8 Studies of APC  nonsynonymous variant 11307K in Ashkenazi Jews and non-Ashkenazi Jewish groups. Pts= patients.
o
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and with a family history of CRC who was heterozygous for the I1307K allele. A 
Swedish study (Evertsson etal, 2001) did not find I1307K in a 194 cases of familial 
CRC. However, Dundar et al, (2007) observed a significant over-representation of 
I1307K in 30 of 56 Turkish patients with CRC when compared to a small healthy 
control group (0/18; P<0.05).
In our study, we show that significantly more non-FAP non-MAP patients with CRAs 
carry E1317Q as compared to controls, clearly supporting a role for this variant in 
predisposing to CRAs. Although we did not find a similar over-representation of 
I1307K, this variant was less frequently observed since it is normally found in 6%-7% 
of the Ashkenazi Jewish population (Gryfe, etal, 1999; Woodage, etal, 1998) and 
<4% of our patients were from this ethnic background. Importantly, our study showed 
that even when I1307K and E1317Q were excluded, significantly more non-FAP 
non-MAP patients carried a variety of other rare non-synonymous variants, indicating 
that other rare variants in APC act as low penetrance disease alleles. However, 
apart from the variant I1307K, which has been shown to create a hypermutable tract 
that predisposes to somatic mutations (Laken, et al 1997), the mechanism of 
pathogenesis underlying almost all of these variants in APC remains unclear.
3.4.3 Functional analysis of nonsynonymous variants within the p-catenin 
down regulating domain.
We assessed the functional consequences of sixteen of the nonsynonymous 
variants identified within the P-catenin down-regulating domain using CRT assays.
As expected, the six synonymous variants and the wild-type APC construct all 
suppressed CRT in an APC-defident cell line. Consistent with the notion that 
mutations resulting in the retention of different numbers of 20AARs lead to different 
levels of p-catenin-assodated signalling, 1309A, that is assodated with a severe 
FAP phenotype, failed to suppress CRT (F<0.0001), whereas 1450A, 1517A and 
1914A suppressed CRT more effectively than 1309A but not as effectively as the 
wild type construct (P<0.05). There was a dear relationship between the predicted 
number of 20AARs retained and CRT activity (7>5>3>2»1). Next, we tested the 
sixteen non-synonymous variants and in accordance with our hypothesis that some 
of these rare variants may compromise function, seven (43.8%) had a significantly
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reduced ability to suppress CRT. Amongst the seven, I1307K and E1317Q were 
found to be functionally compromised. This analysis implicates a reduced ability to 
degrade intracellular p-catenin levels as a mechanism of propagating aberrant Wnt 
signalling leading to unregulated cell growth.
We attempted to measure the effect of the nonsynonymous variants on the 
expression profiles of Wnt target genesin SW480 cell lines transfected with APC 
constructs by RT-PCR, but initial validation of our model system with the truncating 
mutant 1309A failed to show any significant difference when compared to wildtype 
APC. We also attempted to examine the effect of nonsynonymous variants on p- 
catenin distribution within the cell but immunostaining to visualise any partitioning 
between cytosolic and nuclear p-catenin following transfection with the 1309A 
truncating mutant and WT APC failed to demonstrate a difference. This is likely to 
reflect limitations of our in vitro model to assess the subtle changes required to elicit 
changes in gene expression for example, and highlights the difficulties faced when 
attempting to characterise the functional affects of rare nonsynonymous variants. A 
primary limitation may have been that the transient transfection of a colon cancer cell 
line with a pCMV-APC construct would have resulted in intracellular over expression 
of APC. Immunostaining for total p-catenin by Western blot (WB) could have been 
used to determine p-catenin turnover in our cell model. The use of hyper- and 
hypotonic lysis buffers followed by Western blotting for p-catenin could have been 
used to ascertain subcellular distribution of cellular p-catenin and may have been a 
better alternative to the immunocytochemical analyses performed.
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3.4.4 In silico analyses
We used the programs PolyPhen and Align-Grantham Variation/Grantham Deviation 
(Align-GVGD) to help predict the functional consequences of 61 different 
nonsynonymous variants that we identified in APC. In silico analyses using PolyPhen 
predicted that 24 non-synonymous variants were likely to be damaging whereas 
Align-GVGD predicted that 28 variants, 17 of which were also identified as 
‘damaging’ by PolyPhen. Taken together, these analyses predicted that (57.4%) of 
the nonsynonymous variants were likely to alter the function of APC. Functional 
studies’ using the CRT assay show that six nonsynonymous variants (I1307K, 
E1317Q, V1352A, 11579V, R1676G, D1714N, G1921S) significantly failed to repress 
(3 -catenin regulated transcription; Polyphen results also indicated that I1307K was 
possibly deleterious to protein function and Align GVGD indicated that V1352A and 
11599V were deleterious to protein function (Table 3.9). However, neither predicted 
that E1317Q, R1676G, D1714N or G1921S would result in aberrant protein function. 
Conversely M1413V, K1454E, P1467S, I1572T, C1578G and P1934L were 
highlighted by one, or both programs (Table 3.9) as possibly having a negative effect 
on protein function. In cases where the CRT assay show repressed |3 -catenin 
regulated transcription (i.e. non-pathogenic) but in silico predictions indicated 
deleterious effects, the latter might infer that a protein function other than (3 -catenin 
regulation is compromised by the variant. The accuracies of these programs have 
been assessed against known disease causing mutations; Ng and Heinkoff (2006) 
assessed program error for a number of in silico programs summarising the rates of 
false negative and false positive predictions. False negatives were defined as amino 
acid changes that are known to be disease causing predicted as not damaging to the 
protein and false positives were defined as amino acid changes that are beliieved to 
have no disease causing association that were predicted as damaging to the protein. 
Polyphen has been shown to correctly identify pathogenicity 60% of the time and has 
a false positive rate of 9% and a false negative rate of 31%. Align has been shown to 
correctly identify pathogenicity 59% of the time and has a false positive rate of 12% 
and a false negative rate of 29%.
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Variant CRT Assay Polyphen Align-GVGD
I1307K Pathogenic Poss. deleterious Neutral
E1317Q Pathogenic Benign Neutral
V1352A Pathogenic Benign Deleterious
M1413V Non-pathogenic Poss. deleterious Deleterious
T1445A Non-pathogenic Benign Neutral
A1446T Non-pathogenic Benign Neutral
K1454E Non-pathogenic Benign Deleterious
P1467S Non-pathogenic Poss. deleterious Deleterious
A1474T Non-pathogenic Benign Neutral
I1572T Non-pathogenic Poss. deleterious Deleterious
C1578G Non-pathogenic Poss. deleterious Deleterious
11579V Pathogenic Benign Deleterious
R1676G Pathogenic Benign Neutral
D1714N Pathogenic Benign Neutral
G1921S Pathogenic Benign Neutral
P1934L Non-pathogenic Poss. deleterious Unclassified
Table 3.9 Summary or results from the functional CRT assay and in silico predictions 
for the nonsynonymous variants within the p-catenin down regulating domain. Poss 
= possibly.
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3.4.5 Multifactorial inherited susceptibility to CRAs
The rare variant hypothesis states that changes such as nonsynonymous variants in 
a number of genes may have a cumulative pathogenic effect resulting in a model of 
multifactorial inheritance for CRAs. Here, we found that individually rare, but 
collectively common inherited non-synonymous variants were significantly over­
represented in patients who did not carry conventional pathogenic mutations in the 
APC or MUTYH genes (non-FAP/non-MAP patients; 81/480,16.9%) as compared to 
patients with FAP or MAP (20/211, 9.6%; P=0.0113) and that this over- 
representation was highest in those non-FAP non-MAP patients with 11-99 CRAs 
(30/161,18.6%, P=0.0103). Such variants are therefore likely to play a significant 
role in multifactorial inherited predisposition to CRAs and that a specific CRA 
phenotype of 11 to 99 CRAs is associated most significantly to the presence of rare 
nonsynonymous variants in APC. Only a minority of patients with this phenotype 
have been shown previously to have conventional mutations in APC of MUTYH. 
Further characterization of these and other low penetrance alleles promises to clarify 
the molecular basis of inherited predisposition to CRAS.
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Chapter Four: The APC variant E1317Q predisposes to colorectal adenomas 
by a novel mechanism of relaxing the target for tumourigeneic somatic APC
mutations
4.1 Introduction
Germline mutations that lead to AFAP cluster within exons 3 and 4 (5* of codon 169) 
of APC, in the alternatively spliced region of exon 9 (codons 312-412) and in the 
terminal region of exon 15 (3* of codon 1581) (Fearnhead etal, 2001; Knudson etal 
2003). In agreement with Knudson’s ‘2-hit’ hypothesis, inactivation of both (Miyoshi 
et al 1992; Powell et al 1992) APC alleles is observed in most familial and sporadic 
CRAs and CRC (Miyoshi etal 1992; Powell etal 1992). However, it has recently 
been shown that type and location of the somatic ^ -h it ’ in FAP tumours is 
determined by the type and location of the germline lesion (Lamlum et al, 1999), and 
that the position of the mutations in sporadic CRCs are also interdependent (Rowan, 
et al, 2000; Cheadle 2002). Careful examination of somatic mutations has revealed 
that one of the two mutant APC alleles within a tumour is generally selected for 
retention of one, or rarely, two of the 20-amino acid p-catenin binding and 
degradation repeats (20AARs). This has led to the suggestion that a ‘just-right’ level 
of p-catenin signalling within the Wnt pathway is required for colorectal tumour 
formation (Albuquerque et al, 2002).
In AFAP, a subset of tumours appear to harbour two somatic mutations, one on the 
wild type allele, the other on the attenuated APC (AFAP) allele carrying the germline 
mutation (Spirio etal, 1998; Su e ta l2000; Sieber etal, 2006). The identification of 
this so-called ‘3rd hit’ has suggested that AFAP alleles sometimes require further 
inactivation to confer the optimum signalling for tumourigenesis. Where the germline 
AFAP-associated mutation lies at the 5’ end of the gene, the residual activity is most 
likely mediated via alternative splicing of exon 0.1 to an intra-exonic splice acceptor 
in exon 5 (Samowitz et al, 1995) or via translation initiation from the internal 
ribosome entry site (IRES) between codon 157 and the AUG at codon 184 (Heppner 
Goss et al, 2002). Likewise in AFAP patients carrying exon 9 mutations, direct 
splicing of exon 8 to exon 10 in a subset of APC mRNAs allows functional APC 
expression (Su e ta l2000; Groden etal, 1991).
Mechanisms by which nonsynonymous variants act is unclear except for I1307K. 
This variant results in a hypermutable tract that predisposes to somatic mutations 
(Laken et al, 1997). We investigated the effect of E1317Q, which lies between the 
first and second 20AAR, by comparing the pattern of somatic APC mutations found 
in tumours from an AFAP family carrying an exon 4 truncating mutation as their only 
germline APC coding region alteration, to that found in tumours from members of a 
large AFAP family who carry similar exon 4 truncating mutation and the E1317Q 
variant on the same germline APC allele.
4.2 Methods
4.2.1 Patients and Samples
The study was approved by the Wales Multicentre Research Ethics Committee. 
Family S consisted of two generations affected with CRC, a mother (Patient L) and 
her daughter (Patient M). Patient L had no prior family history and presented with 
CRC at 44 years of age. Only one additional adenoma was noted at surgery. She re­
presented with symptomatic polyposis at 58 years of age at which time several 
hundred macroscopic colorectal adenomas, ranging from 2-1 Omm, were noted. 
Patient M had 36 colorectal polyps removed following a total colectomy at 34 years 
of age. Following histopathological inspection 6 were CRAs and the remaining 17 
were benign hyperplastic growths. Family B included at least four successive 
generations affected with CRAs or early onset CRC (Figure 4.1). Macroscopic 
adenomas ranged in number from less than ten to several hundred, but were 
generally small (<2mm), even in patients in their 4th and 5th decades, and affected 
predominantly the caecum and proximal colon. Apart from duodenal adenomas, no 
extracolonic features of FAP were observed in any patients.
DNA was prepared from venous blood samples taken from all available members of 
families S and B, and from 72 fresh frozen CRAs from Patients L and M of Family S 
and 105 fresh frozen CRAs from seven affected individuals from Family B (Patients 
A-G, Figure 4.1). RNA was extracted from fresh frozen normal colonic tissue. All 
tissues were examined histologically to verify their nature.
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4.2.2 PCR and RT-PCR
Exons 1 to 14 oi APC were amplified as 14 fragments and the first 2.8kb of exon 15 
as 18 overlapping fragments, as previously described (Al-Tassan, N etal, 2002). We 
amplified the MCR as either a 1.1kb fragment using the primers MCR_F (5’- 
CCATCCAAGTTCTGCACAGAGTAGA) and MCR (5’- 
AGGTGGAGGTAAi 11 IGAAGCAGTC), or as two overlapping 0.8kb fragments 
using the primers 15.6F (5-AATCAAAATGTAAGCCAGTCT) and 15.7R (5’- 
ATTCCACTGCATGGTTCAC), and, 15.8F (5’-CAAAAGTGGTGCTCAGACAC) and 
15.9R (5-CCCCGGT GTAAAACTAACA). The 3’ region of exon 15 of APC was 
amplified as 22 overlapping fragments (Table 4.1), using genomic DNA as a 
template. For RT-PCR, we amplified a 158bp region of exons 11 and 12 using the 
primers APCRNA_11F (5-CAGGCCATTGCAGAATTAT) and APCRNA_12R2 (5’- 
CAGCCTTTCATAGAGCATAGC), and a 1.2kb fragment from exon 3 to exon 12 
using the primers APCRNA_3Fnew (5’-CTGTTCCTATGGGTTCATTTC) and 
APCRNA_12R2. RT-PCR products were cloned into pGEM-T Easy, propagated in E. 
coli JM109 and sequenced. In Family B, clones were assigned to the wild type or 
AFAP allele using the exon 11 polymorphism 1458 C-»T.
4.2.3 Assays for the germline variants
Y159X was assayed using normal (N-ASO 5-AAGTTGAGCGTAATACCAG) and 
mutant (M-ASO 5-AAGTTGAGCCTAATACCAG) allele-specific oligonucleotide 
(ASO) probes. Five micro litres of denatured exon 4 PCR product was spotted onto 
duplicate membranes of Hybond N \ dried, prehybridised at 42°C for 30mins, 
hybridised with either normal or mutant y-32P end-labelled ASOs at 42°C for 2 hrs, 
washed, and exposed to film. E1317Q was assayed using a PvuW digest of a 506bp 
PCR product generated using the primers E1317QLF (5 - 
GCAGTAAAACCGAACATATG) and E1317QR (5-TGGACTTTTGGGTGTCTG).
10(4,1 of PCR product was digested according to manufacturers’ recommendations 
and analysed on a 3% Nusieve 3:1 agarose gel. These were carried out by Dr. S 
Jones, Cardiff University, UK.
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Exon/Primer Primer sequence (5-3’)
PCR
conditions
(°C)
Sequencing
F R
1
F-AGGTCCAAGGGTAGCCAAGG
55 Y Y
R-TAAAAATGGATAAACTACAATTAAAAG
2
F-AAATACAGAATCAT GTCTTGAAGT
55 N Y
R-ACACCTAAAGATGACAATTTGAG
3
F-T GCTTAAAGCAATTGTTGTAT
55 Y Y
R-GTACACAAGGCAATGTTTACT
4
F-T GCAGTCTTTATTAGCATTGTT
58 N Y
R-CAGGCCTAAAGTTGGGTAA
5
F-CTTTT T IGC 1 ITTACTGATTAACG
55 Y Y
R-IGIAAIICAI I I I A I  ICCIAAIAGCIC
6
F-GGTAGCCATAGTAT GATTATTT CT
55 Y Y
R-CTACCTATTTTTATACCCACAAAC
7
F-AAGAAAGCCTACACCATTTTTGC
57 Y Y
R-GATCATT CTTAGAACCAT CTTGC
8
F-ACCTATAGT CTAAATTATACCAT C
55 Y Y
R-GT CATGGCATTAGT GACCAG
9
F-AGTCGTAATTTTGTTT CTAAACTC
55 Y Y
R-CTTTGAAACATGCACTACGA
10
F-AAACATCATTGCTCTTCAAATAAC
55 Y Y
R-TACCATGATTTAAAAATCCACCAG
10a
F-CCTGTATTCCAATGGATTGTAG
55 Y Y
R-CTATGTCCCCAGCAGTCAC
11
F-GATGATTGTCTTi I ICCICI I GC
58 Y Y
R-CT GAGCTAT CTTAAGAAATACAT G
12
F-AAGCTTGGCTTCAAGTTGTC
55 Y Y
R-CAGAGTGAGACCCT GCCTC
13
F-TCCCAAAGTGATAGGATTACA
58 Y Y
R-AGGGAATCT CAT GGCTAAA
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14
F-TAGAT GACCCATATT CT GTTT C
55 Y Y
R-CAATTAGGTCI I I I IGAGAGTA
15.1
F-CAAAAGGAGATGTGGAATACT
55 Y Y
R-AGCCAGGAGACATAATATT G
15.2
F-CAGGAAGCATTAT GGGACAT
55 Y Y
R-GAGGAGCTGGGTAACACTGTAG
15.3
F-AAGGCATCT CATCGTAGTAA
55 Y Y
R-TT CCGACTTAGT GAAATT GTA
15.4
F-CT GGGT CTACCACT GAATTAC
55 Y Y
R-AGTT GTACTTTGATTCCTT GAT
15.5
F-CCTAGCCCATAAAATACATAGT
52 Y Y
ATAGGCTGATCCACATGAC
15.6
F-AATCAAAATGTAAGCCAGTCT
55 Y Y
R-AGCTGAT GACAAAGAT GATAA
15.7
F-CT GCCACTTGCAAAGTTT C
52 Y Y
R-ATTCCACTGCATGGTTCAC
15.8
F-CAAAAGT GGTGCTCAGACAC
58 Y Y
R-TT CCTGAACTGGAGGCATTA
15.9
F-GACCTAAGCAAGCTGCAGTA
55 Y Y
R-CCCCGGTGTAAAACTAACA
15.10
RF-CCCAGACTGCTTCAAAATTAC
55 Y Y
R-C ACGGAAAGGCTT GTGACT
15.11
F-AAAACCT CATCT GTAACCATAC
55 Y Y
R-TT CCTT CAATAGGCGT GTA
15.12
F-AATTTAAAT GCT GAGAGAGT
55 Y Y
R-CCCT CTGT CTGGTAT GT CT
15.13
F-TACCAGCCACACAGAACTAAC
58 Y Y
R-CACCCATATTTCTGGGACTAT
15.14
F-CACAGGGAGAACCAAGTAAAC
58 Y Y
R-AAT GGT GAT CCCAGAGAGAT
15.15
F-GAAGGTGCAAATTCCATAGTA
55 Y Y
R-GGCT GTTT GACCTT CACTAG
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15.16
F-AGGCAGGACAATGATTCATAT
55 Y Y
R-GGCATT CTT GGATAAACCT G
15.17
F-CCCTAGTACTGCTTCAACTAAG
55 Y Y
R-TGGTCTTCCATCATTATACTCT
15.18
F-AGACCAGCTTCTCCCACTAG
55 Y Y
R-ACCTGAGGAAACGGT CT GA
15.19
F-ACAAAGTAAAGAAAACCAAGTA
55 Y Y
R-GGGGTACGTTCCACTATAG
15.20
F-TCGCCTGAACTCCTTTATTC
55 Y Y
R-TTCCAGAACAAAAACCCTCTA
Table 4.1 Oligonucleotide primers used to amplify exon 15 of APC.
4.2.4 Assays for LOH at the APC locus
FAM-labelled PCR products encompassing E1317Q were digested with PvuM, mixed 
with highly deionised formamide and heat denatured before running on an ABI 
PRISM 3100 Genetic Analyser. Results were analysed using Genescan software 
and peak heights compared to a series of five control DNAs extracted from adjacent 
normal colon. Ratios exceeding 1.8:1, after adjusting for normal variation, were taken 
as indicative of LOH. The nonsense mutation Q163X in exon 4, the variant in intron 5 
(647+32 C-+T), and the silent polymorphisms in exon 11 (1458 C-+T) and 15 (1493 
G-+A and 5880 A->G) were similarly assayed in informative individuals using 
Hpy188l, 7spRI, Rsal, Btg\ and BsaWI restriction digests, respectively. All assays 
were carried out in duplicate. These were carried out by Dr. S Jones, Cardiff 
University, UK.
4.2.5 dHPLC analysis
dHPLC was carried out using the 3500HT WAVE nucleic acid fragment analysis 
system. To enhance the formation of heteroduplexes prior to analysis, the PCR 
products were denatured at 94°C and re-annealed by cooling to 50°C at a rate of 1°C 
per min; dHPLC was carried out at the melting temperatures predicted by 
Wavemaker (version 4.1) software with a 12% acetonitrile gradient over 2.5 min.
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Samples displaying aberrant dHPLC elution profiles were sequenced directly. These 
were carried out by Dr. S Jones, Cardiff University, UK.
4.2.6 Direct sequencing
Amplification products were purified by incubation with exonuclease I and shrimp 
alkaline phosphatase. Automated sequencing was carried out using the Big Dye 
Terminator Cycle Sequencing kit version 3.1. Sequencing reactions were purified 
using the Montage SEQ96 Sequencing Reaction Cleanup kit, and analysed on an 
ABI PRISM 3100 Genetic Analyser.
4.2.7 Clone based re-sequencing
Fragments spanning the MCR (primers MCR_F and MCR_R) were purified using the 
PCR purification kit, cloned into pGEM-T Easy, and propagated in E. coli JM109; at 
least twelve recombinant clones from the wild type and AFAP alleles were 
sequenced (Oswel Services). Sequence data was aligned and variants in two or 
more clones from the same allele were analysed by an independent assay to confirm 
that they were genuine sequence variants and not PCR or cloning induced errors.
Somatic mutations identified in Family B were assigned to an APC allele by cloning 
and sequencing PCR products that included both the somatic mutation and a known 
heterozygous germline variant. These were carried out by Dr. A Dallosso, Cardiff 
University, UK.
4.2.8 Statistical analyses
The pattern of somatic mutations in Family S and Family B were compared using a 
likelihood approach, similar to the one previously described by Cheadle, JP et al 
(2002). Only tumours with single somatic mutations were used for these analyses. 
Tumours with 2 or more somatic mutations were excluded since those mutations 
may not represent independent events. To estimate the Poisson distribution 
parameter (A), we considered a number (n= 2, 3 and 4) of APC coding sequence
sub-regions where the value of the parameter was constant, allowing different 
parameters of the Poisson distribution for each dataset and each region:
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n  ^  ^ ® r -n  n  ^  ^
*=i y=*<-i+i j  * *=1 j=bt-i+i j  *\ , / ' --------------
Likelihood for family (S') Likelihood for family(5)
»
where b is the vector of the borderlines b -  , b0+ 1 - is the beginning and
bn is the end of the region; A(S) = ($ s) ,...9A(p )  and A(B) =(AiB),...9A(f }) are parameters 
of the Poisson distribution and k f*, k{B) are the number of mutations at the position j  
for S and B mutations, respectively. This likelihood was maximised with respect to 
the borderlines b and parameters A{S) and A(B). When these parameters were
identified, the maximum likelihood Lq which assumes the same parameters
A = (Al in both families (Null hypothesis) for each of these sub-regions was
calculated,
n bt s ^  \ k)iS) n bt s i  \ b j B)
w ) - n n ' - , ! l r ' n n < - , ! l r/=1 j=bt_i +1 Kj  • /=1 j=bi_l+1 Kj  •N-------------- w--------------/-->-------------- „-------------- /
Likelihood for family^) Likelihood for family (5 )
The two likelihoods I,(^ 5)9%B)>b) and L0(A,b) were then compared using the
Likelihood Ratio test with n degrees of freedom. Likelihood comparison approach 
carried out by Dr V. Moskvina from the Bioinformatics unit, Cardiff University.
4.2.9 p-catenin/TCF regulated transcription (CRT) assays
Variants were introduced into pCMV-APC constructs using the Quikchange XL site- 
directed mutagenesis kit. All clones were sequenced for the entire APC ORF to 
confirm that the correct variants were incorporated and to ensure that no unwanted 
errors had been introduced. The ludferase reporter plasmids pTOPFLASH and 
pFOPFLASH which contained wild type or mutated TCF-response elements were 
used to assess CRT as previously described (section 2.4.11.8).
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4.3 Results
4.3.1 Germline APC defects in Family S and Family B
We sequenced the entire APC open reading frame (ORF) in a peripheral blood DNA 
sample from an AFAP patient (Patient L) from Family S and identified the exon 4 
nonsense mutation Q163X (487 C->T) as the only coding region variant. We 
confirmed the presence of this mutation in the probands affected daughter (Patient 
M).
We also sequenced the entire APC ORF in a peripheral blood DNA sample from an 
affected member (III.3, Fig. 1) of a second, larger, AFAP family (Family B) and 
identified the nonsense mutation Y159X (477 C-»G) in exon 4 and the non- 
synonymous variant E1317Q (3949 G-»C) in exon 15. Screening of 26 living 
members of Family B for these two variants, using either ASO or restriction digestion 
based assays, showed that both variants co-segregated with the AFAP phenotype 
(Figure 4.1). Y159X and E1317Q therefore lie on the same APC allele (hereafter 
termed the ‘AFAP allele’). We carried out RT-PCR from exons 3-12 and/or exons 11- 
12 of APC using RNA extracted from normal colonic mucosa of one member of 
Family S and two members of Family B. Cloning and sequencing of these products 
showed that the mutant AFAP allele was expressed at the mRNA level in both 
families, albeit at a -2.4 - 3 fold lower level compared to the wild type allele (46 
AFAP vs. 138 wild type clones from Family S and 96 AFAP vs. 233 wild type clones 
from Family B).
4.3.2 Somatic APC mutations in Families S and B
We sought somatic APC mutations in 72 CRAs from 2 affected individuals from 
Family S by assaying for LOH using 2 intragenic markers and by direct sequence 
analysis of the entire APC ORF. We identified somatic mutations in 58 (80.6%) 
tumours (Table 4.2, Figure 4.2); 55 (94.8%) of these carried single somatic 
mutations and 3 (5.2%) carried 2 somatic mutations.
We also sought somatic APC mutations in 105 CRAs from 7 affected individuals 
from Family B by assaying for LOH at 4 intragenic loci and by using a combination of 
dHPLC, direct and clone based re-sequencing of the entire APC ORF. We identified
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somatic mutations in 46 (43.8%) tumours; 36 (78.3%) of these carried single somatic 
mutations, 9 (19.6%) carried 2 somatic mutations, and 1 carried 3 somatic mutations 
(Table 4.2, Figure 4.2). Of the 36 tumours with single somatic mutations, 17 were 
proven to have a mutation on the wild type APC allele and 1 was proven to have a 
mutation on the AFAP allele. In 2 tumours, two somatic mutations were observed 
independently on the WT allele, likely reflecting a mixed population of tumour cells.
In 6 of the remaining 7 tumours with two somatic mutations, one of the somatic 
mutations was proven to affect the AFAP allele and therefore these are likely to 
represent genuine 3rd hit tumours. In the single tumour with 3 somatic mutations 
(A5S), one mutation was proven to lie on the AFAP allele and the other 2 somatic 
mutations were proven to lie on different WT alleles. This tumour likely contained a 
mixture of “2-hit” and “3-hit” cells. In total therefore, mutations were identified on the 
AFAP allele in 8/49 (16.3%) tumours from Family B. In terms of pathology, we found 
no obvious differences between tumours with 2 or 3-hits: adenomas with somatic 
mutations on the AFAP allele were 1.5mm to 3.5mm in size with mild dysplasia and 
tubular morphology and adenomas with somatic mutations on only the wild type 
allele were 0.5mm to 10mm in size with varying degrees of dysplasia (77.8% mild, 
11.1% moderate, 5.6% severe, 5.6% unknown) and morphology (50% tubular,
11.1% tubulovillous, 38.9% unknown).
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Figure4.1 Pedigree of Family B and cosegregation of the APC variants Y159X and E13170. w ith AFAP. ASO and restriction 
digest assays were used to screen for the germline mutation Y159X (477 C-*G)and the non-synonymous variant E13170 (3949 
G-»C), respectively. E l 317Q was assayed using a PvuW  digest of a 506bp PCR product, the wild type allele was cut at two sites to 
generate 234bp, 173bp, and 99bp products, while the E1317Q allele was cut at only one site generating 272bp (lower arrow marked 
M) and 234bp products. Both variants cosegregated with the multiple CRA phenotype indicating that they were present on the same 
APC allele. U pper arrow marked M -  mutant ASO, middle arrow marked WT -  wild type ASO.
Tumours with 1 somatic mutation
Family S
(Germline -  Q163X)
Family B
(Germline - Y159X and E1317Q)
No. of
20AARs
retained
No. of 20AARs 
retained
L1 3967 dell 3bp 1 A1S R213Xwr 0
L3 Q1367X 1 A3 3476 delCWI 0
L6 Q1367X 1 A3S R232XAFAP 0
L7 Q1291X 1 A6 LOHwl 0
L9 E1317X 1 B3 Q1378XW* 1
L10 E1322X 1 B4 LOHWT 0
L13 3925 deiG 1 C1S R1114X 0
L22 E1322X 1 C6S S1281X 0
L23 4188 delT 2 C11S Q1242X 0
L24 R216X 0 C16S 3921 dei5bp 1
L26 E1285X 1 C17S R1450X 2
127 3840 deIGT 0 C49S R216X 0
L29 E1379X 1 C51S R232X 0
L30 LOHwt 0 C56S R216X 0
L35 3511 insA 0 C57S R213X 0
L40 R876X 0 C65S R302X 0
L41 3927 del5bp 1 C73S 4390 delAG 2
L43 E1285X 1 C76S E1209X 0
L45 Q1338X 1 C78S 4463 delT 2
L47 Q1309X 1 C80S R216X 0
L49 3921 dei5bp 1 C84S R232X 0
L53 Q423X 0 C96S S1282X 0
L54 Q1367X 1 C99S Q1228X 0
L55 Q1378X 1 C106S R232X 0
L56 R1090X 0 D7 4661 insAWT 3
L57 3917 delA 1 E10S 4575 delGwl 3
L59 R216X 0 F1S 4470 insV * 2
L60 E1283X 0 F4S 4641 3
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insLINE1wl
L61 3921 dellObp 1 F6S R232XW1 0
L64 4080 delTC 1 F11S
3631-2
delAT™7
0
L65 G1312X 1 G1S 4470 del'Twr 2
L65 Q1345X 1 G3S
4461-4468
delSbp™1
2
L67 E1309X 1 G4S
4370-4371
insCA™7
2
L68 Q1156X 0 G6S Q1447X^ 2
L69 Q1291X 1 G7 R1450Xwt 2
L70 3921 dei5bp 1 G8S R1450X*T 2
L73 3634 del8bp 0
L75 Q1406X 2
L76 3873 ins8bp 1
L78 S1392X 1
L79 3941 deIG 1
L83 3473 FS 0
L85 S1281X 0
L89 3471 delA 0
L94 Q1294X 1
L95 E1306X 1
L101 R1450X 2
L102 4023 delT 1
L108 Q1193X 0
MA2 R1450X 2
MA3 E1309X 1
MA4 E1309X 1
MA5 C1289X 1
MA9 Q1406X 2
MA12 Q1317X 1
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T umours with 2 somatic mutations
L25
Y1166X + 4373 
insAC
0 ; 2 A2S
Q1517X H +
2814-2817
insTATA*"
3 ; 0
L36
Q1294X + 4373 
insAC
1 ;2 aB2
S1346X*'1;
LOH*"
1 ;0
L84
R213X + 4210 
delT
0 ;2 C2S
R213X+
LOHafap
0 ; 0
C4S
S1282X
+LOHafap
0 ; 0
C63S
4390 insA + 
W2504X
2 ; 7
C68S
4316 deIC +
l o h afap
2; 0
E11S
R1450X'**1' + 
4463 insA*"
2 ; 2
F12S
R232Xafap + 
4479 deIG*"
0 ; 2
aG5S
R1450XWI;
LOH*"
2 ; 0
Tumours with 3 somatic mutations
aA5S
LO H""', 4461- 
2 deITT*", 
E1286X*"
0 ; 1; 2
Table 4.2 Somatic APC mutations identified in Family S and Family B 
WT, inherited wild type APC allele; AFAP, AFAP allele; aTwo somatic mutations were 
detected on different wild type alleles in samples A5S, B2 and G5S and are likely to 
reflect mixed populations of tumour cells. Therefore, in total, 49 tumours from Family 
B harboured somatic mutations.
119
Family S
LOHWT
2
▼  Q163X
A Y 5 9 X  
U
1* i 2nd 3rd 
20AARI 20AAR 20AARI
500 1000 E1317Q A
■ ■ wmm Id a  a a
L H
1500 
H 1 in
Lohafap
Lohafap
LOHAFap
LOHAFap
LOHwtLOHWT
LOHwtLOHWTLOHWTLOHWT
Family B
2500
i
Figure 4.2 Distribution of somatic APC mutations in Family S and Family B. Somatic mutations (black squares) from Family S are 
plotted above, and those from Family B are plotted below, the schematic APC locus. The positions of the 1st, 2nd and 3rd 20AARs are 
shown as black vertical lines, the germline exon 4 truncating mutations are shown as grey triangles and the position of the germline 
E1317Q variant is shown as a black triangle and dashed line. LOHm and LOHAFAP indicate tumours exhibiting loss of the wild type and 
attenuated alleles respectively, and pairs of numbers indicate somatic mutations that occur in the same tumour.
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4.3.3 Comparing the somatic mutation spectra in Families S and B
We compared the somatic mutational spectra in Families S and B and found that the 
greatest difference was observed by considering four regions: nucleotides 637-694, 
695-3840, 3841-3967 and 3968-4661 and the results of maximum likelihood Poisson 
parameters are shown in Table 4.2. The patterns of somatic mutation in
Families S and B are dearly different (P= 2.44 x 10’5) and this difference is most 
marked in the sub-region ^  (nucleotides 3841-3967). This region encompasses the
MCR (Miyaki et al, 1994) and first three 20AARs, as well as the variant E1317Q at 
nucleotide 3949.
4.3.4 Retention of 20AARs in tumours from Family S and Family B
In Family S, there was a distinct dustering of somatic mutations around codon 1300 
and 62.1% (36/58) of the tumours had somatic mutations that were predicted to 
generate mutant APC polypeptides retaining one 20AAR (Figure 4.3). This pattern of 
mutant alleles is very similar to that found by two other studies looking at somatic 
APC mutations in tumours from families with inherited exon 4 truncating mutations 
(4/7, 57%, Sieber et at, 2006; and 6/8, 75%, Albuquerque et al, 2002) and is in dose 
agreement with the just-right signalling hypothesis. In contrast, only 8.2% (4/49) of 
tumours collected from Family B (that carry E1317Q between the 1st and 2nd 
20AARs) had somatic mutations that were predicted to result in mutant polypeptides 
that retained a single 20AAR (Figure 4.3), which is significantly less than found in 
Family S (P= 5.64x10"9) and the two other aforementioned studies (P=0.005, Sieber 
et al, 2006; P=0.0001, Albuquerque et al, 2002).
Consistent with the just-right signalling hypothesis, a low level (8/58,13.8%) of 
tumours from Family S had somatic mutations that were predicted to generate 
mutant APC polypeptides retaining two 20AARs and no tumours contained somatic 
mutations predicted to generate mutant polypeptides retaining three or more 
20AARs (Figure 4.3). In contrast, 40.8% of tumours from Family B had somatic 
mutations predicted to generate mutant polypeptides retaining two (16 tumours) or 
three (4 tumours) 20AARs (P=0. 002) (Figure 4.3). Furthermore, only 5/58 tumours 
from Family S had LOH or a somatic mutation early within the APC ORF (upstream 
of codon 500), whereas 20/49 (40.8%) of tumours from Family B carried these types
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of mutation (Figure 4.3). Therefore, complete inactivation of an APC allele was 
considerably more frequent in tumours from Family B as compared to Family S (P= 0. 
00009).
Region A \ A A
Nucleotide N°. (637-694) (695-3840) (3841-3967) (3968-4661)
Family S 0.035 0.0032 0.213 0.022
Family B 0.193 0.0022 0.032 0.023
Table 4.3 Comparing the patterns of somatic APC mutations in Family S and Family 
B using a maximum likelihood approach. The greatest difference between the 
somatic mutation spectra was observed when the region was split into four sub- 
regions: nucleotides 637-694, 695-3840, 3841-3967 and 3968-4661 and the results
of maximum likelihood Poisson parameters ( 4 -A) are shown. The two distributions
are significantly different overall (/^2.44x10*5), and sub-region ^  demonstrates the 
maximum difference.
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Figure4.3 Graphical illustration of tho numbers of retained 20AARs in tumours from Family S and Family B. In
agreement with the just right signalling hypothesis, 62.1% of tumours from Family S were predicted to generate mutant 
APC polypeptides retaining one 20AAR, which contrasts with only 8.2% of tumours from Family B (P=5.64x10*®). 
Furthermore, 40.8% of tumours from Family B had somatic mutations predicted to generate mutant polypeptides 
retaining two or three 20AARs and such mutations were rare in Family S (P=0.002). These data suggest that E1317Q 
relaxes the target of somatic mutagenesis.
4.3.5 E1317Q alters p-catenin-regulated transcription (CRT)
Previously work investigating the ability of rare APC nonsynonymous variants to 
repress (3-catenin-regulated transcription (CRT) has shown that E1317Q on an 
otherwise wild-type APC background has a reduced ability to repress CRT relative to 
the normal wild type construct (P<0.005) (Chapter 3). Here, we studied the effect of 
E1317Q on CRT in the context oMPC alleles predicted to retain one, two, three and 
five 20AARs, respectively, by introducing E1317Q onto four different truncating 
mutant backgrounds - 4PC1309A, ^PC1450A, APC1517A and ^PC1914A. When 
E1317Q was introduced into the ‘weak mutant1 constructs APC1914A and 
APC 1517A (predicted to retain five and three 20AARs, respectively), the E1317Q 
containing mutants showed on average a 1.20 -1.21 fold reduced ability to repress 
CRT relative to the normal truncating mutants (P<0.05). However, when E1317Q 
was introduced into the ‘strong mutant constructs APC1450A and APC1309A 
(predicted to retain two and one 20AARs, respectively), the E1317Q containing 
mutants showed no difference in activity relative to the normal truncating mutants 
(Figure 4.4).
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Figur«4.4 Functional analysis of E1317Q in both wild type and truncating mutant contexts.
Relative CRT levels following transfection of wild type APC  and the four truncating mutants, together with their corresponding 
glutamine (Q) containing clones at residue 1317. Corresponding schematics indicate the position of the truncating mutation 
relative to the number of retained 20AARs (black lines and associated numbers) and showing the presence or absence of 
E1317Q (’Q‘ and 'E\ respectively) (N E. Grey font E and Q indicate that the truncating mutation occurs upstream of codon 
1317). E1317Q significantly impaired (3-catenin regulated transcription in both the wild type (P<0.005) and 'weak' truncating 
mutant (P<0.05) contexts (data is presented as fold values relative to the corresponding E1317-containing clones).
4.4 Discussion
Our recent work has shown that multiple rare non-synonymous variants in APC, 
including E1317Q, predispose to CRAs (Chapter 3) and whilst we have already 
demonstrated that a proportion of these variants have a direct effect on CRT, the 
exact mechanism of the tumour predisposition still remains unclear. Since the nature 
of the germline APC mutation in patients with FAP dictates the position and type of 
somatic APC mutations that are selected in colorectal tumours (Lamlum et at, 1999), 
we investigated whether the germline non-synonymous variant E1317Q also has an 
effect on the pattern of somatic APC mutations. Using a likelihood approach, we 
showed that there was a significant difference in the distributions of somatic 
mutations between Family S, who carried only a germline exon 4 truncating 
mutation, and Family B, affected members of which carried an exon 4 truncating 
mutation and E1317Q on the same germline allele. We examined these differences 
in relation to the numbers of retained 20AARs in the predicted mutant polypeptides. 
We found that in Family S, 62.1% of tumours had somatic mutations that were 
predicted to generate mutant APC polypeptides retaining one 20AAR. This was very 
similar to the pattern of somatic APC mutation found in two previously reported 
families with inherited exon 4 truncating mutations (Albuquerque et al, 2002, Sieber 
et al, 2006) and in dose agreement with the pattern predicted by the “just-right" 
signalling hypothesis (Albuquerque et al, 2002). In contrast, only 8.2% of tumours 
from Family B had somatic mutations that were predicted to result in mutant 
polypeptides that retained a single 20AAR, suggesting that E1317Q has an effect of 
relaxing the requirement for this type of somatic mutation. Indeed, 40.8% of tumours 
from Family B had somatic mutations predicted to generate mutant polypeptides 
retaining two or more 20AARs and such mutations were rare in Family S. These data 
suggest that mutant polypeptides retaining two or three 20AARs offer the necessary 
growth advantage when found in combination with a mutant allele expressing 
E1317Q.
Complete inactivation of the entire wild type APC allele is generally only found in 
tumours from classical FAP patients with ‘strong’ germline mutations that are 
predicted to generate mutant polypeptides retaining a single 20AAR, such as 
1309del5bp (Lamlum etal, 1999). Interestingly, 40.8% of tumours from Family B had 
LOH or a somatic mutation early within the APC ORF which was significantly more
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frequent than in Family S. These data suggest that an AFAP allele carrying an exon 
4 truncating mutation in combination with E1317Q can sometimes mimic a more 
highly selected mutation, further illustrating how E1317Q may play a role in 
colorectal tumourigenesis. Although all individual members of Family B showed a 
paucity of somatic mutations that were predicted to generate polypeptides retaining 
one 20AAR, it is interesting to note that tumours from family member G showed a 
preference for mutant alleles that were predicted to encode polypeptides retaining 
two 20AARs (7/8 tumours) whereas those from family member C showed a 
preference for retaining no 20AARs (16/22). No additional inherited APC coding 
region variants were identified in these individuals after screening their entire APC 
ORFs, suggesting that factors independent of APC may also play a role in the 
targeting of somatic mutations.
We showed that the mutant AFAP allele was expressed at the mRNA level in normal 
colonic tissue from both Patient S and two members of Family B demonstrating a 
potential for APC protein expression from these AFAP alleles either through internal 
translation initiation or translation of alternatively spliced transcripts (Samowitz et al, 
1995, Heppner et al, 2002). Despite the potential for this residual activity, we found a 
low level of somatic (3rd hit) mutations on the AFAP alleles. In Family S, we identified 
only three (5.2%) tumours with two somatic mutations that may represent genuine 3- 
hit lesions (although some of these may simply represent tumours that have grown 
together after arising from neighbouring crypts). In Family B, ~16% of tumours 
potentially carried 3-hits. It remains unclear why only a minor proportion of tumours 
require these 3rd hits; however, the most likely explanation comes from careful 
examination of the pattern of somatic mutations in the three potential 3-hit tumours 
from Family S. Of the six somatic mutations in these tumours, only one is predicted 
to generate a polypeptide that retains a single 20AAR, which is significantly less than 
in tumours from Family S with single somatic mutations (P=0.038). Therefore, we 
hypothesize that a 3rd hit may be required in tumours where the 2nd hit is a weak 
mutation (i.e. those that are predicted to generate mutant polypeptides that do not 
retain a single 20AAR). An alternate hypothesis is that the requirement for a 3rd hit 
could be reduced by variants in other Wnt signalling genes, such as p-catenin 
(activating mutations of f3-catenin are thought to be functionally equivalent to 
inactivating APC mutations in their effect on Wnt signalling, Sparks et al, 1998).
We previously demonstrated that E1317Q has a direct effect on CRT using an in 
vitro assay and show in the current study that the magnitude of this effect depends 
upon the number of 20AARs in the expressed polypeptide. On a wild type 
background, or when expressed with ‘weak’ truncating mutants that would generate 
polypeptides with three or five 20AARs, the effect is significant; however, when 
expressed with ‘strong’ truncating mutants that would generate polypeptides with 
one or two 20AARs, there is no measurable effect. These results are consistent with 
our hypothesis that E1317Q itself acts as a weak mutant allele that has a subtle yet 
significant effect on the level of p-catenin within the cell thereby relaxing the target 
for somatic mutagenesis on the wild type allele.
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Chapter Five: MUTYH-deficient cells fail to engage apoptosis upon exposure to
oxidative stress
5.1 Introduction
Cell cycle checkpoints are surveillance mechanisms that monitor cellular physiology, 
maintain telomere stability and preserve genomic integrity (Zhou and Elledge 2000). 
DNA damage triggers signal transduction pathways involving sensor, transducer and 
effector proteins. Human ATM (ataxia telangiectasia mutated) and ATR (ATM- and 
Rad3-related protein) are phosphoinositol phosphate 3-kinase-related kinases. ATM 
or ATR activation occurs in response to stress and transduces the DNA damage 
signal by phosphorylating many downstream proteins in a Rad9, Radi, Hus1 and 
Rad 17-dependent manner. Radd, Radi and Hus 1 form the so-called ‘9-1-T  
complex; a heterotrimeric complex that has predicted structural homology to 
proliferating-cell nuclear antigen (PCNA) sliding clamp (Shiomi et al, 2002;
Vendovas and Thelen, 2000). Rad17 is a paralogue of the largest subunit of 
replication factor C (RFC), and it forms the alternative damp loader with RFC2-5.
The 9-1-1 complex is loaded on to DNA lesion sites by RAD17-RFC (Bermudez et al, 
2003). ATM/ATR, the 9-1-1 complex and Rad17 are proposed to act as an early step 
of DNA damage response to sense the DNA damage and to lead to cell cyde arrest 
or apoptosis (Zhou and Elledge, 2000). These checkpoint proteins may detect a 
common intermediate, such as a single stranded DNA coated with replication protein 
A (RPA), which is processed by various DNA repair pathways (Bermudez, et al,
2003). Several reports support a hypothesis that checkpoint proteins may require a 
series of ‘adaptors’ to recognise DNA damage (Zou and Elledge, 2003; Giannattasio 
et al, 2004; Lavin 2004). These adaptor proteins may be DNA damage recognition 
proteins involved in mismatch repair (MMR), nucleotide exdsion repair (NER) and 
double-strand break (DSB) repair.
MUTYH has been directly assodated with PCNA in Schizosaccharomyces pombe 
(S. pombe) and human cells (Chang and Lu, 2002; Parker etal, 2001). The coupling 
between the MUTYH BER pathway and DNA replication may provide a signal to 
target MUTYH repair to daughter DNA strands (Parker et al, 2001). DNA damage 
induced SpHusI phosphorylation is dependent on SpMYH expression (Chang and 
Lu, 2002). Shi et al, (2006) have shown that human MUTYH physically interacts with
129
Hus1 and Radi, and co-localises to nuclear foci with Radd following oxidative 
damage and recently the 9-1-1 complex has been shown to interact with and 
stimulate the enzymes involved in BER, which include polymerase p (Toueille et al,
2004), FEN1 (flap endonuclease 1) (Friedrich-Heineken etal, 2005) and DNA ligase 
1 (Wang et al, 2006). Thus the 9-1-1 complex serves both as a damage sensor and 
as a component of BER.
We assessed the response of primary MUTYH defdent cell lines to oxidative 
damage to examine the mechanisms of MAP-associated cell survival/death.
5.2 Methods
5.2.1 Cell Lines
MUTYH-defident primary cell lines MAPI, MAP2, and MAP3 are human epithelial 
fibroblast cell lines derived from clinical biopsies obtained from colectomy specimens 
from unrelated MAP patients. 161BR is a MUTYH-profident human epithelial 
fibroblast cell line obtained from the ECACC. All cells were maintained in 5% C02 
atmosphere in DMEM medium with 15% (v/v) foetal bovine serum, 1% non essential 
amino acids, 1% L-glutamine and 1% penicillin/streptomycin at 37°C.
5.2.2 Cell Survival Assays
Cells were seeded in triplicate at 2x103 cells per well into Optilux 96-well plates 24 
hours before treatment to allow suffident adherence. Hydrogen peroxide (H2O2) and 
f-butyl hydroperoxide (TBH) treatments (0,12.5, 25, 50,100 and 200pM) were given 
for 1 hour at room temperature. Cells were rinsed twice with cold PBS before 
replenishing with media. ATP measurement medium alone, untreated control cells 
and treated cells (with peroxide) were assessed immediately after peroxide 
treatment and at 24 hour intervals for 7 days using the CellTiter-Glo Luminescent 
Cell Viability Assay that quantifies the amount of ATP present in a homogenous lysis 
solution, according to the manufacturer's instructions. The luminescence of each 
sample was measured with TR717 microplate luminometer.
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5.2.3 Caspase-3 Activation Assay
Caspase-3 activation assays were performed using a Caspase-Glo™3/7 assay kit 
according to the manufacturer's instructions. Briefly, cells were seeded in 96-well 
plates at a density of 2x103 cells/well. After 24 hours, cells were exposed to H2O2 
and TBH solutions (0,12.5 and 25 pM) as described in section 5.2.2. Caspase-Glo 
3/7 reagent (100pl) was then added to each well including medium alone, untreated 
control cells or cells treated with peroxide 1,24,48 and 72h post exposure. The 
luminescence of each sample was measured with TR717 Microplate Luminometer.
5.2.4 immunoprecipitation and Western blotting
Following exposure to peroxide at 1, 3 ,6  and 9 hours, cells were lysed on ice for 10 
minutes in NP-40 lysis buffer (50mM Tris-HCI pH 8 ,150mM NaCI, 1% NP-40, 50mM 
PMSF in isopropanol, 1ug/ml of Leupeptin, Aprotinin, and Pepstatin). Half volume 
was used to determine phosphorylation of Chk1 whilst the remaining half was used 
to determine total Chk1 as a control. Briefly, lysates were incubated with 1pg of anti- 
phosphoChk1(Ser317) for 1 hour at 4°C (1:500 dilution). Twenty microlitres of 
Protein G-Sepharose bead solution was added and the mixture was incubated at 
4°C for 2 hours. After three wash/centrifugation steps at 3000gfor 1 minute the pellet 
was resolved by SDS/PAGE and transferred to a nitrocellulose membrane. The 
membranes were allowed to react with antibodies against phCHKI. Western blotting 
was detected by the enhanced chemiluminescence (ECL) analysis system according 
to the manufacturer's protocol. Each Western blot experiment was repeated.
5.2.5 Immunofluorescence
After exposure to H2O2 for 3 hours, cells were fixed with 0.4% formal saline for 15 
minutes at room temperature. Cells were permeabilised with 100% methanol for 5 
minutes at -20°C. After being blocked in PBS containing 15% foetal bovine serum 
(FBS) for 1 hour at room temperature, the cells were reacted with rabbit polyclonal 
antibodies for MUTYH (1:250 dilution) and mouse monoclonal antibody for RAD9 
(1:20 dilution) at 37°C for 30 minutes. Next the cells were washed three times for 15 
minutes each in TBS-Triton and incubated with Alexa Fluor® 594 goat anti-rabbit 
and Alexa Fluor® goat anti mouse IgG antibodies at a 1:250 dilution in PBS for 30 
minutes at 37°C. The cells were then washed three times in PBS. Nuclear DNA was 
counterstained with DAPI (4'6’-diaminido-2-phenylindole). Images were captured
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with an Olympus BX51 BF fluorescent microscope with an attached mercury lamp 
charge coupled device (CCD) camera.
5.2.6 Statistical analysis
The students’ f-test was used to assess statistical significance.
5.3 Results
5.3.1 MUTYH-deficient cells are resistant to the cytotoxic effects of peroxides
We established primary fibroblast lines from three unrelated patients with MAP 
(MAPI, MAP2 and MAP3), all of whom shared the same common MUTYH genotype 
Y165C/G382D (Sieber et al, 2003), and a wild type control. We determined the 
growth rate of each cell line under normal conditions to ensure that cell survival 
assay results were not skewed due to differences in population size and variable 
growth rates. We used standard luminescent cell viability assays to quantify the 
number of metabolically active cells based on the detection of cellular ATP. Each cell 
line grew at a similar rate at every time point measured (0 -7  days) validating their 
inclusion in this study (figure 5.1).
To determine the role of MUTYH in oxidative stress-mediated cytotoxicity, we 
compared the relative sensitivities of the cells to H2O2 and TBH. MUTYH-deficient 
cells were significantly more resistant to H2O2 induced cytotoxicity as compared to 
wild type cells (Figure 5.2). At 48 hours post exposure to 12.5pM or 25pM H2O2, the 
MUTYH deficient cells had a mean viability of 45-64% and 43-49%, respectively, 
whereas the wild type cells had a viability of 20 and 9%, respectively (P<0.001). 
Similarly, after 7 days post exposure to 12.5-25pM, MUTYH deficient cells had an 
average cell viability of 70-83% and 60-77%; significantly higher than that of the wild- 
type (25 and 15%), At a higher dose of 50pM H20 2, cell lines MAPI and MAP2 had a 
mean viability of 52-77% whereas the mean viability of MAP3 had fallen to 23%; 
these levels were still significantly higher than the wild-type (F<0.001). MUTYH- 
deficient cells were also significantly more resistant to TBH induced cytotoxicity as 
compared to wild type cells. At 4 days post exposure to 12.5pM or 25pM TBH, the 
MUTYH deficient cells had mean viabilities of 30-36% and 29-33% compared to the 
wild-type cell lines that showed 17% mean viability to both concentrations(P>0.001).
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At 100-200|jM H2O2 or TBH, both MUTYH-defident and wild type cells showed 
similar sensitivities.
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Figure 5.1 MUTYH proficient (WT) and MUTYH deficient (M A PI, MAP2 and 
MAP3) growth rates. Cell survival assays of untreated cell lines over a seven day 
period indicate that all cell lines grow at a similar rate after initial seeding into Optilux 
plates.
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Figure 5.2 Cell viability in MUTYH proficient (WT) and MUTYH deficient (M API, 
MAP2, MAP3) cell lines after treatment with peroxides. (A-C) show percentage 
viability of cell lines over a period of 7 days following exposure to H2O2 and TBH. 
Results are shown as the percentage relative to do mock treated control and 
represent the mean ±SD of experiment carried out in triplicate.
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5.3.2 MUTYH-deficient cells fail to undergo apoptosis
Increased resistance to the cytotoxic effects of H2O2 or TBH may result from a 
decrease in cell death due to necrosis or apoptosis. To determine the route and 
extent of cell death induced by peroxide treatment we measured caspase 3 
activation in Ml/7YH-defident and proficient cells 1, 24, 48 and 72 hours after 
treatment with H2O2 or TBH. Caspase-3 is one of the key executioners of apoptosis 
as it is either partially or totally responsible for the proteolytic cleavage of many key 
proteins such as the nuclear poly (ADP-ribose) polymerase (PARP) (Fernandes- 
Alnemri et al, 1994) and as such, caspase-3 activation is often used as an early 
indicator of this process. Wild type cells showed a dose dependent increase in 
caspase activation after exposure to 12.5-25pM H20 2or TBH, indicating that 
cytotoxic effects of peroxide exposure were initiating apoptosis in these cells (Figure 
5.3).
At 1 hour post-exposure to 12.5pM H20 2, the MUTYH deficient cells had a mean 
caspase activation level 0.7 fold less than that of the wild-type cell line (F<0.001) and 
on average 0.35 fold less activation (P<0.001) than that of the wild-type cell line at 
each subsequent time point (24,48 and 72 hours). After exposure to 25pM H20 2) 
Ml/TYH-defident cell lines initially exhibited caspase-3 activation at levels 0.6 fold 
less than the wild-type cell line after 1 hour of treatment (F<0.0001) which 
subsequently fell to 0.2 fold less at 24,48 and 72 hours post exposure (F<0.001). 
Caspase-3 activation in Ml/7YH-deficient cells was also significantly reduced 
following TBH exposure as compared to wild type cells. One hour after exposure to 
12.5-25pM TBH, the MUTYH deficient cells exhibited caspase-3 activation 0.5-0.6 
fold less than the wild type cell line (F<0.001) and 0.4-0.6 fold less (P<0.0001) at 24, 
48 and 72 hours.
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Figure 5.3 Activation of caspase-3 in MUTYH (WT) proficient and MUTYH 
(MAPI, MAP2 and MAP3) deficient cell lines after treatment with peroxides.
Normalised luminescence values (RLUs) indicate level of active caspase-3 detected 
following exposure to stated concentrations of H2C>2 (left) and TBH (right). Error bars 
indicate the ± SD of experiments carried out in triplicate.
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5.3.3 Lack of Chk1 phosphorylation/activation post damage permits cell 
survival
We determined whether MUTYH-deficiency altered the phosphorylation status of the 
checkpoint protein Chk1 (which drives cell cycle arrest) after oxidative stress. We 
exposed cells to 0,12.5 and 25pM H20 2 and measured Chk1 phosphorylation over a 
9 hour period. No phosphorylation of Chk1 occurred in any lines after exposure to 
the control (no H2O2) (Figure 5.4). At 3, 6 and 9 hours post exposure to H2O2, Chk1 
phosphorylation was detected in all wild type cells in a dose-dependent manner. In 
contrast, at 3 and 6 hours post exposure, all MUTYH-deHdenX cells showed 
significantly lower levels of Chki phosphorylation (PS0.01) and by 9 hours, no 
MUTYH-deficient lines exhibited Chk1 phosphorylation (P<0.05) as assessed by 
Western blot analysis.
5.3.4 Lack of MUTYH and Rad9 nuclear co-localisation in MUTYH deficient 
cells upon peroxide treatment
We determined whether MUTYH and Rad9 move to the same nuclear fod following 
H2O2 treatment using immunofluorescent staining analysis. In untreated cells 
MUTYH was visible as granular staining distributed within the cytoplasm and peri­
nuclear region of the cell, whilst RAD9 was consistently found within the peri-nuclear 
region. After exposure to H2O2, in -82% of wild-type cells MUTYH and Rad9 formed 
discrete nuclear foci (Figure 5.5a). The remaining 18% of wild-type cells had MUTYH 
and RAD9 co-localisation within the peri-nuclear region of the cell. Conversely, in the 
three MUTYH deficient cell lines most staining for both proteins remained in the peri­
nuclear region of the cytoplasm (-60-70%; PS0.008) whilst significantly less nuclear 
staining was observed (PS0.01) (figure 5.5b and 5.5c). A small proportion of cells 
contained MUTYH that appeared to have remained completely in the ‘pre-exposure’ 
cytoplasmic localisation (3-7%; P<0.004/
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Figure 5.4 Phosphorylation status of Chk1 following exposure to oxidative 
damage. M UTYH  proficient (WT) and M UTYH  deficient (M API, MAP2 and MAP3) 
cell lines were exposed to 0, 12.5 and 25pM of H20 2 and Chk1 phosphorylation was 
determined at 1, 3, 6 and 9 hours after exposure by western blot analysis. 
Endogenous total Chk1 was determined by the same method to act as a positive 
control ensuring that differential phosphorylation was not due to differences in total 
protein expression.
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Figure 5.5c Intracellular localisation of MUTYH and Rad9. Data obtained 3 hours post 
exposure to 12.5pM H20 2. Cells were cultured on chamber slides and following oxidative 
damage were fixed and stained with antibodies against MUTYH and RAD9. The nucleus is 
visualised using DAPI staining. A) All cell lines treated with negative control. MUTYH is 
found predominantly in the cytoplasm and RAD9 is located within the peri-nuclear space 
(-80%;). B) Following exposure to hydrogen peroxide both MUTYH and RAD9 co-localised 
within the nucleus in the wildtype cell line. In the MUTYH deficient cell lines however staining 
for both proteins remained peri nuclear (P=0.008).
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5.4 Discussion
5.4.1 MUTYH deficiency results in decreased apoptosis in response to 
peroxide mediated oxidative damage
We have used patient derived MUTYH deficient epithelial fibroblast primary cell lines 
to demonstrate a role for MUTYH in mediating an apoptotic response to the 
peroxides H2O2 and TBH. We found that apoptotic response of MUTYH deficient 
cells to the cytotoxic effects of oxidants was significantly decreased compared to the 
normal control. One MUTYH deficient cell line (MAP3; figure 5.2C) had a more 
marked apoptotic response to 50pM H2O2 compared to the two other MUTYH 
deficient cell lines. However, mean viability of this cell line seven days after exposure 
to H2O2 was still significantly higher than the wildtype cell line. All three MUTYH 
deficient cell lines had the same germline MUTYH mutations so differences in 
genotype cannot explain the variability seen. Cell lines were maintained at similar 
passage numbers to eliminate this acting as a variable. Active caspase 
measurement and Chk1 activation were similar for each cell line also so variability in 
cell viability appears to be determined by other factors
Interestingly, previous studies did not find any difference between H2O2 induced 
cytotoxicity in Mutyh '^and wild type murine embryo fibroblasts that had 
spontaneously immortalised (Xie et al, 2008) or in Epstein-Barr virus transformed 
lymphocytes from patients with MAP and controls (Parker et al, 2001). However, our 
studies are based on primary cultures of human fibroblasts and are likely to 
represent a better in vitro model of MAP. The decrease in cell death in response to 
peroxides was accompanied by a lack of caspase-3 activation and lack of 
phosphorylation of the cell cycle checkpoint protein Chk1, suggesting that cell 
survival in MUTYH-defident cells is due to an inability to execute programmed cell 
death in parallel with a failure to initiate cell cycle arrest.
5.4.2 Overlapping roles for DNA repair proteins in cell cycle progression
A potential role for MUTYH, or other members of the BER system, regulating cell 
cyde has not been demonstrated before. Interaction between proteins in other repair 
pathways and checkpoint activation proteins at DNA lesions has been previously 
demonstrated in other model organisms. (Meister et al, 2003; Giannattasio et al,
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2004; Kai and Wang, 2003). DNA damage checkpoints ensure a proper cellular 
response to a range of genotoxic insults. Malfunctioning of such systems is linked to 
premature aging, uncontrolled cellular proliferation, genome instability and ultimately 
tumourigenesis (Hartwell 2002). Failure to detect the primary lesion results in 
defective activation of the checkpoint response and failure to arrest cell cycle 
progression and DNA replication. Moreover, if the primary damage is not detected by 
the checkpoint, it may be channelled into other cellular processes (e.g. aberrant 
recombination) that can cause DNA instability. The biochemical mechanisms 
involved in the sensing step of the checkpoint response are still relatively poorly 
understood. How do cells identify that their DNA has been damaged? How are the 
lesions found within the genome and how is the first protein kinase in the cascade 
activated?
Yoshioka et at (2006) showed that the MMR proteins MutSa and MutLa act as direct 
sensors of methylation damage and help recruit ATR-ATRIP to sites of cytotoxic O6- 
methyl-G (Oe-meG) adducts to initiate ATR checkpoint signalling in yeast, In vitro 
assays showed that following DNA methylation, cell cycle checkpoint machinery is 
engaged during S-phase and that after DNA replication Oe-meG adducts are 
regularly mispaired with thymine residues and that these mispairs are a target of 
MutSa. ATR-ATRIP is preferentially recruited to 0 6-meG/T mismatches in a MutSa 
and MutLa dependent manner. Furthermore, ATR kinase is activated to 
phosphorylate Chk1 in the presence of Oe-meG/T mispairs and MMR proteins. MMR 
and the corresponding antimutator role can be separated functionally from the DNA 
damage response role of MMR proteins. For example, cells having reduced levels of 
MSH2 or MLH1 protein are competent for MMR but fail to carry out checkpoint 
activation or undergo apoptosis in response to DNA alkylation (Lettieri et al, 1999; 
Cejka et al, 2003; Claij and te Riele, 2004). Even more intriguing has been recent 
report of two separation of function alleles in murine Msh2 and Msh6 that encode the 
two subunits of MutSa. These mutations in or near the nucleotide binding site of 
MSH2 and MSH6 disable mismatch repair but leave intact the apoptotic response to 
DNA damaging agents, including MNNG (Yang et al, 2004; Lin et al, 2004). The 
separation of function alleles argue strongly that MMR and damage signalling involve 
distinct pathways. This notion is supported by protein-protein interactions between 
Msh6p and Meklp, the ATR homolog in budding yeast (Gavin etal, 2006), and
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between human Msh2 and the checkpoint proteins Chk1 and Chk2 (Adamson et al, 
2005; Brown et al, 2003).
One caveat not explored by this study is the upregulation of catalase in response to 
oxidative stress. Catalase is responsible for degradation of hydrogen peroxide 
encountered from exogenous sources or produced intracellularly as a result of 
celular metabolism. Two enzymes, glutathione peroxidase (GpX) and catalase are 
the two principal scavengers of hydrogen peroxide. Exposure to oxidative stress 
results in the upregulation of the enzymatic activity of the antioxidant enzymes such 
as GpX, catalase and the superoxide scavenger superoxide dismutase (SOD). 
Increased activity, enhanced protein and higher mRNA levels have been reported for 
the enzyme catalase in cells subjected to oxidative stress (Rohrdanz and Kahl, 2009; 
Rohrdanz et al, 2001). It is well-known that pre-exposure to stress upregulates 
cellular anti-oxidant defense mechanisms resulting in adaptation to stress (Rohrdanz 
and Kahl, 2009; Rohrdanz etal, 2001; Lai et al, 1996; Luo and Rando, 2003). The 
characterisation of the MUTYH deficient cells would not be complete without 
investigating the ‘catalase upregulation’ response to oxidative damage under similar 
experimental conditions and should be proposed as future work.
Having an established role for MMR proteins in checkpoint signalling sets the 
precedent for DNA repair enzymes behaving as genotoxic stress ‘sensors' and 
‘adaptors’. This supports further examination of the role of MUTYH in response to 
oxidative damage outside of the remit of a classic ‘repair protein’. A model using data 
generated in this study is described in detail in chapter 6. By identifying a suitable 
panel of in vitro model systems, future studies of damage signalling mediated by 
BER proteins will aid and facilitate the identification of the full complement of proteins 
required to elicit the damage response. In the context of inherited colorectal 
polyposis syndromes this would allow deeper insight into the complex mechanisms 
of pathogenesis required to initiate adenoma development and subsequent 
tumourigenesis.
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Chapter six: General discussion
6.1 High and low penetrance alleles predisposing to CRC
Approximately 5% of cases of CRC are associated with dominantly inherited, familial 
Mendelian susceptibility. FAP, MAP and HNPCC are caused by highly penetrant 
mutations in APC, MUTYH and the MMR genes respectively. An additional 15 -  30% 
of cases are believed to be due to inherited susceptibility that is polygenic i.e. 
associated with much lower penetrance variants that do not give rise to clear cut 
familial patterns of inheritance. The genetic basis of most inherited CRC 
susceptibility is thought to be due to low penetrance alleles and these are now being 
identified. Genes in which highly penetrant CRC susceptibility alleles have been 
described may also harbour incompletely penetrant changes. In collaboration with 
Myriad Genetic Laboratories and Genzyme Genetics we comprehensively 
sequenced the entire ORF of APC in order to identify the full repertoire of 
nonsynonymous variants within the gene. We have reported that multiple rare (MAFs 
<2%) inherited APC nonsynonymous variants may predispose to CRAs. A higher 
proportion of patients without truncating APC mutations or biallelic MUTYH 
mutations (non-FAP, non-MAP) carried rare APC nonsynonymous variants than did 
the FAP or MAP cases. The highest over representation of these rare 
nonsynonymous variants was in non-FAP non-MAP patients. Compared to healthy 
controls, significantly more non-FAP non-MAP cases carried rare nonsynonymous 
variants in the p-catenin down-regulating domain of APC and again the highest over- 
representation was in patients with 11 -  99 CRAs. When only variants with a 
MAF<0.5% were considered (thereby excluding I1307K, E1317Q and G2502S), 
there was still an excess of rare APC missense variants in non-FAP non-MAP cases. 
Rare synonymous variants and common polymorphisms were detected at similar 
frequencies in non-FAP non-MAP patients, FAP or MAP cases and healthy controls 
(all of whom were of similar ethnic backgrounds) so the findings are unlikely to be 
the result of population stratification. Not all nonsynonymous variants would be 
expected to have a detrimental effect on APC function but in silico analysis predicted 
39-46% of the variants were likely to be damaging.
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Functional analysis of 16 nonsynonymous variants found in the p-catenin down 
regulating domain showed that 7 altered (3 -catenin transcription in vitro. N1026S, a 
novel APC nonsynonymous mutation has recently been reported to be associated 
with AFAP in a single family. The variant co-segregated with the disease in the 
reported family and functional analysis showed that it altered (3 -catenin-regulated 
transcription (Menendez etal, 2008).
The effect the rare nonsynonymous variant E1317Q had on a genetic level was 
examined by comparing the somatic mutation spectra of two AFAP families. Family 
S carried an early germline truncating mutation at codon 163 and Family B carried a 
germline truncating at codon 159 as well as the E1317Q variant. Several genetic 
studies of CRAs from FAP patients have shown that somatic APC mutations are 
dependent on the position of the germline APC mutation (reviewed in more detail in 
chapter 1). The APC protein contains seven 20AARs which are involved in 
degrading the transcriptional co-factor (3-catenin and so negatively regulates Wnt 
signalling. In colorectal polyps, germline mutations between codons 1285 and 1378 
leave only one 20AAR intact and are strongly associated with somatic loss of the 
wildtype APC allele. LOH usually occurs through mitotic recombination, thus leaving 
two identical alleles and a total of two 20AARs in the tumour cell (Sieber et al, 2002). 
FAP patients who carry germline mutations before codon 1285 (no 20AARs) tend to 
have somatic mutations which leave one or, more commonly two 20AARs in the 
protein. Finally, patients with germline mutations after codon 1398 (two or three 
20AARs) tend to have somatic mutations before codon 1285 resulting in a truncated 
protein with no 20AARs. The same associations have also been found in sporadic 
colorectal tumours (Rowan et al, 2000).
This interdependence of ‘first’ and ‘second’ hits shows that selective constraints on 
APC mutations are active and that an optimum level of p-catenin signalling must be 
achieved for a nascent tumour cell to grow (Albuquerque et al, 2000). We sequenced 
the entire ORF of APC from DNA extracted from tumour biopsies from all family 
members to establish any differences in the somatic mutation spectra of each family. 
With this established interdependence in mind we would expect the majority of 
‘second’ hit mutations to result in a truncated protein predicted to retain one 20AARs 
but there was a significant difference between the families; approximately 60% of
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tumours from Family S (without the E1317Q variant) had somatic mutations that 
were predicted to result in truncated APC retaining a single 20AAR compared to 
<10% from family B (with the E1317Q variant). Conversely a larger proportion of 
tumours from Family B were predicted to result in a truncated APC protein retaining 
two 20AARs. These data suggest that mutant polypeptides retaining two or three 
20AARs offer the necessary growth advantage when found in combination with a 
mutant allele expressing E1317Q at a low level.
6.2 Genetic susceptibility to disease
Two models of susceptibility to complex human disease have been proposed. The 
‘common disease-common variant’ model states that genetic susceptibility to 
common disease is conferred primarily by common alleles (within the general 
population) that have very modest phenotypic effects (Lander 1996; Chakravati 
1999). The alternative ‘common disease-rare variant’ model proposes that 
susceptibility to common diseases is due to the effect of multiple rare alleles, each 
conferring a more substantial increase in relative risk and their mechanisms are 
complementary, rather than mutually exclusive. Although individually rare, these 
alleles may be collectively common in the population. Despite the fact that, 
theoretically, such variants may have diverse effects on protein function, disease- 
phenotype biological fitness, many rare nonsynonymous variants are believed to 
elicit insignificant functional effects (Glazier et al, 2002).
6.3 Common variants and CRC
Genome-wide association studies (GWAS) are aiding the identification of common 
low penetrance CRC predisposition alleles at loci previously unassodated with an 
inherited CRC syndrome or colorectal tumourigenesis. Such studies have recently 
identified a CRC susceptibility locus at 8q24.21 (Tomlinson etal, 2007; Zanke eta!, 
2007). Two common SNPs (rs6983267 and rs10505477) that are in linkage 
disequilibrium were strongly assodated with colorectal neoplasia (Tomlinson etal, 
2007; Zanke etal, 2007) and mapped to a haplotype block which and been 
previously assodated with prostate cancer risk (Haiman et al, 2007; Yeager et al, 
2007). This locus does not contain any known genes but does have two predicted 
ORFs. One appers to be an uncharacterised gene with multiple alternatively spliced 
transcripts and harbours rs10505477 within an intron. The other is a processed
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psuedogene of POU5F1 (which encodes a transcription factor) and is found 20kb 
telomeric to rs6983267 (Tomlinson et al, 2007; Zanke et a/, 2007). The MYC 
oncogene lies 116kb telomeric to rs6983267 and outside the haplotype block but its 
function could be influenced by the risk variant through genomic instability or long- 
range regulation of expression. The CRC susceptibility locus at 8q24.21 influences 
the risk of CRAs and so may be affecting tumour initiation rather than progression 
(Tomlinson et al, 2007). Three common SMAD7 SNPs which influence CRC risk 
were also recently identified through a GWAS. This gene is involved in TGF-P and 
Wnt signalling and all three variants map to the same block of linkage disequilibrium 
located in intron 3 of this gene. Similar to the 8q24.21 locus, the SMAD7 SNPs 
significantly influence the risk of CRAs so may be affecting tumour initiation rather 
than progression (Broderick et al, 2007).
Hereditary mixed polyposis syndrome (HMPS) reported in Ashkenazi families is 
associated with the highly penetrant CRAC1 locus and is characterised by multiple 
colorectal polyps (which are not classical adenomas) and CRC. A GWAS of UK CRC 
cases (selected for family history and/or early onset) and unaffected controls found 
that common SNPs within the CRAC1 locus were strongly associated with an 
increased CRC risk suggesting that common low penetrance alleles at this locus can 
contribute to CRC predisposition in the general population (Jaeger et al, 2008).
However, despite the power of large population association studies, rare 
nonsynonymous variants will not be detectable because of their low allele frequency 
and individually small contributions to the overall inherited susceptibility of a disease. 
Current literature suggests that the most successful strategy for identifying rare 
nonsynonymous variants implicated in disease involves comparing the overall 
frequencies of such variants identified in candidate genes in disease and control 
groups. In such studies the patient groups may be shown to contain genes ‘enriched’ 
with rare variant. Critically, this approach is heavily biased since investigators are 
ultimately only able to identify variants they are searching for and this approach does 
not highlight true associations between ‘unknown’ rare nonsynonymous variants 
within these genes other than the one(s) of interest.
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Significantly, the technology used to resquence (or ‘deep’ resquencing) genes is 
becoming relatively cheaper and more accessible. Genes implicated in disease 
predisposition can now have all variation comprehensively identified in both disease 
and control groups ensuring a thorough and systematic investigation, when before, 
limitations such as cost and time will have caused biased analysis.
The potential consequences for protein function of each rare variant can also be 
assessed for features suggesting pathogenicity i.e. occurrence in conserved regions, 
charge changes, and bulky changes likely to affect protein structure and also by 
direct biochemical or functional assays. In the context of these criteria, a potentially 
pathogenic variant is one that shows a significant difference in frequency between 
disease and control population either singly or more often, as a member of a group 
of variants affecting the same gene or a set of genes with related functions. Ideally, 
such variants will be characterised functionally by suitable in vitro assays to assess 
their eventual effect on the function of the relevant gene product.
6.4 Applications of CRC predisposition alleles in clinical practice
High penetrance CRC predisposition alleles can be used by medical genetics 
services to improve the counselling and surveillance of families at high risk. If a 
patient carries a pathogenic mutation(s), they can undergo colonic surveillance and 
prophylactic surgery if necessary whereas family members who do not carry the 
mutant allele(s) do not require additional surveillance. However, genetic counselling 
and management of patients who carry variants of unknown pathogenicity such as 
missense changes is difficult, with a requirement for unequivocal genetic and 
functional data before the variant can be used with confidence in the setting of pre- 
symptomatic testing.
Testing for low penetrance alleles should not be applied in a clinical setting at 
present but this situation is likely to change as the risks associated with such alleles 
are clarified. In practice, family history is currently used as an indicator of risk in 
families in which no high penetrance genetic defect can be identified. It is my opinion 
that testing for low penetrance alleles should be used in a diagnostic setting only 
when they have been determined to result in a pathogenic effect and are dearly 
shown to compromise the function of a protein, given the degree of academic
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uncertainty surround their effects it would be irresponsible to see them tested for in 
the present day. Large scale GWAS have identified 11 lod that are associated with 
CRC incidence but only two of these studies have been followed up with functional 
studies to determine the mechanism that results in pathology. I feel this is the start of 
a process that will lead to the inclusion of low pentrance alleles in clinical 
diagnostics.
In the future, rare SNPs associated with increased CRC risk may well be used to 
identify individuals in the general population for whom additional CRC screening is 
appropriate -  this prospect would appear to fit in with the ideal of personalised 
medicine that has been bom out of the ‘genomic era’ , however this concept seems a 
million miles away from current public health priorities and cancer screening 
strategies. One would also be mindful of the psychological aspects this type of 
screening and would not want to burden the individual with a positive diagnosis 
without good reason.
6.5 DNA repair mechanisms and cancer predisposition
MUTYH is one of many DNA repair genes implicated in cancer predisposition 
(Vogelstein and Kinzler, 2004). Inherited defects in these genes are believed to 
cause tumourigenesis by increasing the rate of somatic mutations in key tumour 
suppressor genes, perfectly illustrated by the synergy of biallelic inactivating MUTYH 
mutations resulting in somatic inactivation of APC (Thibodeau et a/, 1993; Al -  
Tassan et at, 2002). In contrast with other major repair pathways, inherited defects in 
just a single component of the BER system has so far not been found to predispose 
to cancer. Inactivation of the other BER proteins could result in programmed cell 
death, rather than leading to tumourigenesis.
Mutations of genes within identical repair pathways can also result in different 
phenotypes. Inactivation of ATM, the homologous recombination repair pathway 
(HRR) protein, causes ataxia telangiectasia which predisposes to lymphomas and 
leukaemias (Rotman and Shiloh, 1998). Similar cancer susceptibilities are observed 
in patients with germline mutations in the NBS1, MRE11, and Fanconi anaemia 
genes which are also found in this pathway. However, Rothmund-Thompson and 
Bloom’s syndromes are both caused by defects in RecQ like-helicases that
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recognise and promote branch migration of Holiday junctions, but the former leads to 
bone tumours and the latter is characterised by cancers of the haematopoietic and 
lymphatic systems (Hoejimakers, 2001). BRCA1 and BRCA2 also have roles in 
recombination repair; BRCA1 is a substrate for ATM and interacts with RAD50 
(Zhong, 1999), BRCA2 is involved in the nuclear translocation of RAD51 (Davies et 
al, 2001) and both may assist HRR through histone acetylation and deacetylation 
(Scully, 2001). Mutations in these genes predispose to breast and ovarian cancers 
(Narod and Foulkes, 2004).
In contrast to mouse models of nucleotide excision and recombination repair 
deficiency, severe BER knockout mice do not display significantly enhanced 
susceptibility to DNA damage or cancer. (Tanaka et al, 2001; Moynahan, 2002; 
Takao etal, 2002; Klungland etal, 1999). In addition MUTYH'7' OggT7' mice exhibit a 
more severe phenotype than their single knockout counterparts, suggesting that 
there is a functional overlap (Russo et al, 2004). A higher level of functional 
redundancy may exist between the BER system than in other repair pathways and 
MUTYH may be unusual in that its role cannot be adequately filled by other 
glycosylases.
6.6 Is MAP due to defective repair and failure to initiate correct cell-cycle 
surveillance?
The biochemical responses recorded from our MUTYH deficient cell lines provides 
novel data and suggests some overlap between the BER system and the replication 
checkpoint response. This is typified by a significant lack of Chk1 phosphorylation in 
MUTYH deficient cell lines and subsequent failure to engage in apoptosis as 
compared to a wildtype cell line. The primary question arising out of this is at what 
stage does checkpoint signalling become activated and where does MUTYH 
participate in this pathway? It is established that 8-oxoG lesions induced by oxidative 
damage, if left unrepaired, result in 8-oxoG/A mispairs following DNA replication. We 
can therefore state that such lesions have no effect on DNA replication i.e. stalling, 
and would not bring about a checkpoint signalling response. Another facet of 
oxidative damage is therefore implicated; ROS are also known to cause single­
strand breaks in DNA that are blocked with 3’-phosphoglycolate (Barzilai and 
Yamamoto, 2004). This would inevitably result in stalled replication if left alone and a
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role in replication coupled repair has previously been proposed for MUTYH (Boldogh 
et at, 2001). By examining the normal response to stalled replication could we 
speculate a model for BER mediated checkpoint signalling?
The mammalian replication checkpoint response system slows down cell cycle 
progression and stabilises stalled replication forks so that further DNA damage is 
prevented. At the heart of this checkpoint are two protein kinases, ataxia 
telangiectasia mutated and Rad3 related (ATR) and Chk1 (Chen and Sanchez,
2004; Zhang et al, 2006; Paulsen and Cimprich, 2007). A model proposing how 
these proteins mediate repair of stalled replication forks is as follows (figure 6.1). 
Stalled replication forks activate ATR which subsequently phosphorylates and 
activates Chk1. Because ATR is critical in replication stress response, the 
biochemical mechanism governing ATR activation has been extensively examined. 
During replication, if a DNA polymerase stalls, the minichromosome maintenance 
helicase continues to unwind DNA ahead of the stalled polymerase (Byun et al,
2005). This produces long tracts of single-stranded DNA (ssDNA), which become 
coated with replication protein A (RPA). Additional factors are required i) ATR- 
interacting protein (ATRIP), an ATR binding partner that interacts directly with RPA 
to load the ATR-ATRIP complex onto ssDNA (Cortez et al, 2001; Zou and Elledge, 
2003; Unsal-Kacmaz and Sancar, 2004; Ball et al, 2005; Namiki and Zou, 2006), and 
ii) the 9-1-1 complex is loaded onto DNA by a clamp-loader protein consisting of 
Rad17 and four subunits of the replication factor C (RFC) complex (Parrilla-Castellar 
et al, 2004). What is less dearly understood is how components of the 9-1-1 
complex are recruited to sights of DNA damage.
The response of DNA glycosylase enzymes to oxidative damage is relatively well 
characterised in both bacterial and mammalian cells. In several studies involving 
both eukaryotic and yeast systems MUTYH has been shown to interact and/or 
associate with proteins that are not directly implicated in BER; Chang and Lu (2002) 
showed in S. pombe that DNA damage induced phosphorylation of SpHusI is 
dependent on SpMYH expression. Subsequent studies in HeLa cell lines by Shi et al 
(2006) showed they MUTYH physically interacted with Hus1 and Radi following 
oxidative damage induced by hydrogen peroxide. It would appear that the 
relationship between MUTYH and the separate components of the 9-1-1 complex
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merits further investigation and may explain the results generated from our 
biochemical characterisation of patient derived MUTYH deficient cell lines. 
Significantly, other enzymes in the BER system have been shown to interact with the 
9-1 >1 complex. These include NEIL1 (Guan etal, 2007), APE1 (Gembka etal, 2007), 
Pol(3 (Toueilleetal, 2004), FEN1 (Friedrich-Heineken etal, 2005; Wang etal, 2004) 
TDG (Guan et al, 2007) and DNA ligase 1 (Smirnova et al, 2005; Wang et al, 2006).
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Figure 6.1 S tep-w ise assem bly o f the ch eckpo in t s ignalling  m achinery at 
stalled replication forks. Replication fork stalling leads to the production of ssDNA, 
which is then coated by RPA. The RPA coated DNA then recruits Cut5, which in turn 
facilitates the binding of ATR and DNA polymerase a. DNA polymerase a is then 
required for the recruitment of the Rad17-RFC clamp loader and the loading of the 9- 
1-1 complex onto DNA. The chromatin bound 9-1-1 complex via the Rad9 phospho- 
tail, then facilitates the ATR-mediated phosphorylation of Chk1.
155
The 9-1-1 complex, Rad 17 and ATM/ATR are proposed to act at an early step to 
sense DNA damage (Zhou et al, 2000; Melo et al, 2001). There are two models to 
address how these sensors are recruited to the damaged sites. In the first model, 
these checkpoint proteins may detect a common intermediate, such as single­
stranded DNA coated by replication protein A (RPA), which is processed by various 
DNA repair pathways (Zou and Elledge, et al, 2003). RPA has been shown to 
directly interact with the 9-1-1 complex (Wu et al, 2005). In the second model, these 
checkpoint proteins may require a series of ‘adaptors’ to recognize DNA damage. 
Such adaptor proteins may be DNA damage recognition proteins involved in BER, 
MMR, NER and DSB repair (Brown et al, 2003; Giannattasio et al, 2004; Lavin 2004; 
Wang and Qin, 2003; Yoshioka and Hsieh, 2006).
Our findings support the model that checkpoint proteins require a series of ‘adaptors’ 
to recognize DNA damage. We speculate a model (figure 6.2) where MUTYH first 
recognizes these DNA lesions because of an interaction with APE1 through a 
binding motif at residues 318-395. APE1 is considered to be the major protein 
responsible for the enzymatic removal of 3-phosphoglycolate in human cells 
(Parsons etal, 2004) and ssDNA arising as a result of ROS is blocked with 3’- 
phosphoglycolate (Barzilai and Yamamoto, 2004). Recruitment of Hus1 and Radi 
proteins could occur through physical interaction with MUTYH (Shi et al, 2006) at the 
Hus1 binding domain (residues 295-350), which is highly conserved and overlaps 
with the APE1 binding domain.
Whilst, the signal to recruit Rad9 remains unknown, the 9-1-1 complex forms near 
the damaged site and the complex is loaded onto DNA by the Rad17-RFC clamp 
loader. The recruitment of 9-1-1 to the lesion is a pre-requisite for ATR activation 
and could explain why our cell lines show lack of Chk1 activation and as a result, 
continued growth.
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Figure 6.2 Step-wise assembly of the checkpoint signalling machinery at 
single strand breaks caused by ROS. Single strand breaks are blocked with 3’- 
phosphoglycolate which is enzymatically cleared by APE1. MUTYH is targeted to the 
site via a direct interaction with APE1 and recruits Hus1 and Radi to the site. The 
Rad17-RFC clamp loads the assembled 9-1-1 complex onto the DNA. The chromatin 
bound 9-1-1 complex via the Rad9 phospho-tail, then facilitates the ATR-mediated 
phosphorylation of Chk1. Similar to figure 6.1, the presence of RPA recruits DNA 
polymerase a, ATR-ATRIP complex and Cut5 to enable new DNA synthesis where 
possible.
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Our results therefore, indicate that there is an uncharacterised relationship between 
MUTYH and components of the 9-1-1 complex. These initial functional experiments 
indicate that MUTYH deficient cells avoid induction of cell death and checkpoint 
mediated cell-cycle arrest. We propose that this feature, coupled with their inability to 
repair 8-oxoG:A mismatches (leading to a G:C-»T:A mutator phenotype), underlies 
the tumourigenic process in MAP.
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Appendix
B-catenin regulated transcription assay results
Variant
Non­
normalised
Luciferase
Value
Normalised 
Luciferase Value
Standard Error Independent T-Test P-value
APC1309A 32 4.9 0.6 4.9±0.6
APC 1450A 24 1.9 0.20 0.00026
APC 1517A 27 1.7 0.10 0.00035
APC 1914A 26 1.5 0.20 0.034
P1442 16 1.1 0.12 0.725
T1493 21 1.2 0.15 0.379
G1678 16 0.7 0.08 0.836
A1755 25 1.2 0.12 0.438
S1756 23 1.0 0.11 0.738
P1960 22 1.1 0.17 0.647
I1307K 27 1.5 0.07 0.008
E1317Q 25 1.5 0.11 0.014
V1352A 15 1.0 0.14 1.000
M1413V 27 1.4 0.14 0.024
T1445A 17 0.8 0.08 0.118
A1446T 15 0.8 0.08 0.283
K1454E 16 1.1 0.13 0.794
P1476S 24 1.0 0.14 0.342
A1474T 29 1.0 0.06 0.813
I1572T 27 1.3 0.18 0.171
C1578G 26 1.2 0.10 0.256
11579V 29 1.5 0.16 0.012
R1676G 24 1.4 0.11 0.033
D1714N 30 2.0 0.20 0.000
G1921S 43 2.0 0.13 0.000
P1934L 26 0.8 0.11 0.234
Data shown is the result of three independent assays.
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